

Article

An access to C5-alkylated indolines/indoles via Michael-type Friedel-Crafts alkylation using aryl-nitroolefins

Berrak Ertugrul, Haydar Kilic, Farrokh Lafzi, and Nurullah Saracoglu

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.8b00973 • Publication Date (Web): 19 Jun 2018

Downloaded from <http://pubs.acs.org> on June 20, 2018

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

An access to C5-alkylated indolines/indoles via Michael-type Friedel-Crafts alkylation using aryl-nitroolefins


Berrak Ertugrul,[‡] Haydar Kilic,^{‡,§} Farrokh Lafzi,[‡] Nurullah Saracoglu,^{‡,*}

[‡] Department of Chemistry, Faculty of Sciences, Atatürk University, Erzurum, 25240, Turkey

[⊥] Oltu Vocational Training School, Atatürk University, Erzurum, 25400, Turkey

[§] East Anatolia High Technology Application and Research Center (DAYTAM), Atatürk University, Erzurum, 25240, Turkey

ABSTRACT: A straightforward synthetic route toward C5-alkylated indolines/indoles has been developed. The strategy is composed of Zn(OTf)₂-catalyzed Friedel–Crafts alkylation of *N*-benzylindolines with nitroolefins, and a series of diverse indolines was first obtained in up to 99% yield. This reaction provides a direct and practical route to a variety of the C5-alkylated indolines which were also utilized for accessing corresponding indoles. Indoline derivatives with free NH groups could be obtained through an *N*-deprotection reaction. Moreover, the primary alkyl nitro groups in both indolines and indoles are amenable to further synthetic elaborations thereby broadening the diversity of the products.




■ INTRODUCTION

The indole scaffold is one of the most widely studied organic templates over the past century as it is associated with biologically active compounds and natural products it is and crucial for the discovery of new drugs.¹ The indole motif is a bacterial intercellular signaling molecule and is found in the structure of many natural products such as tryptophan (**1**) (essential amino acid), and serotonin (**2**) (neurotransmitter).² In 2014, the indole ring was reported to present in 24 marketed drugs as the fourth most prevalent heteroaromatic ring used for the discovery of drugs.³ For example, sumatriptan (**3**)⁴ and eletriptan hydrobromide (**4**)⁵ are two of the triptan class drugs used for the treatment of migraine and cluster headaches. Indomethacin (**5**) is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain or inflammation caused by many conditions such as arthritis, gout, ankylosing spondylitis, bursitis, or tendinitis.⁶ Indoline skeleton is found in the structures of natural products and

biologically active compounds.⁷ Their simple or complex structures are responsible for their potent biological activities in a range of molecules. Physostigmine (**6**) is a reversible inhibitor of acetylcholinesterase and used to reverse the effects of certain drugs or substances that interfere with nerve-muscle communication.⁸ Silodosin (**7**), a drug that is including indoline ring, is a selective antagonist of alpha-1 adrenoreceptors and is used for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).⁹ The binary indole–indoline alkaloids such as vincristine (**8**) and vinblastine (**9**) were also isolated from *Catharanthus roseus* and used clinically in the treatment of cancers including various lymphomas and sarcomas, advanced testicular cancer, breast cancer, and acute leukemia (Figure 1).¹⁰

Figure 1. Several examples of alkaloids and drugs containing the indole and indoline motifs.



The indole is one of the most important of the privileged structures not only in the area of medicinal chemistry/drug discovery but also in other research areas such as agrochemistry and material science.¹¹ Furthermore, indole-based phosphorus ligands are reported to perform in catalytic systems.¹² Accordingly, the development of new methods for the construction of the indole ring has been extensively investigated for more than a century. Access to the functionalized indoles can be broadly categorized into three main strategies.¹³ The first approach involves many name reactions wherein the indole ring and embedded functionalities are constructed from benzenoid precursors or other structures through condensation reactions or by metal-catalyzed means.^{1a,14,15} Classical

syntheses such as Fischer,¹⁶ Bartoli,¹⁷ and Larock¹⁸ are at the forefront among a multitude of other synthetic protocols. The second and third protocols include the derivatization of the indole nucleus itself, either through halogenation and following cross-coupling methodology or direct C-H activation.¹⁹


Nitroolefins are important and invaluable building blocks in organic synthesis and have been widely used in a number of carbon-carbon bond-forming reactions.²⁰ Particularly, the Friedel–Crafts reactions employing nitroolefins as the electrophilic partner are very attractive in indole chemistry, since the nitro groups of the products allow subsequent versatile transformations such as the synthesis of tryptamine and carboline derivatives.²¹ While many alkylation methods exist for the functionalization of indoles in a directly or directed C–H and N–H functionalization at N1,^{22,23} C2,²⁴ and C3²⁵ in chiral and achiral meaning as a result of the inherent reactivity of the pyrrole-type ring, C–H functionalization on the benzenoid ring is limited. Despite this, the directing group-assisted catalytic methods that allow derivatization at the less activated positions, C4–C7, have been recently developed.²⁶ In fact, the most sparingly observed selectivity in the direct functionalization of the indole benzenoid ring is the access to the C5 position. However, to the best of our knowledge, there has been no previous report on catalytic C–H alkylation at the C5-position of indoles. Herein, we described a facile approach for the C5-selective Friedel–Crafts type C–H alkylation of *N*-benzylindoline with β -aryl-nitroolefins. Notably, the resultant *N*-benzyl-C5-alkylated indolines can be readily converted to C5-alkylated indoles under oxidative conditions and deprotected.

■ RESULTS AND DISCUSSIONS

In our previous studies, a series of nitrostyrene derivatives were evaluated to yield *N*-alkylated indolines as electrophilic partners against indoline.²³ To our surprise, we noticed that the reaction between β -nitrostyrene and indoline using Zn(OTf)₂ as a catalyst afforded a C5-alkylated product along with an *N*-alkylation product. This observation encouraged us to study this reaction in detail. To prevent the *N*-alkylation, the nitrogen atom of indoline was protected by the benzyl group. The reaction of indoline with benzyl bromide in the conditions reported in the literature led to 1-benzylindoline (**10a**).²⁷ Using a similar reaction, we also obtained the 1-benzyl-2-methylindoline (**10b**) and ethyl 1-benzylindoline-2-carboxylate (**10c**). The reaction of 1-benzylindoline (**10a**) and β -nitrostyrene (**11a**) was initially tested as a model reaction to optimize the reaction conditions with different catalysts, solvents, and temperature. The optimization results are summarized in Table 1. We found that zinc salts gave the expected reaction. Gratifyingly, the best result was obtained with a catalytic amount of zinc triflate (0.2 equiv) in ethanol at 25 °C (Table 1, entry 16), where the desired

product **12aa** was obtained in 98% yield as the only product. The structure of **12aa** was unequivocally determined by NMR spectroscopy.

Table 1. Optimization Conditions for Reaction of 1-Benzylindoline (**10a**) and β -Nitrostyrene (**11a**).



entry	catalyst	x (mol%)	solvent	T (°C)	t (h)	yield (%)
1	Bi(NO ₃) ₃ ·5H ₂ O	0.5	CH ₂ Cl ₂	25	2	-
2	Bi(NO ₃) ₃ ·5H ₂ O	0.1	CH ₂ Cl ₂	25	2	-
3	Bi(NO ₃) ₃ ·5H ₂ O	0.5	CH ₂ Cl ₂	25	24	-
4	Bi(NO ₃) ₃ ·5H ₂ O	0.5	CH ₂ Cl ₂	40	2	-
5	Bi(NO ₃) ₃ ·5H ₂ O	1	CH ₂ Cl ₂	40	2	-
6	Bi(NO ₃) ₃ ·5H ₂ O	0.2	EtOH	25	12	-
7	Pb(CH ₃ COO) ₄	0.2	CH ₂ Cl ₂	25	2	-
8	Mg(OTf) ₂	0.1	CH ₂ Cl ₂	25	24	-
9	Mg(OTf) ₂	0.5	CH ₂ Cl ₂	25	24	-
10	Zn(CF ₃ CO ₂) ₂	0.2	CH ₂ Cl ₂	25	4	-
11	Zn(CF ₃ CO ₂) ₂	0.2	CH ₂ Cl ₂	25	24	-
12	Zn(CF ₃ CO ₂) ₂	0.2	Toluene	25	24	-
13	Zn(CF ₃ CO ₂) ₂	0.2	EtOH	25	5	95
14	Zn(OTf) ₂	0.2	CH ₂ Cl ₂	25	5	-
15	Zn(OTf) ₂	0.2	Toluene	25	5	90
16	Zn(OTf)₂	0.2	EtOH	25	5	98
17	Cu(OTf) ₂	0.2	EtOH	25	12	-


^aReaction conditions: **10a** (1.0 equiv), **11a** (1.0 equiv). Isolated yield.

With the optimized conditions in hand, we next examined the scope of nitroolefins (**11a-k**)²⁸ with 1-benzylindoline (**10a**) to test the feasibility of preparing a variety of 5-alkylated indolines (Scheme 1). The reaction of *N*-benzylindoline (**10a**) could tolerate a wide range of nitroolefins (**11a-k**) bearing electron-withdrawing and donating groups on the aryl ring, and all of the cases delivered the desired products (**12aa–12ak**) in good to excellent yields (57–99% yields). Then, the influence of the electronic nature of the substituent at the 2-position on the saturated ring of indoline was examined. The 2-methyl-*N*-benzylindoline (**10b**) was studied, and the results revealed that the methyl substituent had no impact on the reaction progress and yields (**12ba–bk**, 74–97%). But, indoline (**10c**) with electron-withdrawing ester substituent exhibited lower reactivity, affording the some of the desired products in much lower yields (**12ca–ce**, 42–56%). We postulated that electron donating rings adjacent to olefin system deactivate the nitroolefin by increasing the electron density, whereas the ester substituent on indoline leads to relatively lower reactivity due to both electronic reasons (which can be mesomeric or inductive) and the possible interactions between the catalyst and the ester. On the other hand, in comparison with the electron-donating benzyl group, when *N*-acetylindoline (**10d**) with an electron-withdrawing group was employed as a substrate, no reaction occurred because of the presumably



1
2
3 reduced nucleophilicity. A possible mechanism for the $\text{Zn}(\text{OTf})_2$ catalyzed Michael-type Friedel–Crafts
4 reaction between 1-benzylindolines (**10**) and nitroolefins (**11**) is proposed in Scheme 2. The nitroolefin
5 was activated upon chelation to $\text{Zn}(\text{II})$ to form a four-membered intermediate **[A]**, which undergoes a
6 nucleophilic addition of indoline from the accessible C5-position to provide the Friedel–Crafts
7 alkylation adduct **[B]**. Subsequently, H–transfer to provide aromatization leads to product formation.
8 We postulate that tertiary nitrogen atom of indoline directs substitution to the *ortho*- and *para*-
9 positions. But an absence of *ortho*-product **13** has been attributed to a steric hindrance between
10 benzyl and the electrophile, which, do not tolerate intermediate **[C]**.
11
12
13
14
15
16
17

18 It was hoped that the methodology will provide a facile access to Friedel–Crafts product **12l**, which can
19 be a precursor of silodosin using a medication for the symptomatic treatment of benign prostatic
20 hyperplasia. However, the reaction of indoline **10a** and 2-nitroprop-1-ene (**11l**) failed to give the
21 corresponding product **12l** under the above optimum and other conditions (Table 2, Entries 1-14), the
22 starting materials are recovered in almost quantitative yields. This suggests that both an electron-rich
23 nitroolefin fails to play a role in this type of Friedel–Crafts and a methyl group attached to an alkene
24 prevents the approach of the donor molecule.
25
26
27
28
29
30

31 Next, we intended to dehydrogenate indolines **12aa-12ak** to give the corresponding indoles. Firstly,
32 **12aa** as a model molecule was subjected to oxidation reaction with oxidizing reagents such as MnO_2
33 and 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ),²³ and these dehydrogenations resulted in a
34 complex mixture. Our previous study showed that DEAD oxidized protection-free indoline to indole.²³
35 To our great pleasure, the oxidation of **12aa** with diethyl azodicarboxylate (DEAD) as a milder oxidant
36 in methylene chloride at room temperature for 2 h worked well and the expected product **13aa** was
37 obtained in 55% yield (Scheme 3). Encouraged by this result, the oxidations of other indolines **12ab-aj**
38 under same conditions were studied, and the corresponding 1-benzyl indoles **13ab-13aj** were obtained
39 with good yields (55-90%) (Scheme 3). The oxidation of the indoline **12ai** including furan ring under
40 the same conditions gave inseparable product mixture. Recently, Davis and group reported an
41 oxidation of amines to imines utilizing DEAD.²⁹ The proposed mechanisms for the oxidation reaction
42 of indoline are shown in Scheme 4. The first has been previously proposed by Davis and group via a
43 triazane intermediate **[D]** for the conversion of seconder amines to imines (Scheme 4, A-pathway).
44 Secondly, the oxidation can occur through an intermolecular hydride transfer (Scheme 4, B-pathway).
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Scheme 1. Scope of Indolines (**10a-c**) and Nitroolefins (**11a-k**).


^aReaction conditions: **10a-c** (1.0 equiv), **11a-k** (1.0 equiv). Isolated yield.

Scheme 2. Plausible Reaction Mechanism for C5-Alkylation of 1-Benzylindoline (**10a**).**Table 2.** Reaction between 1-Benzylindoline (**10a**) and 2-Nitroprop-1-ene (**11**).

entry	catalyst	x (mol%)	solvent	T (°C)	t (h)
1	Zn(CF ₃ CO ₂) ₂	0.2	EtOH	25	5
2	Zn(OTf) ₂	0.2	EtOH	25	5
3	Zn(OTf) ₂	0.5	EtOH	25	5
4	Zn(OTf) ₂	0.2	Toluen	80-100	12
5	Zn(OTf) ₂	0.2	DMF	25	12
6	AuCl ₃	0.2	EtOH	25	5
7	SnCl ₂	0.2	EtOH	25	5
8	AlCl ₃	0.2	EtOH	25	5
9	AlCl ₃	0.2	THF	25	5
10	Zn(OTf) ₂ -TFA	0.2	EtOH	25	3
11	Zn(OTf) ₂ - <i>p</i> -TSA	0.2	EtOH	25	3
12	TFA	0.2	EtOH	25	5
13	<i>p</i> -TSA	0.2	EtOH	25	5
14	Zn(OTf) ₂	0.2	2-nitropropen	25	5


^aReaction conditions: **10a** (1.0 equiv), **11** (1.0 equiv).

Scheme 3. Scope of Indolines (**12aa-ak**) to Indoles (**14aa-ak**).




*Reaction conditions: **12** (1.0 equiv) and DEAD (1.1 equiv) in DCM were stirred at room temperature for 12 h. Isolated yield.

Scheme 4. Proposed Mechanisms for the Oxidation of Indolines (**12**) to Indoles (**14**).




Next, we turned our attention to the removal of the benzyl-protecting group of C5-alkylated indolines **12** and indoles **14** to access main skeletons. The corresponding *N*-benzylindoline **12aa** and indole **14aa** were chosen as representative substrates. To observe its behavior toward catalytic hydrogenation of both benzyl and nitro group, indoline **12aa** was subjected to a Pd-catalyzed hydrogenation reaction. Catalytic hydrogenation gave an inseparable mixture of amine and hydroxylamine derivatives **15-17** via the reduction of the nitro group, whereas no deprotection of benzyl group was observed (Scheme 5). The formation of indole **17** can be attributed to the Pd-catalyzed oxidation of indoline **15**. Furthermore, neither hydrogenolysis catalyzed by palladium hydroxide on carbon (Pd(OH)₂/C),³⁰ nor oxidative debenzoylation with cerium (IV) ammonium nitrate (CAN)³¹ resulted in any reaction. The starting material was recovered in nearly quantitative yields in both cases. Since three debenzoylation attempts were not successful, we decided to investigate whether Deaton-Rewolinski's³² and Gigg-Conant's³³ debenzoylation conditions were viable for our purpose. According to this procedure, while treatment of *N*-benzylindoline **12aa** with potassium *tert*-butoxide/dimethyl sulfoxide (DMSO) and oxygen at room temperature afforded unexpected ketones **18** and **19** in 39 and 43% yield, indole derivative **14aa** gave ketone **20** in 48% yield under the same conditions (Scheme 6). The proposed mechanism for this unexpected transformation is shown in Scheme 7. This mechanism was adapted from a proposed mechanism for the *N*-debzoylation of amides by Gigg and Conant.³³ The resulting benzylic anion **[E]** under basic conditions reacts with oxygen. The peroxy anion intermediate, **[F]**, is easily reduced in the presence of DMSO to afford dimethyl sulfone and an alkoxide, **[G]**, which breaks down to generate ketone **19** and nitromethane. We propose that the formation of ketone **18** involves debenzoylation of **19** followed by an oxidation of indoline to indole (Scheme 7).


Scheme 5. Catalytic hydrogenation of **12aa**.



Scheme 6. Reaction of **12aa** and **14aa** with *t*-BuOK/DMSO and Oxygen.




Scheme 7. Proposed Mechanism for Formation of Ketones **18/19**.




To overcome this problem, we explored a two-step protocol which has been successfully applied for debenzylation of 5-trimethylsilyl-*N*-benzylindoline.²⁷ The first step of this protocol was the hydrogenolysis in the presence of acetic anhydride so that following the splitting off of the *N*-benzyl group, the amino group was acetylated. In the second step, *N*-acetyl group was hydrolyzed by KOH in diethylene glycol to the corresponding indoline. Catalytic hydrogenolysis in acetic anhydride of indoline **12aa** as a test reaction gave 5-alkylated-*N*-acetylindoline **21aa** in 50% yield. Unfortunately, an alkaline hydrolysis of **21aa** provided a complex product mixture which cannot be separated. Probably, the nitro-alkane structure is not stable under basic conditions, therefore, we decided to use *tert*-butoxycarbonyl (Boc) group as the protecting group, which can be easier deprotected, instead of an acetyl group. Using di-*tert*-butyl dicarbonate (Boc₂O), the desired product **22aa** was formed in 93% yield (Scheme 8). In connection with this result, we examined such consecutive debenzylation/Boc-deprotection reaction on other *N*-benzylindolines **12ab-ah** and successfully obtained the corresponding indolines in 80–93% yield (Scheme 8). Unfortunately, the use of **12aj** and **12ak** as substrates failed to give the desired products **22aj** and **22ak** during the deprotection step using such reagents as trifluoroacetic acid (TFA),³⁴ molecular iodine,³⁵ tetrabutylammonium fluoride (TBAF),³⁶ and boron trifluoride diethyl etherate (BF₃·OEt₂).³⁷ It is noteworthy that the reaction of indoline substrate **12ae** bearing a bromine atom on the phenyl ring under the optimized conditions led to an inseparable mixture of the expected product **22ae** and the by-product **22aa** via reduction of the bromine atom. Notably, Pd(OH)₂-catalyzed hydrogenation in the presence of Boc₂O followed by deprotection with TFA afforded the debrominated product **22aa**. Furthermore, when we evaluated the debenzylation of *N*-benzylindole derivatives **12aa** as a model compound with both the consecutive debenzylation/Boc-deprotection reaction and Pd/C-catalyzed hydrogenation in MeOH, Pd(OH)₂/C-catalyzed hydrogenation in *t*-BuOH/H₂O, and oxidative debenzylation with a CAN, no formation of **23aa** occurred and the starting material was recovered in almost quantitative yield. Gratifyingly, the oxidation of the unprotected-indolines with DEAD gave the desired indole **23** in a moderate yield (40-58%), as demonstrated in Scheme 9.

Scheme 8. Scope of Debencylation for Indolines.




33 ^aReaction conditions: **12** (1.0 equiv), Boc_2O (1.1 mmol), and Pd/C (0.2 mmol) in MeOH/DCM were stirred under hydrogen atmosphere. To a
 34 solution of **21** in DCM was added TFA (1 mL). Isolated yield.

35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59 **Scheme 9.** Scope of Unprotected indolines to Indoles.



33 *Reaction conditions: **22** (1.0 equiv) and DEAD (1.1 equiv) in DCM were stirred at room temperature for 12 h. Isolated yield.

34
35
36 To access new silodosin precursors, we also probed the scope of the reduction of the aliphatic nitro
37 groups in the indolines/indoles to amines. *N*-BenzyIndoline **12aa** was taken as the model substrate and
38 subjected to reduction with LiAlH_4 and Zn-HCl. However, complex mixtures were observed. When
39 $\text{SnCl}_2/\text{AcOH}$ was used reduction was not observed. Using $\text{NaBH}_4\text{-NiCl}_2$ system in methanol as reducing
40 agent, the reaction produced a mixture of the desired amine **24aa** as a major product along with a
41 possible partial reduction product which could not be separated by chromatography and
42 crystallization. Therefore, the crude reduction mixture in methanol was reacted with concentrated HCl
43 to precipitate the amine as its insoluble hydrochloride salt, which could then be recrystallized from
44 ether (Scheme 10). Furthermore, while nine hydrochloride salts **25** were obtained from the
45 corresponding nitro groups in excellent yields (84-97%), only indolines **12ac** and **12aj** did not produce
46 the desired results (Scheme 10). Contrarily, the reduction with the $\text{NaBH}_4\text{-NiCl}_2$ system in methanol
47 was also applied to reduce the aliphatic nitro group of indole derivatives **14** and afforded the
48 corresponding amines **26** in high to excellent yields (78-95%) (Scheme 11). Finally, the reduction of the
49 nitro group in indole **23aa** without *N*-benzyl group as a model compound with $\text{NaBH}_4\text{-NiCl}_2$ system
50 afforded the corresponding amine **27aa** with 92% yield (Scheme 12).
51
52
53
54
55
56
57
58
59
60

Scheme 10. Reduction Scope of Nitro Groups in *N*-Benzylindolines.


*Reaction conditions: **12** (1.0 equiv), $\text{NiCl}_2 \cdot 6\text{H}_2\text{O}$ (1.0 equiv), and NaBH_4 (5.0 equiv) in MeOH were stirred at 0 °C for 0.5 h. To a solution of **24** in MeOH (0.5 mL) was added HCl (12 M, 1.2 equiv). Isolated yield.

■ CONCLUSION

In summary, we have developed an effective strategy for the synthesis of diverse C5-alkylated indolines by zinc triflate-catalyzed Michael-type Friedel-Crafts reaction of *N*-benzylindolines with nitroolefins. The new approach displays a powerful method for the direct C5-alkylation of indolines. The corresponding indolines were oxidized using diethyl azodicarboxylate to afford a series of C5-alkylated indoles in good to excellent yields. Furthermore, the C5-alkylated *N*-benzylindolines were further functionalized through debenzoylation and oxidation reactions. Nitroalkane groups could be


transformed into corresponding amine-hydrochloride salts and amines with sodium borohydride catalyzed by nickel(II) chloride. The present protocol provides a useful synthetic strategy to access various biologically active C5-alkylated indolines/indoles. The asymmetric synthesis of C5-alkylated indolines/indoles, study their bioactivities and synthesis of new silodosin-analogs will be our focus in the future.

Scheme 11. Reduction Scope of Nitro Groups in *N*-Benzylindoles.



^aReaction conditions: **14** (1.0 equiv), $\text{NiCl}_2 \cdot 6\text{H}_2\text{O}$ (1.0 equiv), and NaBH_4 (5.0 equiv) in MeOH were stirred at 0°C for 0.5 h. Isolated yield.

Scheme 12. Synthesis of Indole **27aa**.



■ EXPERIMENTAL SECTION

General Experimental Methods. All reagents and solvents were purchased from commercial suppliers (Sigma-Aldrich) and used without further purification. Column chromatography and thin-layer chromatography (TLC) were performed using Silica gel 60 (70-230 Fluka) and Silica gel 60 HF254 (Fluka), respectively. Melting points were determined on Buchi 539 capillary melting apparatus and are uncorrected. Infrared spectra were recorded on a Mattson 1000 FT-IR spectrophotometer. ^1H NMR, ^{13}C NMR spectra were recorded on 400 (100)-MHz Varian and Bruker spectrometer and are reported in δ units with SiMe_4 as the internal standard. Data for ^1H NMR are recorded as follows: chemical shift (δ , ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quarted, p = pentet, m = multiplet, bs = broad singlet, bd = broad doublet) and coupling constant(s) in Hz, integration. Elemental analyses were carried out on a Leco CHNS-932 instrument. High-resolution mass spectrometry measurements were recorded on a Q-TOF mass spectrometer.

General Procedure 1 (GP1): Preparation of *N*-Protected indolines (10a, 10b)

N-Protected indolines was synthesized according to literature. Indoline (5.0 g, 42 mmol) was added to saturated NaHCO_3 in 15 mL of water and the mixture was stirred with heating to 90-95 °C. Benzyl bromide (7.2 g, 42 mmol) was added dropwise during 1.5 hr, and stirring and heating was continued for an additional 3.5 hr. After cooling the layers were separated, and the aqueous layer was extracted with ether. The combined organic layers were washed with water and dried over sodium sulfate. Concentration and purification through silica gel column chromatography gave desired *N*-protected indolines.

1-Benzylindoline (10a).³⁸ Compound **10a** was obtained using **GP1**. Column chromatography (EtOAc/Hexane (1:9)) gave the product as colourless oil (8.2 g, 93% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.44 – 7.34 (m, =CH, 4H), 7.34 – 7.26 (m, =CH, 1H), 7.16 – 7.06 (m, =CH, 2H), 6.79 – 6.63 (m, =CH, 1H), 6.56 (d, J = 7.8 Hz, =CH, 1H), 4.30 (s, CH_2 , 2H), 3.36 (t, J = 8.3 Hz, CH_2 , 2H), 3.02 (t, J = 8.3 Hz, CH_2 , 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 152.5, 138.4, 130.0, 128.4, 127.9, 127.3, 127.1, 124.5, 117.7, 107.0, 53.7, 53.6, 28.5. IR (CH_2Cl_2 , cm^{-1}): 3394, 3026, 2919, 2823, 1875, 1607, 1488, 1471, 1453, 1357, 1269, 1154, 1026, 980, 865, 790. Anal. Calcd for $\text{C}_{15}\text{H}_{15}\text{N}$: C, 86.08; H, 7.22; N, 6.69; found: C, 86.01; H, 6.92; N, 6.64. R_f = 0.60 (EtOAc/Hexane (1:9), 254 nm).

1
2
3 *1-Benzyl-2-methylindoline (10b)*.³⁹ Compound **10b** was obtained using **GP1**. Column chromatography
4 (EtOAc/Hexane (1:9)) gave the product as purple oil (16.7 g, 99% yield). ¹H NMR (400 MHz, CDCl₃) δ
5 7.50 – 7.42 (m, =CH, 4H), 7.36 (t, *J* = 7.1 Hz, =CH, 1H), 7.18 (d, *J* = 7.1 Hz, =CH, 1H), 7.11 (t, *J* = 7.1 Hz,
6 =CH, 1H), 6.76 (t, *J* = 7.1 Hz, =CH, 1H), 6.45 (d, *J* = 7.1 Hz, =CH, 1H), 4.48 (d, *J* = 16.1 Hz, A part of AB
7 system, CH₂, 1H), 4.31 (d, *J* = 16.1 Hz, B part of AB system, CH₂, 1H), 3.88 – 3.80 (m, CH, 1H), 3.29 (dd,
8 *J* = 15.4, 9.0 Hz, A part of AB system, CH₂, 1H), 2.80 (dd, *J* = 15.4, 9.0 Hz, B part of AB system, CH₂, 1H),
9 1.42 (d, *J* = 6.0 Hz, CH₃, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 152.8, 139.4, 128.9, 128.6, 127.57, 127.52,
10 127.0, 124.3, 117.6, 107.0, 60.7, 51.3, 37.5, 19.8. IR (CH₂Cl₂, cm⁻¹): 3026, 2963, 2836, 1606, 1483, 1452,
11 1352, 1268, 1236, 1145, 1024, 900, 854, 745. Anal. Calcd for C₁₆H₁₇N: C, 86.05; H, 7.67; N, 6.27; found:
12 C, 86.26; H, 7.45; N, 6.03. R_f = 0.64 (EtOAc/Hexane (1:9), 254 nm). HRMS (APCI-TOF) *m/z*: [M + H]⁺
13 Calcd for C₁₆H₁₈N 224.1434; Found 224.1435.

14
15
16
17
18
19
20
21
22 *Ethyl 1-benzylindoline-2-carboxylate (10c)*.⁴⁰ Ethyl 1-benzylindoline-2-carboxylate (**10c**) was
23 synthesized according to literature.⁴⁰ A mixture of ethyl indoline-2-carboxylate (1.0 g, 5.23 mmol),
24 K₂CO₃ (2.17 g, 15.69 mmol) and benzyl bromide (2.68, 15.69 mmol) in 10 mL DMF was heated with an
25 oil bath to 100 °C. On cooling the reaction mixture was poured into ice water and extracted with ether.
26 The extract was washed with water and dried over sodium sulfate. Concentration and purification
27 through silica gel column chromatography (EtOAc/Hexane (2:8)) gave the product as light yellow oil
28 (1.35 g, 91% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.41 – 7.27 (m, =CH, 4H), 7.27 – 7.20 (m, =CH, 1H), 7.05
29 – 7.00 (m, =CH, 2H), 6.67 (t, *J* = 7.6 Hz, 1H), 6.43 (d, *J* = 7.6 Hz, 1H), 4.51 (d, *J* = 15.5 Hz, A part of AB
30 system, CH₂, 1H), 4.30 (d, *J* = 15.5 Hz, B part of AB system, CH₂, 1H), 4.23 (dd, *J* = 10.2, 8.3 Hz, CH, 1H),
31 4.18–4.03 (m, CH₂, 2H), 3.37 (dd, *J* = 15.9, 10.2 Hz, A part of AB system, CH₂, 1H), 3.19 (dd, *J* = 15.9, 8.3
32 Hz, B part of AB system, CH₂, 1H), 1.20 (t, *J* = 7.1 Hz, CH₃, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 172.9, 151.5,
33 137.9, 128.5, 127.9, 127.8, 127.2, 127.0, 124.2, 118.2, 107.2, 65.5, 61.0, 52.2, 33.5, 14.2. IR (CH₂Cl₂,
34 cm⁻¹): 3556, 3060, 3029, 2980, 2930, 2905, 2855, 1878, 1728, 1607, 1485, 1453, 1328, 1262, 1191,
35 1162, 1028, 745, 698. Anal. Calcd for C₁₈H₁₉NO₂: C, 76.84; H, 6.81; N, 4.98; found: C, 76.77; H, 6.61; N,
36 4.91. R_f = 0.48 (EtOAc/Hexane (1:9), 254 nm).

37
38
39
40
41
42
43
44
45
46
47
48 *N-Acetylindoline (10d)*.⁴¹ *N*-Acetylindoline (**10d**) was synthesized according to literature.⁴¹ Indoline
49 (2.00 g, 16.78 mmol) is dissolved in acetic anhydride (7.92 mL, 83.92 mmol) at room temperature,
50 followed by addition of pyridine (0.812 mL, 10.07 mmol). The reaction mixture is heated with an oil
51 bath to 120 °C and maintained for 4 h. The reaction is quenched by addition of 2N NaOH (10 mL), and
52 the resulting mixture is diluted with ethyl acetate (2×30 mL). The phases are separated, and the organic
53 phase is washed with saturated aqueous NaHCO₃ (20 mL), dried over anhydrous Na₂SO₄. Concentration
54 and purification through silica gel column chromatography (EtOAc/Hexane (2:8)) gave the product as
55 white crystals (2.62 g, 96% yield; mp 97–98 °C (CH₂Cl₂/hexane)). ¹H NMR (400 MHz, CDCl₃) δ 8.20 (d, *J*
56
57
58
59
60

= 7.7 Hz, =CH, 1H), 7.21 – 7.10 (m, =CH, 2H), 6.99 (t, J = 7.7 Hz, =CH, 1H), 4.01 (t, J = 8.5 Hz, CH₂, 2H), 3.16 (t, J = 8.5 Hz, CH₂, 2H), 2.19 (s, CH₃, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 168.8, 143.1, 131.3, 127.7, 124.7, 123.7, 117.1, 48.9, 28.1, 24.4. Anal. Calcd for C₁₀H₁₁NO: C, 74.51; H, 6.88; N, 8.69; found: C, 74.70; H, 6.99; N, 8.52. R_f = 0.13 (EtOAc/Hexane (3:7), 254 nm).

General Procedure 2 (GP2): Synthesis of Nitroolefines (11a-k)

Nitroolefines were synthesized according to literature.^{28b} Aldehyde (1.0 equiv), nitromethane (6.0 equiv) and piperidine (0.1 equiv) were added sequentially to a round-bottomed flask containing toluene (3 mL). To this mixture anhydrous FeCl₃ (0.1 equiv) was added, and the mixture was heated to reflux slowly for 4 h. Progress of the reaction was monitored by TLC. After completion of the reaction, the mixture was cooled to room temperature. The excess solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography (EtOAc/Hexane (1:9)) to give desired nitroalkenes **11a-k**.

(E)-1-(2-Nitrovinyl)-4-(trifluoromethyl)benzene (**11b**).⁴² Compound **11b** was obtained using **GP2**. Column chromatography (EtOAc/Hexane (1:9)) gave the product as light yellow crystals (392 mg, 87% yield; mp 76–77 °C (CH₂Cl₂/hexane)). ¹H NMR (400 MHz, CDCl₃) δ 8.03 (d, J = 13.7 Hz, A part of AB system, =CH, 1H), 7.74 – 7.72 (m, AA' part of AA'BB' system, =CH, 2H), 7.69 – 7.67 (m, BB' part of AA'BB' system, =CH, 2H), 7.63 (d, J = 13.7 Hz, B part of AB system, =CH, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 138.9, 137.1, 133.6 – 133.3 (m, 1C), 129.2, 126.36 (q, J = 3.7 Hz, 1C), 124.8, 122.1. IR (CH₂Cl₂, cm⁻¹): 3435, 3110, 1925, 1640, 1524, 1416, 1342, 1325, 1165, 1115, 1068, 968, 830. Anal. Calcd for C₉H₆F₃NO₂: C, 49.78; H, 2.79; N, 6.45; found: C, 49.99; H, 2.91; N, 6.21. R_f = 0.73 (EtOAc/Hexane (3:7), 254 nm).

(E)-*N,N*-Dimethyl-4-(2-nitrovinyl)aniline (**11f**).⁴³ Compound **11f** was obtained using **GP2**. Column chromatography (EtOAc/Hexane (2:8)) gave the product as red crystals (216 mg, 82% yield; mp 179–180 °C (CH₂Cl₂/hexane)). ¹H NMR (400 MHz, CDCl₃) δ 7.98 (d, J = 13.4 Hz, A part of AB system, =CH, 1H), 7.51 (d, J = 13.4 Hz, B part of AB system, =CH, 1H), 7.45 – 7.43 (m, AA' part of AA'BB' system, =CH, 2H), 6.71 – 6.69 (m, BB' part of AA'BB' system, =CH, 2H), 3.10 (s, CH₃, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 153.0, 140.3, 132.0, 131.4, 117.2, 111.9, 40.0. IR (CH₂Cl₂, cm⁻¹): 2917, 1617, 1555, 1438, 1417, 1327, 1236, 1068, 968, 808, 798. Anal. Calcd for C₁₀H₁₂N₂O₂: C, 62.49; H, 6.29; N, 14.57; found: C, 62.28; H, 6.24; N, 14.45. R_f = 0.32 (EtOAc/Hexane (3:7), 254 nm).

(E)-1,2,3-Trimethoxy-5-(2-nitrovinyl)benzene (**11h**).⁴⁴ Compound **11h** was obtained using **GP2**. Column chromatography (EtOAc/Hexane (3:7)) gave the product as yellow crystals (1.04 g, 85% yield; mp 144–145 °C (CH₂Cl₂/hexane)). ¹H NMR (400 MHz, CDCl₃) δ 7.93 (d, J = 13.6 Hz, A part of AB system, =CH, 1H), 7.53 (d, J = 13.6 Hz, B part of AB system, =CH, 1H), 6.76 (s, =CH, 2H), 3.91 (s, CH₃, 3H), 3.90 (s, CH₃, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 153.9, 142.0, 139.5, 136.6, 125.5, 126.6, 61.3, 56.5. IR (CH₂Cl₂, cm⁻¹): 2945, 2841, 1625, 1581, 1509, 1491, 1420, 1337, 1249, 1193, 1132, 971, 819. Anal. Calcd for C₁₁H₁₃NO₅: C, 55.23; H, 5.48; N, 5.86; found: C, 55.45; H, 5.43; N, 5.61. R_f = 0.28 (EtOAc/Hexane (3:7), 254 nm).

(E)-5-(2-Nitrovinyl)-1*H*-indole (**11j**).⁴⁵ Compound **11j** was obtained using **GP2**. Column chromatography (EtOAc/Hexane (3:7)) gave the product as dark yellow crystals (545 mg, 83% yield; mp 154–155 °C (Acetone/hexane)). ¹H NMR (400 MHz, Acetone-d₆) δ 10.67 (bs, NH, 1H), 8.22 (d, *J* = 13.5 Hz, =CH, A part of AB system, =CH 1H), 8.08 (s, =CH, 1H), 7.93 (d, *J* = 13.5 Hz, =CH, B part of AB system, =CH, 1H), 7.61 (dd, *J* = 8.6, 1.6 Hz, A part of AB system, =CH, 1H), 7.56 (d, *J* = 8.6 Hz, B part of AB system, =CH, 1H), 7.49 – 7.44 (m, =CH, 1H), 6.68 – 6.57 (m, =CH, 1H). ¹³C NMR (100 MHz, Acetone-d₆) δ 142.1, 139.4, 135.5, 129.5, 127.6, 125.4, 122.7, 122.5, 113.3, 103.7. IR (Acetone, cm⁻¹): 3376, 2733, 1605, 1494, 1329, 1300, 1285, 1217, 1129, 973, 894, 805, 766. Anal. Calcd for C₁₀H₈N₂O₂: C, 63.83; H, 4.29; N, 14.89; found: C, 63.50; H, 4.53; N, 14.57. R_f = 0.40 (Acetone/Hexane (3:7), 254 nm).

(E)-3-(2-Nitrovinyl)-1*H*-indole (**11k**).⁴⁰ Compound **11k** was obtained using **GP2**. Column chromatography (EtOAc/Hexane (3:7)) gave the product as dark yellow crystals (420 mg, 78% yield; mp 167–168 °C (Acetone/hexane)). ¹H NMR (400 MHz, Acetone-d₆) δ 11.29 (bs, NH, 1H), 8.40 (d, *J* = 13.5 Hz, A part of AB system, =CH, 1H), 8.19 – 8.18 (m, =CH, 1H), 8.02 – 7.96 (m, =CH, 1H), 7.93 (d, *J* = 13.5 Hz, B part of AB system, =CH, 1H), 7.65 – 7.56 (m, =CH, 1H), 7.41 – 7.22 (m, =CH, 2H). ¹³C NMR (100 MHz, Acetone-d₆) δ 138.2, 135.1, 134.0, 132.1, 125.2, 123.7, 122.2, 120.6, 112.9, 108.9. IR (Acetone, cm⁻¹): 3433, 2078, 1638, 1476, 1310, 1237, 1132, 965. Anal. Calcd for C₁₀H₈N₂O₂: C, 63.83; H, 4.29; N, 14.89; found: C, 63.97; H, 4.43; N, 14.66. R_f = 0.27 (Acetone/Hexane (3:7), 254 nm).

2-Nitroprop-1-ene (**11l**). *2-Nitroprop-1-ene* (**11l**) was synthesized according to literature.⁴⁶ *2-Nitro-1-butanol* (2.10 g, 20 mmol) and phthalic anhydride (5.92 g, 40 mmol) was added to a round-bottomed flask. The reaction mixture was heated to 150–200 °C and distilled under water aspirator pressure. The desired product distilled over with water into an ice-cooled receiving flask. The aqueous layer was separated and the organic layer was dried over sodium sulfate to give compound **11l**. Compound **11l** was recovered as blue-green oil (890 mg, 52% yield). ¹H NMR (400 MHz, CDCl₃) δ 6.4 (s, =CH, 1H), 5.6 (s, =CH, 1H), 2.2 (s, CH₃, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 154.2, 118.2, 17.1. IR (CH₂Cl₂, cm⁻¹): 3363, 2889, 1718, 1556, 1361, 1230, 1002, 849. Anal. Calcd for C₃H₅NO₂: C, 41.38; H, 5.79; N, 16.09; found: C, 41.13; H, 5.86; N, 15.72. R_f = 0.43 (EtOAc/Hexane (1:9), 254 nm).

General Procedure 3 (GP3): Preparation of C5-Alkylated Indolines

To a solution of β-nitrostyrene derivatives (1.0 equiv.) in ethanol (10 mL) was added Zn(OTf)₂ (0.2 equiv.) at room temperature. After stirring for 30 min, a solution of *N*-alkyl indoline (1.0 equiv.) in

ethanol (5 mL) was added dropwise for 5 min to the solution. The mixture was stirred for 12 h at room temperature. After removal of the solvent, the residue was dissolved in CH₂Cl₂ (30 mL) and washed with water (2×30 mL). The combined organic layer was dried over Na₂SO₄. Concentration and purification through silica gel column chromatography gave desired C5-alkylation products.

(±)-1-Benzyl-5-(2-nitro-1-phenylethyl)indoline (**12aa**). Compound **12aa** was obtained using **GP3**. Column chromatography (EtOAc/Hexane (1:9)) gave the product as light yellow crystals (2.36 g, 98% yield; mp 77–78 °C (CH₂Cl₂/hexane)). ¹H NMR (400 MHz, CDCl₃) δ 7.34 – 7.21 (m, =CH, 10H), 6.94 – 6.87 (m, =CH, 2H), 6.40 (d, *J* = 8.0 Hz, =CH, 1H), 4.94 (dd, *J* = 11.7, 7.4 Hz, A part of AB system, CH₂, 1H), 4.89 (dd, *J* = 11.7, 7.4 Hz, B part of AB system, CH₂, 1H), 4.78 (t, *J* = 8.2 Hz, CH, 1H), 4.20 (s, CH₂, 2H), 3.30 (t, *J* = 8.3 Hz, CH₂, 2H), 2.91 (t, *J* = 8.3 Hz, CH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 152.0, 140.1, 138.3, 130.9, 128.9, 128.5, 128.2, 127.9, 127.6, 127.3, 127.2, 126.6, 124.0, 106.9, 79.7, 53.7, 53.6, 48.7, 28.5. IR (CH₂Cl₂, cm⁻¹): 3430, 3028, 2916, 2827, 1615, 1551, 1496, 1453, 1377, 1271, 1156, 1079, 1029, 890, 809, 734. Anal. Calcd for C₂₃H₂₂N₂O₂: C, 77.07; H, 6.19; N, 7.82; found: C, 76.85; H, 6.26; N, 7.70. Rf = 0.64 (EtOAc/Hexane (1:9), 254 nm). HRMS (APCI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₃H₂₃N₂O₂ 359.1760; Found 359.1740.

(±)-1-Benzyl-5-(2-nitro-1-(4-(trifluoromethyl)phenyl)ethyl)indoline (**12ab**). Compound **12ab** was obtained using **GP3**. Column chromatography (EtOAc/Hexane (1:9)) gave the product as light yellow oil (141 mg, 78% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.49 – 7.47 (m, AA' part of AA'BB' system, =CH, 2H), 7.28 – 7.26 (m, BB' part of AA'BB' system, =CH, 2H), 7.24 – 7.23 (m, =CH, 4H), 7.20 – 7.13 (m, =CH, 1H), 6.80 – 6.76 (m, =CH, 2H), 6.31 (d, *J* = 8.0 Hz, =CH, 1H), 4.90 – 4.80 (m, CH₂, 2H), 4.78 – 4.72 (m, CH, 1H), 4.12 (s, CH₂, 2H), 3.23 (t, *J* = 8.4 Hz, CH₂, 2H), 2.83 (t, *J* = 8.3 Hz, CH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 152.3, 144.2, 138.1, 131.1, 129.7, 129.4, 128.5, 127.9, 127.8, 127.2, 127.11, 126.6, 125.9 (q, *J* = 3.7 Hz), 123.8, 106.9, 79.1, 53.5, 53.4, 48.4, 28.4. IR (CH₂Cl₂, cm⁻¹): 3439, 1618, 1554, 1497, 1376, 1326, 1266, 1164, 1118, 1069, 736, 701. Anal. Calcd for C₂₄H₂₁F₃N₂O₂: C, 67.60; H, 4.96; N, 6.57; found: C, 67.47; H, 4.74; N, 6.29. Rf = 0.32 (EtOAc/Hexane (1:9), 254 nm). HRMS (APCI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₄H₂₂F₃N₂O₂ 427.1633; Found 427.1661.

(±)-4-(1-(1-Benzylindolin-5-yl)-2-nitroethyl)phenol (**12ac**). Compound **12ac** was obtained using **GP3**. Column chromatography (EtOAc/Hexane (2:8)) gave the product as brown oil (2.28 g, 99% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.36 – 7.34 (m, =CH, 4H), 7.31 – 7.25 (m, =CH, 1H), 7.10 – 7.09 (m, AA' part of AA'BB' system, =CH, 2H), 6.96 – 6.86 (m, =CH, 2H), 6.75 – 6.74 (m, BB' part of AA'BB' system, =CH, 2H), 6.45 (d, *J* = 8.3 Hz, =CH, 1H), 4.90 – 4.89 (m, CH₂, 2H), 4.88 (bs, OH, 1H), 4.73 (t, *J* = 8.3 Hz, CH, 1H), 4.23 (s, CH₂, 2H), 3.31 (t, *J* = 8.3 Hz, CH₂, 2H), 2.92 (t, *J* = 8.3 Hz, CH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 155.1, 152.1, 138.4, 132.3, 131.2, 129.0, 128.9, 128.8, 128.2, 127.5, 126.7, 124.2, 116.0, 107.3, 80.2, 53.90,

53.89, 48.2, 28.7. IR (CH₂Cl₂, cm⁻¹): 3361, 3025, 2823, 1613, 1550, 1513, 1496, 1376, 1265, 1174, 834, 734. Anal. Calcd for C₂₃H₂₂N₂O₃: C, 73.78; H, 5.92; N, 7.48; found: C, 73.92; H, 5.63; N, 7.27. Rf = 0.31 (EtOAc/Hexane (3:7), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₃H₂₃N₂O₃ 375.1709; Found 375.1683.

(±)-1-Benzyl-5-(1-(4-fluorophenyl)-2-nitroethyl)indoline (**12ad**). Compound **12ad** was obtained using **GP3**. Column chromatography (EtOAc/Hexane (1:9)) gave the product as yellow oil (2.11 g, 93% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.30 – 7.37 (m, =CH, 4H), 7.34 – 7.32 (m, =CH, 1H), 7.28 – 7.25 (m, =CH, 2H), 7.05 (t, *J* = 8.5 Hz, =CH, 2H), 7.00 – 6.88 (m, =CH, 2H), 6.49 – 6.46 (m, =CH, 1H), 4.93 (dd, *J* = 8.3, 2.8 Hz, CH₂, 2H), 4.86 – 4.79 (m, CH, 1H), 4.27 (s, CH₂, 2H), 3.36 (t, *J* = 8.3 Hz, CH₂, 2H), 2.97 (t, *J* = 8.3 Hz, CH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 162.2 (d, *J* = 245.9 Hz), 152.3, 138.4, 136.1, 131.3, 129.4 (d, *J* = 8.1 Hz), 128.8, 128.19, 128.14, 127.5, 126.7, 124.1, 116.1 (d, *J* = 21.4 Hz), 107.1, 79.9, 53.9, 53.7, 48.1, 28.7. IR (CH₂Cl₂, cm⁻¹): 3029, 2918, 2830, 1889, 1604, 1551, 1508, 1376, 1268, 1228, 1160, 1098, 1015, 943, 890, 837. Anal. Calcd for C₂₃H₂₁FN₂O₂: C, 73.39; H, 5.62; N, 7.44; found: C, 73.27; H, 5.57; N, 7.27. Rf = 0.32 (EtOAc/Hexane (1:9), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₃H₂₂FN₂O₂ 377.1665; Found 377.1642.

(±)-1-Benzyl-5-(1-(4-bromophenyl)-2-nitroethyl)indoline (**12ae**). Compound **12ae** was obtained using **GP3**. Column chromatography (EtOAc/Hexane (1:9)) gave the product as yellow oil (1.90 g, 99% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.45 – 7.43 (m, AA' part of AA'BB' system, =CH, 2H), 7.35 – 7.23 (m, =CH, 5H), 7.13 – 7.11 (m, BB' part of AA'BB' system, =CH, 2H), 6.89 – 6.83 (m, =CH, 2H), 6.40 (d, *J* = 8.0 Hz, =CH, 1H), 4.91 (dd, *J* = 11.4, 7.0 Hz, A part of AB system, CH₂, 1H), 4.86 (dd, *J* = 11.4, 7.0 Hz, B part of AB system, CH₂, 1H), 4.78 – 4.71 (m, CH, 1H), 4.21 (s, CH₂, 2H), 3.32 (t, *J* = 8.3 Hz, CH₂, 2H), 2.92 (t, *J* = 8.3 Hz, CH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 152.2, 139.1, 138.2, 132.0, 131.1, 129.3, 128.5, 127.8, 127.5, 127.2, 126.6, 123.8, 121.3, 106.9, 79.4, 53.6, 53.4, 48.1, 28.4. IR (CH₂Cl₂, cm⁻¹): 3414, 3025, 2806, 1678, 1551, 1488, 1376, 1202, 1071, 1006, 883, 802, 730. Anal. Calcd for C₂₃H₂₁BrN₂O₂: C, 63.17; H, 4.84; N, 6.41; found: C, 63.40; H, 4.83; N, 6.32. Rf = 0.30 (EtOAc/Hexane (1:9), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₃H₂₂BrN₂O₂ 437.0859; Found 437.0834.

(±)-4-(1-(1-Benzylindolin-5-yl)-2-nitroethyl)-*N,N*-dimethylaniline (**12af**). Compound **12af** was obtained using **GP3**. Column chromatography (EtOAc/Hexane (2:8)) gave the product as light green oil (61 mg, 57% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.26 – 7.22 (m, =CH, 4H), 7.20 – 7.17 (m, =CH, 1H), 7.03 – 7.01 (m, AA' part of AA'BB' system, =CH, 2H), 6.89 – 6.77 (m, =CH, 2H), 6.60 – 6.58 (m, BB' part of AA'BB' system, =CH, 2H), 6.32 (d, *J* = 8.2 Hz, =CH, 1H), 4.80 (d, *J* = 8.3 Hz, CH₂, 2H), 4.62 (t, *J* = 8.3 Hz, CH, 1H), 4.13 (s, CH₂, 2H), 3.21 (t, *J* = 8.3 Hz, CH₂, 2H), 2.94 – 2.70 (m, CH₂, CH₃, 8H). ¹³C NMR (100 MHz, CDCl₃) δ 151.8, 149.7, 138.3, 130.8, 129.1, 128.5, 128.2, 127.8, 127.6, 127.1, 126.4, 123.9, 112.7, 106.8, 80.0,

53.7, 53.6, 47.8, 40.5, 28.4. IR (CH₂Cl₂, cm⁻¹): 2918, 2850, 1734, 1611, 1552, 1521, 1351, 1265, 1078, 881, 737. Anal. Calcd for C₂₅H₂₇N₃O₂: C, 74.79; H, 6.78; N, 10.47; found: C, 74.85; H, 6.52; N, 10.33. Rf = 0.54 (EtOAc/Hexane (3:7), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₅H₂₈N₃O₂ 402.2182; Found 402.2156.

(±)-1-Benzyl-5-(1-(2,5-dimethoxyphenyl)-2-nitroethyl)indoline (**12ag**). Compound **12ag** was obtained using **GP3**. Column chromatography (EtOAc/Hexane (2:8)) gave the product as green oil (1.78 g, 89% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.40 – 7.35 (m, =CH, 4H), 7.33 – 7.24 (m, =CH, 1H), 7.03 – 6.99 (m, =CH, 2H), 6.84 (d, *J* = 8.4 Hz, =CH, 1H), 6.78 – 6.75 (m, =CH, 2H), 6.46 (d, *J* = 8.4 Hz, =CH, 1H), 5.20 – 5.16 (m, CH, 1H), 5.01 (dd, *J* = 12.7, 8.3 Hz, A part of AB system, CH₂, 1H), 4.90 (dd, *J* = 12.7, 8.3 Hz, B part of AB system, CH₂, 1H), 4.24 (s, CH₂, 2H), 3.82 (s, CH₃, 3H), 3.75 (s, CH₃, 3H), 3.33 (t, *J* = 8.3 Hz, CH₂, 2H), 2.95 (t, *J* = 8.3 Hz, CH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 153.8, 152.1, 151.3, 138.6, 130.9, 129.8, 128.7, 128.1, 127.8, 127.4, 127.1, 124.5, 115.8, 112.1, 112.0, 107.1, 78.6, 56.3, 55.8, 53.96, 53.95, 43.2, 28.7. IR (CH₂Cl₂, cm⁻¹): 3435, 2953, 2834, 1615, 1551, 1497, 1376, 1226, 1048, 1025, 805, 736. Anal. Calcd for C₂₅H₂₆N₂O₄: C, 71.75; H, 6.26; N, 6.69; found: C, 71.78; H, 5.98; N, 6.61. Rf = 0.60 (EtOAc/Hexane (3:7), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₅H₂₇N₂O₄ 419.1971; Found 419.1942.

(±)-1-Benzyl-5-(2-nitro-1-(3,4,5-trimethoxyphenyl)ethyl)indoline (**12ah**). Compound **12ah** was obtained using **GP3**. Column chromatography (EtOAc/Hexane (2:8)) gave the product as green oil (1.43 g, 65% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.27 (m, =CH, 5H), 6.97 – 6.88 (m, =CH, 2H), 6.49 – 6.39 (m, =CH, 3H), 4.92 (dd, *J* = 12.4, 8.1 Hz, A part of AB system, CH₂, 1H), 4.87 (dd, *J* = 12.4, 8.1 Hz, B part of AB system, CH₂, 1H), 4.73 (t, *J* = 8.1 Hz, CH, 1H), 4.22 (s, CH₂, 2H), 3.83 (s, CH₃, 6H), 3.82 (s, CH₃, 3H), 3.33 (t, *J* = 8.3 Hz, CH₂, 2H), 2.94 (t, *J* = 8.3 Hz, CH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 153.7, 152.3, 138.4, 137.4, 135.8, 131.2, 128.8, 128.2, 128.0, 127.4, 126.6, 124.1, 107.1, 104.9, 79.9, 61.0, 56.4, 53.8, 53.7, 49.1, 28.7. IR (CH₂Cl₂, cm⁻¹): 2937, 2837, 1614, 1590, 1551, 1495, 1454, 1421, 1377, 1329, 1238, 1127, 1005, 908, 814. Anal. Calcd for C₂₆H₂₈N₂O₅: C, 69.63; H, 6.29; N, 6.25; found: C, 69.63; H, 6.43; N, 6.64. Rf = 0.44 (EtOAc/Hexane (3:7), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₆H₂₉N₂O₅ 449.2076; Found 449.2053.

(±)-1-Benzyl-5-(1-(furan-2-yl)-2-nitroethyl)indoline (**12ai**). Compound **12ai** was obtained using **GP3**. Column chromatography (EtOAc/Hexane (2:8)) gave the product as brown oil (2.29 g, 91% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.39 – 7.33 (m, =CH, 4H), 7.33 – 7.22 (m, =CH, 2H), 6.99 (s, =CH, 1H), 6.96 – 6.94 (m, AA' part of AA'BB' system, =CH, 1H), 6.45 – 6.43 (m, BB' part of AA'BB' system, =CH, 1H), 6.32 (dd, *J* = 3.2, 2.0 Hz, =CH, 1H), 6.12 (d, *J* = 3.2 Hz, =CH, 1H), 4.97 (dd, *J* = 11.9, 7.6 Hz, A part of AB system, CH₂, 1H), 4.85 – 4.79 (m, CH, 1H), 4.75 (dd, *J* = 11.9, 7.6 Hz, B part of AB system, CH₂, 1H), 4.24 (s, CH₂,

2H), 3.35 (t, $J = 8.3$ Hz, CH₂, 2H), 2.96 (t, $J = 8.3$ Hz, CH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 153.2, 152.6, 142.5, 138.4, 131.1, 128.7, 128.0, 127.4, 127.2, 125.9, 124.1, 110.5, 107.1, 107.1, 78.7, 53.8, 53.6, 43.4, 28.6. IR (CH₂Cl₂, cm⁻¹): 3445, 2845, 1617, 1552, 1497, 1376, 1267, 1146, 1013, 810, 736. Anal. Calcd for C₂₁H₂₀N₂O₃: C, 72.40; H, 5.79; N, 8.04; found: C, 72.51; H, 5.72; N, 8.15. Rf = 0.67 (EtOAc/Hexane (1:9), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₁H₂₁N₂O₃ 349.1552; Found 349.1528.

(±)-5-(1-(1-Benzylindolin-5-yl)-2-nitroethyl)-1H-indole (**12aj**). Compound **12aj** was obtained using **GP3**. Column chromatography (Acetone/Hexane (2:8)) gave the product as brown oil (1.85 mg, 78% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.13 (s, NH, 1H), 7.51 (s, =CH, 1H), 7.37 – 7.23 (m, =CH, 6H), 7.20 – 7.15 (m, =CH, 1H), 7.08 – 7.03 (m, =CH, 1H), 7.00 – 6.93 (m, =CH, 2H), 6.53 – 4.48 (m, =CH, 1H), 6.42 (d, $J = 7.9$ Hz, =CH, 1H), 5.03 – 4.95 (m, CH₂, 2H), 4.94 – 4.86 (m, CH, 1H), 4.21 (s, CH₂, 2H), 3.29 (t, $J = 8.3$ Hz, CH₂, 2H), 2.91 (t, $J = 8.3$ Hz, CH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 152.0, 138.6, 135.1, 131.8, 131.0, 129.5, 128.7, 128.3, 128.1, 127.4, 126.7, 125.0, 124.3, 122.3, 119.5, 111.7, 107.1, 102.9, 80.5, 53.9 (2C), 49.0, 28.7. IR (CH₂Cl₂, cm⁻¹): 3422, 1614, 1549, 1496, 1377, 1266, 1094, 894, 732. Anal. Calcd for C₂₅H₂₃N₃O₂: C, 75.55; H, 5.83; N, 10.57; found: C, 75.29; H, 5.99; N, 10.24. Rf = 0.41 (EtOAc/Hexane (3:7), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₅H₂₄N₃O₂ 398.1869; Found 398.1854.

(±)-3-(1-(1-Benzylindolin-5-yl)-2-nitroethyl)-1H-indole (**12ak**). Compound **12ak** was obtained using **GP3**. Column chromatography (Acetone/Hexane (2:8)) gave the product as brown oil (1.85 mg, 78% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.03 (s, NH, 1H), 7.49 (d, $J = 8.0$ Hz, =CH, 1H), 7.35 – 7.23 (m, =CH, 6H), 7.21 – 7.15 (m, =CH, 1H), 7.10 – 6.98 (m, =CH, 4H), 6.41 (d, $J = 8.7$ Hz, =CH, 1H), 5.10 – 4.97 (m, CH₂, 2H), 4.90 – 4.82 (m, CH, 1H), 4.19 (s, CH₂, 2H) 3.31 – 3.24 (m, CH₂, 2H), 2.92 – 2.86 (m, CH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 152.6, 138.4, 136.5, 130.8, 128.5, 128.3, 127.9, 127.2, 126.8, 126.3, 124.0, 122.6, 121.4, 119.8, 119.2, 115.3, 111.3, 106.9, 80.1, 53.7 (2C), 41.2, 28.5. IR (CH₂Cl₂, cm⁻¹): 3419, 3047, 2957, 2913, 2829, 1615, 1548, 1495, 1456, 1378, 1265, 1098, 808, 741. Anal. Calcd for C₂₅H₂₃N₃O₂: C, 75.55; H, 5.83; N, 10.57; found: C, 75.31; H, 6.00; N, 10.63. Rf = 0.36 (EtOAc/Hexane (3:7), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₅H₂₄N₃O₂ 398.1869; Found 398.1847.

(*dia*)-1-Benzyl-2-methyl-5-(2-nitro-1-phenylethyl)indoline (**12ba**). Compound **12ba** was obtained using **GP3**. Thin layer chromatography (EtOAc/Hexane (1:9)) gave the product as yellow oil (1.08 mg, 86% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.53 – 7.31 (m, =CH, 10H), 7.04 (s, =CH, 1H), 6.98 – 6.93 (m, =CH, 1H), 6.39 – 6.37 (m, =CH, 1H), 5.06 – 4.82 (m, CH, CH₂, 3H), 4.45 (d, $J = 16.0$ Hz, B part of AB system, CH₂, 1H), 4.28 (d, $J = 16.0$ Hz, B part of AB system, CH₂, 1H), 3.88 – 3.81 (m, CH₂, 1H), 3.27 – 3.20 (m, CH₂, 1H), 2.75 (dd, $J = 15.6, 9.4$ Hz, CH₂, 1H), 1.44 – 1.37 (m, CH₃, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 152.5, 140.6, 139.4, 130.0, 129.2, 128.9, 128.4, 127.9, 127.7, 127.6, 127.3, 127.0, 126.9, 124.0, 123.9, 107.0, 79.9, 61.1, 51.5, 49.0, 37.6, 20.0. IR (CH₂Cl₂, cm⁻¹): 3061, 3028, 2963, 2925, 2839, 1615, 1551,

1
2
3 1494, 1453, 1377, 1354, 1270, 1161, 1109, 1002, 910, 879. Anal. Calcd for C₂₄H₂₄N₂O₂: C, 77.39; H, 6.50;
4 N, 7.52; found: C, 77.35; H, 6.50; N, 7.61. R_f = 0.68 (EtOAc/Hexane (1:9), 254 nm). HRMS (APCI-TOF)
5 m/z: [M + H]⁺ Calcd for C₂₄H₂₅N₂O₂ 373.1916; Found 373.1894.
6
7

8
9 *(dia)*-1-Benzyl-2-methyl-5-(2-nitro-1-(4-(trifluoromethyl)phenyl)ethyl)indoline (**12bb**). Compound **12bb**
10 was obtained using **GP3**. Thin layer chromatography (EtOAc/Hexane (1:9)) gave the product as yellow
11 oil (756 mg, 74% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.57 – 7.55 (m, AA' part of AA'BB' system, =CH,
12 2H), 7.37 – 7.35 (m, BB' part of AA'BB' system, =CH, 2H), 7.33 – 7.27 (m, =CH, 4H), 7.27 – 7.18 (m, =CH,
13 1H), 6.84 (s, =CH, 1H), 6.79 (dd, *J* = 8.0, 2.4 Hz, =CH, 1H), 6.21 (dd, *J* = 8.0, 1.2 Hz, =CH, 1H), 5.07 – 4.63
14 (m, CH, CH₂, 3H), 4.32 (d, *J* = 16.0 Hz, A part of AB system, CH₂, 1H), 4.14 (d, *J* = 16.0 Hz, B part of AB
15 system, CH₂, 1H), 3.78 – 3.69 (m, CH, 1H), 3.12 (dd, *J* = 15.7, 9.0 Hz, A part of AB system, CH₂, 1H), 2.62
16 (dd, *J* = 15.7, 9.0 Hz, B part of AB system, CH₂, 1H), 1.28 (d, *J* = 6.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ
17 152.5, 144.3, 139.0, 130.1, 128.7, 128.1, 127.4, 127.2, 127.0, 126.89, 126.84, 126.1 – 126.0 (m, C),
18 123.7, 123.6, 106.9, 79.3, 60.8, 51.17, 51.16, 48.6, 37.3, 19.8. IR (CH₂Cl₂, cm⁻¹): 3434, 2963, 1618, 1553,
19 1494, 1376, 1325, 1163, 1117, 1069, 808, 731, 700. Anal. Calcd for C₂₅H₂₃F₃N₂O₂: C, 68.17; H, 5.26; N,
20 6.36; found: C, 68.41; H, 5.36; N, 6.23. R_f = 0.70 (EtOAc/Hexane (1:9), 254 nm). HRMS (APCI-TOF) m/z:
21 [M + H]⁺ Calcd for C₂₅H₂₄F₃N₂O₂ 441.1790; Found 441.1763.
22
23
24
25
26
27
28
29
30

31 *(dia)*-4-(1-(1-Benzyl-2-methylindolin-5-yl)-2-nitroethyl)phenol (**12bc**). Compound **12bc** was obtained
32 using **GP3**. Thin layer chromatography (EtOAc/Hexane (2:8)) gave the product as brown oil (1.15 g, 97%
33 yield). ¹H NMR (400 MHz, CDCl₃) δ 7.38 – 7.29 (m, =CH, 4H), 7.27 – 7.25 (m, =CH, 1H), 7.10 – 7.08 (m,
34 AA' part of AA'BB' system, =CH, 2H), 6.88 (s, =CH, 1H), 6.82 (d, *J* = 8.0 Hz, =CH, 1H), 6.75 – 6.73 (m, BB'
35 part of AA'BB' system, =CH, 2H), 6.24 – 6.22 (m, =CH, 1H), 5.00 (bs, OH, 1H), 4.91 – 4.80 (m, CH₂, 2H),
36 4.71 (t, *J* = 8.2 Hz, CH, 1H), 4.33 (d, *J* = 16.0 Hz, A part of AB system, CH₂, 1H), 4.15 (d, *J* = 16.0 Hz, B part
37 of AB system, CH₂, 1H), 3.80 – 3.62 (m, CH, 1H), 3.12 (dd, *J* = 15.2, 8.6 Hz, A part of AB system, CH₂, 1H),
38 2.63 (dd, *J* = 15.2, 9.5 Hz, B part of AB system, CH₂, 1H), 1.29 (d, *J* = 6.1 Hz, 3H). ¹³C NMR (100 MHz,
39 CDCl₃) δ 154.9, 152.2, 139.2, 132.4, 129.99, 129.97, 129.0, 128.7, 127.5, 127.2, 126.7, 126.6, 123.8,
40 123.7, 115.9, 106.9, 80.1, 60.9, 51.3, 48.1, 37.4, 19.8. IR (CH₂Cl₂, cm⁻¹): 3434, 2964, 2077, 1614, 1550,
41 1513, 1494, 1377, 1266, 1175, 1103, 835. Anal. Calcd for C₂₄H₂₄N₂O₃: C, 74.21; H, 6.23; N, 7.21; found:
42 C, 74.10; H, 6.08; N, 7.16. R_f = 0.44 (EtOAc/Hexane (3:7), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺
43 Calcd for C₂₄H₂₅N₂O₃ 389.1865; Found 389.1836.
44
45
46
47
48
49
50
51
52
53

54 *(dia)*-1-Benzyl-5-(1-(4-fluorophenyl)-2-nitroethyl)-2-methylindoline (**12bd**). Compound **12bd** was
55 obtained using **GP3**. Thin layer chromatography (EtOAc/Hexane (1:9)) gave the product as yellow oil
56 (1.05 g, 90% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.39 – 7.17 (m, =CH, 7H), 7.06 – 6.97 (m, =CH, 2H), 6.87
57 (s, =CH, 1H), 6.82 (bd, *J* = 8.0 Hz, 1H), 6.24 (bd, *J* = 8.0 Hz, 1H), 5.01 – 4.82 (m, CH₂, 2H), 4.80 – 4.72 (m,
58
59
60

1
2
3 CH, 1H), 4.34 (d, $J = 16.0$ Hz, A part of AB system, CH₂, 1H), 4.20 (d, $J = 16.0$ Hz, B part of AB system,
4 CH₂, 1H), 3.84 – 3.71 (m, CH, 1H), 3.17 (dd, $J = 15.6, 9.0$ Hz, A part of AB system, CH₂, 1H), 2.65 (dd, $J =$
5 $15.6, 9.0$ Hz, B part of AB system, CH₂, 1H), 1.33 (d, $J = 6.1$ Hz, CH₃, 3H). ¹³C NMR (100 MHz, CDCl₃) δ
6 162.16 (d, $J = 246.2$ Hz), 152.4, 139.2, 136.1, 130.09, 130.08, 129.43 (d, $J = 8.0$ Hz), 128.7, 127.9, 127.5,
7 127.2, 126.8, 126.7, 123.79, 123.71, 116.00 (d, $J = 21.5$ Hz), 106.9, 79.9, 60.9, 51.33, 51.32, 48.2, 37.4,
8 19.9. IR (CH₂Cl₂, cm⁻¹): 3435, 2964, 2925, 2840, 1615, 1604, 1552, 1495, 1377, 1230, 1160, 1100, 838,
9 813. Anal. Calcd for C₂₄H₂₃FN₂O₂: C, 73.83; H, 5.94; N, 7.17; found: C, 73.74; H, 5.87; N, 7.25. Rf = 0.27
10 (EtOAc/Hexane (1:19), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₄H₂₄FN₂O₂ 391.1822; Found
11 391.1797.
12
13
14
15
16
17
18

19 *(dia)*-1-Benzyl-5-(1-(4-bromophenyl)-2-nitroethyl)-2-methylindoline (**12be**). Compound **12be** was
20 obtained using **GP3**. Thin layer chromatography (EtOAc/Hexane (1:9)) gave the product as yellow oil
21 (961 mg, 97% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.45 – 7.43 (m, AA' part of AA'BB' system, =CH, 2H),
22 7.34 – 7.23 (m, =CH, 5H), 7.13 – 7.11 (m, BB' part of AA'BB' system, =CH, 2H), 6.84 (s, =CH, 1H), 6.79
23 (d, $J = 8.0$ Hz, =CH, 1H), 6.22 (d, $J = 8.0$ Hz, =CH, 1H), 4.94 – 4.81 (m, CH₂, 2H), 4.77 – 4.68 (m, CH, 1H),
24 4.33 (d, $J = 16.0$ Hz, A part of AB system, CH₂, 1H), 4.16 (d, $J = 16.0$ Hz, B part of AB system, CH₂, 1H),
25 3.88 – 3.55 (m, CH, 1H), 3.12 (dd, $J = 15.7, 9.0$ Hz, A part of AB system, CH₂, 1H), 2.63 (dd, $J = 15.7, 9.0$
26 Hz, B part of AB system, CH₂, 1H), 1.29 (d, $J = 6.1$ Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 152.4, 139.3,
27 139.1, 132.2, 130.0, 129.5, 128.7, 127.4, 127.2, 126.8, 126.7, 123.7, 123.6, 121.4, 106.9, 79.5, 60.9,
28 51.2, 48.3, 37.4, 19.8. IR (CH₂Cl₂, cm⁻¹): 3027, 2963, 2923, 2823, 2848, 1616, 1552, 1490, 1376, 1268,
29 1074, 1010, 811, 733. Anal. Calcd for C₂₄H₂₃BrN₂O₂: C, 63.87; H, 5.14; N, 6.21; found: C, 63.75; H, 5.29;
30 N, 6.05. Rf = 0.38 (EtOAc/Hexane (1:9), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₄H₂₄BrN₂O₂
31 451.1021; Found 451.0977.
32
33
34
35
36
37
38
39
40
41

42 *(dia)*-4-(1-(1-Benzyl-2-methylindolin-5-yl)-2-nitroethyl)-N,N-dimethylaniline (**12bf**). Compound **12bf**
43 was obtained using **GP3**. Thin layer chromatography (EtOAc/Hexane (2:8)) gave the product as brown
44 oil (814 mg, 75% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.27 (m, =CH, 3H), 7.27 – 7.21 (m, =CH, 2H),
45 7.09 (d, $J = 8.7$ Hz, =CH, 2H), 6.88 (s, =CH, 1H), 6.82 (d, $J = 8.0$ Hz, =CH, 1H), 6.69 – 6.67 (m, =CH, 2H),
46 6.22 – 6.19 (m, =CH, 1H), 4.87 – 4.85 (m, CH₂, 2H), 4.67 (t, $J = 8.2$ Hz, CH, 1H), 4.31 (d, $J = 16.0$ Hz, A
47 part of AB system, CH₂, 1H), 4.13 (d, $J = 16.0$ Hz, A part of AB system, CH₂, 1H), 3.72 – 3.67 (m, CH, 1H),
48 3.10 (dd, $J = 15.5, 9.1$ Hz, A part of AB system, CH₂, 1H), 2.91 (s, CH₃, 6H), 2.61 (dd, $J = 15.5, 9.1$ Hz, A
49 part of AB system, CH₂, 1H), 1.27 (d, $J = 6.3$ Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 139.3, 129.8, 128.99,
50 128.96, 128.6, 128.4, 127.5, 127.1, 126.6, 126.5, 123.8, 123.7, 113.1, 106.8, 80.2, 61.0, 51.4 (2C), 48.1,
51 37.4, 19.8. IR (CH₂Cl₂, cm⁻¹): 3411, 2918, 2851, 1614, 1549, 1521, 1493, 1351, 1160, 1060, 733. Anal.
52 Calcd for C₂₆H₂₉N₃O₂: C, 75.15; H, 7.03; N, 10.11; found: C, 75.19; H, 7.09; N, 10.20. Rf = 0.56
53
54
55
56
57
58
59
60

(EtOAc/Hexane (2:8), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₆H₃₀N₃O₂ 416.2338; Found 416.2309.

(*dia*)-1-Benzyl-5-(1-(2,5-dimethoxyphenyl)-2-nitroethyl)-2-methylindoline (**12bg**). Compound **12bg** was obtained using **GP3**. Thin layer chromatography (EtOAc/Hexane (2:8)) gave the product as brown oil (862 mg, 83% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.37 – 7.29 (m, =CH, 4H), 7.27 – 7.23 (m, =CH, 1H), 6.95 (s, =CH, 1H), 6.89 (d, *J* = 8.4 Hz, =CH, 1H), 6.80 (d, *J* = 8.4 Hz, =CH, 1H), 6.76 – 6.67 (m, =CH, 2H), 6.24 – 6.22 (m, =CH, 1H), 5.17 – 5.05 (m, CH, 1H), 5.00 – 4.95 (m, CH₂, 1H), 4.90 – 4.81 (m, CH₂, 1H), 4.32 (d, *J* = 16.0 Hz, CH₂, A part of AB system 1H), 4.16 (d, *J* = 16.0 Hz, B part of AB system CH₂, 1H), 3.81 – 3.80 (m, CH₃, 3H), 3.74 – 3.73 (m, CH₃, CH, 4H), 3.12 (dd, *J* = 15.6, 8.5 Hz, CH₂, 1H), 2.64 (m, CH₂, 1H), 1.29 (d, *J* = 6.1 Hz, CH₃, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 153.7, 152.3, 151.3, 139.4, 129.8, 129.7, 128.6, 127.5, 127.16, 127.14, 127.0, 124.1, 124.0, 115.8, 115.7, 112.05, 112.04, 111.9, 106.9, 78.6, 61.1, 61.0, 56.3, 55.8, 51.58, 51.54, 43.15, 43.13, 37.5, 19.9. IR (CH₂Cl₂, cm⁻¹): 3435, 2962, 2834, 1619, 1551, 1495, 1376, 1225, 1049, 802, 733. Anal. Calcd for C₂₆H₂₈N₂O₄: C, 72.20; H, 6.53; N, 6.48; found: C, 72.11; H, 6.43; N, 6.64. R_f = 0.62 (EtOAc/Hexane (3:7), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₆H₂₉N₂O₄ 433.2127; Found 433.2102.

(*dia*)-1-Benzyl-2-methyl-5-(2-nitro-1-(3,4,5-trimethoxyphenyl)ethyl)indoline (**12bh**). Compound **12bh** was obtained using **GP3**. Thin layer chromatography (EtOAc/Hexane (2:8)) gave the product as green oil (792 mg, 82% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.36 – 7.27 (m, =CH, 4H), 7.27 – 7.22 (m, =CH, 1H), 6.88 (s, =CH, 1H), 6.83 (d, *J* = 8.1 Hz, =CH, 1H), 6.44 (s, =CH, 2H), 6.23 (d, *J* = 8.1 Hz, =CH, 1H), 4.98 – 4.76 (m, CH₂, 2H), 4.69 (t, *J* = 8.2 Hz, CH, 1H), 4.32 (d, *J* = 16.0 Hz, CH₂, 1H), 4.15 (d, *J* = 16.0 Hz, CH₂, 1H), 3.82 (s, 6H), 3.80 (s, 3H), 3.75 – 3.70 (m, CH, 1H), 3.12 (dd, *J* = 15.6, 8.6 Hz, A part of AB system, CH₂, 1H), 2.63 (dd, *J* = 15.6, 9.4 Hz, B part of AB system, CH₂, 1H), 1.28 (d, *J* = 6.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 153.4, 152.2, 138.9, 137.2, 135.5, 129.7, 128.5, 127.7, 127.3, 127.0, 126.4, 126.3, 123.5, 123.4, 106.6, 104.8, 79.7, 60.8, 60.75, 60.73, 56.1, 51.1, 51.0, 48.9, 37.2, 19.6. IR (CH₂Cl₂, cm⁻¹): 3424, 2963, 2838, 1590, 1551, 1494, 1454, 1237, 1127, 1005, 733. Anal. Calcd for C₂₇H₃₀N₂O₅: C, 70.11; H, 6.54; N, 6.06; found: C, 69.94; H, 6.43; N, 6.17. R_f = 0.25 (EtOAc/Hexane (2:8), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₇H₃₁N₂O₅ 463.2233; Found 463.2204.

(*dia*)-1-Benzyl-5-(1-(furan-2-yl)-2-nitroethyl)-2-methylindoline (**12bi**). Compound **12bi** was obtained using **GP3**. Thin layer chromatography (EtOAc/Hexane (2:8)) gave the product as brown oil (1.19 mg, 91% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.42 - 7.22 (m, =CH, 6H), 6.96 (s, =CH, 1H), 6.92 – 6.83 (m, =CH, 1H), 6.32 – 6.31 (m, =CH, 1H), 6.26 (d, *J* = 8.0 Hz, =CH, 1H), 6.16 – 6.06 (m, =CH, 1H), 4.96 (dd, *J* = 12.0, 7.6 Hz, A part of AB system, CH₂, 1H), 4.85 – 4.77 (m, CH, 1H), 4.73 (dd, *J* = 12.0, 7.6 Hz, B part of AB system, CH₂, 1H), 4.36 (d, *J* = 16.0 Hz, A part of AB system, CH₂, 1H), 4.19 (d, *J* = 16.0 Hz, B part of AB

1
2
3 system, CH₂, 1H), 3.84 – 3.65 (m, CH, 1H), 3.16 (ddd, *J* = 15.6, 8.5, 1.5 Hz, A part of AB system, CH₂, 1H),
4 2.67 (dd, *J* = 15.6, 9.4 Hz, B part of AB system, CH₂, 1H), 1.31 (d, *J* = 6.2 Hz, CH₃, 3H). ¹³C NMR (100 MHz,
5 CDCl₃) δ 153.2, 152.7, 142.4, 139.2, 129.9, 128.7, 127.5, 127.29, 127.27, 127.23, 125.6, 123.85, 123.83,
6 110.5, 107.1, 106.9, 78.82, 78.81, 60.9, 51.2, 43.4, 37.4, 19.9. IR (CH₂Cl₂, cm⁻¹): 3027, 2964, 2925, 2840,
7 1616, 1553, 1495, 1376, 1274, 1238, 1161, 1146, 1013, 914, 810, 735. Anal. Calcd for C₂₂H₂₂N₂O₃: C,
8 72.91; H, 6.12; N, 7.73; found: C, 72.72; H, 6.09; N, 7.60. R_f = 0.44 (EtOAc/Hexane (2:8), 254 nm). HRMS
9 (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₂H₂₃N₂O₃ 363.1709; Found 363.1683.

10
11
12
13
14
15
16 *(dia)*-5-(1-(1-Benzyl-2-methylindolin-5-yl)-2-nitroethyl)-1H-indole (**12bj**). Compound **12bj** was obtained
17 using **GP3**. Thin layer chromatography (Acetone/Hexane (2:8)) gave the product as yellow oil (18 mg,
18 86% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.97 (s, NH, 1H), 7.41 (d, *J* = 8.0 Hz, =CH, 1H), 7.28 – 7.19 (m,
19 =CH, 5H), 7.18 – 7.07 (m, =CH, 2H), 7.02 – 6.92 (m, =CH, 2H), 6.91 – 6.82 (m, =CH, 2H), 6.14 (d, *J* = 8.0
20 Hz, =CH, 1H), 4.99 – 4.89 (m, CH₂, CH, 2H), 4.77 (dd, *J* = 11.8, 7.7 Hz, CH₂, 1H), 4.23 (d, *J* = 16.0 Hz, A
21 part of AB system, CH₂, 1H), 4.06 (d, *J* = 16.0 Hz, B part of AB system, CH₂, 1H), 3.71 – 3.50 (m, CH, 1H),
22 3.05 – 2.97 (m, CH₂, 1H), 2.58 – 2.46 (m, CH₂, 1H), 1.28 – 1.06 (m, CH₃, 3H). ¹³C NMR (100 MHz, CDCl₃)
23 δ 152.1, 139.1, 136.5, 129.5, 128.4, 127.9, 127.3, 126.9, 126.8, 126.6, 126.3, 123.6, 123.5, 122.5, 121.3,
24 119.7, 119.2, 115.3, 111.2, 106.7, 80.0, 60.84, 60.80, 51.2, 41.1, 37.2, 29.2, 19.6. IR (CH₂Cl₂, cm⁻¹):
25 3435, 2094, 1635, 1338, 1223, 1079, 1049, 882. Anal. Calcd for C₂₆H₂₅N₃O₂: C, 75.89; H, 6.12; N, 10.21;
26 found: C, 75.66; H, 6.15; N, 9.95. R_f = 0.20 (Acetone/Hexane (3:7), 254 nm). HRMS (APCI-TOF) m/z: [M
27 + H]⁺ Calcd for C₂₆H₂₆N₃O₂ 412.2025; Found 412.1985.

28
29
30
31
32
33
34
35
36
37 *(dia)*-3-(1-(1-Benzyl-2-methylindolin-5-yl)-2-nitroethyl)-1H-indole (**12bk**). Compound **12bk** was
38 obtained using **GP3**. Thin layer chromatography (Acetone/Hexane (2:8)) gave the product as yellow oil
39 (18.20 mg, 87% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.93 (bs, NH, 1H), 7.41 (d, *J* = 8.1 Hz, =CH, 1H), 7.26
40 – 7.20 (m, =CH, 4H), 7.17 – 7.15 (m, =CH, 2H), 7.13 – 7.06 (m, =CH, 1H), 7.05 – 6.90 (m, =CH, 2H), 6.91
41 – 6.78 (m, =CH, 2H), 6.14 (d, *J* = 8.1 Hz, =CH, 1H), 5.02 – 4.83 (m, CH₂, 2H), 4.79 – 4.74 (m, CH, 1H), 4.23
42 (d, *J* = 16.0 Hz, A part of AB system, CH₂, 1H), 4.06 (d, *J* = 16.0 Hz, B part of AB system, CH₂, 1H), 3.65 –
43 3.58 (m, CH, 1H), 3.05 – 2.97 (m, CH₂, 1H), 2.65 – 2.43 (m, CH₂, 1H), 1.34 – 0.96 (m, CH₃, 3H). ¹³C NMR
44 (100 MHz, CDCl₃) δ 152.4, 139.3, 136.7, 129.7, 128.9, 128.6, 127.5, 127.1, 126.9, 126.8, 126.2, 123.8,
45 123.7, 122.7, 121.5, 120.9, 119.9, 119.4, 119.3, 118.9, 115.5, 111.4, 109.7, 106.9, 100.7, 80.4, 80.2,
46 61.0, 60.9, 51.5, 51.4, 46.8, 41.9, 41.3, 37.4, 19.9. IR (CH₂Cl₂, cm⁻¹): 3419, 2095, 1634, 1548, 1493,
47 1455, 1377, 1097, 741. Anal. Calcd for C₂₆H₂₅N₃O₂: C, 75.89; H, 6.12; N, 10.21; found: C, 75.96; H, 5.95;
48 N, 10.14. R_f = 0.50 (Acetone/Hexane (3:7), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for
49 C₂₆H₂₆N₃O₂ 412.2025; Found 412.1993.

1
2
3 *(dia)*-Ethyl 1-benzyl-5-(2-nitro-1-phenylethyl)indoline-2-carboxylate (**12ca**). Compound **12ca** was
4 obtained using **GP3**. Thin layer chromatography (EtOAc/Hexane (2:8)) gave the product as light yellow
5 oil (82 mg, 56% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.39 – 7.20 (m, =CH, 9H), 7.10 – 7.01 (m, =CH, 1H),
6 6.92 – 6.87 (m, =CH, 2H), 6.39 – 6.23 (m, =CH, 1H), 4.96 – 4.83 (m, CH₂, 2H), 4.79 (t, *J* = 8.2 Hz, CH, 1H),
7 4.49 (d, *J* = 15.4 Hz, A part of AB system, CH₂, 1H), 4.29 (d, *J* = 15.4 Hz, B part of AB system, CH₂, 1H),
8 4.27 – 4.21 (m, CH, 1H), 4.18 – 4.09 (m, CH₂, 2H), 3.34 (dd, *J* = 16.0, 10.4 Hz, CH₂, 1H), 3.16 (m, CH₂,
9 1H), 1.22 (t, *J* = 7.1 Hz, CH₃, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 172.9, 162.0, 151.1, 140.1, 139.9, 138.9,
10 138.3, 137.9, 132.0, 129.2, 129.1, 128.9, 128.83, 128.76, 128.01, 127.9, 127.8, 127.7, 127.6, 127.5,
11 127.44, 127.39, 127.2, 126.5, 125.6, 124.0, 123.8, 121.4, 111.8, 111.1, 107.3, 79.8, 65.8, 61.4, 60.9,
12 52.4, 49.2, 48.8, 48.2, 33.6, 29.9, 14.5, 14.4. R_f = 0.34 (EtOAc/Hexane (2:8), 254 nm). HRMS (APCI-TOF)
13 m/z: [M + H]⁺ Calcd for C₂₆H₂₇N₂O₄ 431.1965; Found 431.1942.

14
15
16
17
18
19
20
21
22 *(dia)*-Ethyl 1-benzyl-5-(2-nitro-1-(4-(trifluoromethyl)phenyl)ethyl)indoline-2-carboxylate (**12cb**).
23 Compound **12cb** was obtained using **GP3**. Thin layer chromatography (EtOAc/Hexane (2:8)) gave the
24 product as light yellow oil (53 mg, 42% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.60 – 7.55 (m, =CH, 2H),
25 7.45 – 7.17 (m, =CH, 7H), 6.91 – 6.78 (m, =CH, 2H), 6.36 – 6.32 (m, =CH, 1H), 4.99 – 4.88 (m, CH₂, 2H),
26 4.87 – 4.80 (m, CH, 1H), 4.49 (d, *J* = 15.5 Hz, A part of AB system, CH₂, 1H), 4.28 (d, *J* = 15.5 Hz, B part
27 of AB system, CH₂, 1H), 4.29 – 4.21 (m, CH, 1H), 4.17 – 4.02 (m, CH₂, 2H), 3.34 (dd, *J* = 16.1, 10.4 Hz,
28 CH₂, 1H), 3.20 – 3.10 (m, CH₂, 1H), 1.21 (t, *J* = 7.1 Hz, CH₃, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 172.8, 161.9,
29 151.4, 144.2, 137.7, 128.84, 128.78, 128.38, 128.31, 128.17, 127.9, 127.6, 127.4, 127.3, 126.30 –
30 125.93 (m), 123.8, 123.7, 107.3, 79.3, 65.6, 61.4, 52.2, 48.5, 33.5, 29.9, 14.3. R_f = 0.28 (EtOAc/Hexane
31 (2:8), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₇H₂₆F₃N₂O₄ 499.1839; Found 499.1825.

32
33
34
35
36
37
38
39
40 *(dia)*-Ethyl 1-benzyl-5-(1-(4-hydroxyphenyl)-2-nitroethyl)indoline-2-carboxylate (**12cc**). Compound
41 **12cc** was obtained using **GP3**. Thin layer chromatography (EtOAc/Hexane (3:7)) gave the product as
42 light yellow oil (62 mg, 46% yield). ¹H NMR (400 MHz, CDCl₃) 7.35 – 7.18 (m, =CH, 5H), 7.12 – 7.00 (m,
43 =CH, 2H), 6.89 – 6.83 (m, =CH, 2H), 6.78 – 6.70 (m, =CH, 2H), 6.36 – 6.31 (m, =CH, 1H), 5.34 (bs, OH,
44 1H), 4.91 – 4.82 (m, CH₂, 2H), 4.70 (t, *J* = 8.2 Hz, CH, 1H), 4.46 (d, *J* = 15.4 Hz, A part AB system, CH₂,
45 1H), 4.27 (d, *J* = 15.4 Hz, B part of AB system, CH₂, 1H), 4.28 – 4.18 (m, CH, 1H), 4.16 – 4.07 (m, CH₂,
46 2H), 3.33 (dd, *J* = 16.1, 10.5 Hz, CH₂, 1H), 3.19 – 3.08 (m, CH₂, 1H), 1.21 (t, *J* = 7.1 Hz, CH₃, 3H). ¹³C NMR
47 (100 MHz, CDCl₃) δ 173.2, 155.2, 155.1, 151.0, 137.8, 132.3, 132.1, 131.8, 129.3, 129.1, 129.0, 128.82,
48 128.76, 128.0, 127.5, 127.3, 127.0, 126.5, 124.0, 123.7, 115.9, 107.3, 80.1, 65.8, 61.5, 61.0, 52.4, 48.4,
49 48.0, 33.6, 14.5, 14.3. R_f = 0.02 (EtOAc/Hexane (3:7), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd
50 for C₂₆H₂₇N₂O₅ 447.1920; Found 447.1890.

(dia)-Ethyl 1-benzyl-5-(1-(4-fluorophenyl)-2-nitroethyl)indoline-2-carboxylate (12cd). Compound **12cd** was obtained using **GP3**. Thin layer chromatography (EtOAc/Hexane (2:8)) gave the product as light yellow oil (74 mg, 55% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.38 – 7.25 (m, =CH, 5H), 7.21 – 7.16 (m, =CH, 2H), 7.04 – 6.97 (m, =CH, 2H), 6.89 – 6.84 (m, =CH, 2H), 6.38 – 6.32 (m, =CH, 1H), 4.91 – 4.84 (m, CH₂, 2H), 4.82 – 4.73 (m, CH, 1H), 4.49 (d, *J* = 15.4 Hz, A part of AB system, CH₂, 1H), 4.29 (d, *J* = 15.4 Hz, B part of AB system, CH₂, 1H), 4.29 – 4.20 (m, CH, 1H), 4.18 – 4.08 (m, CH₂, 2H), 3.34 (dd, *J* = 15.9, 10.4 Hz, CH₂, 1H), 3.23 – 3.04 (m, CH₂, 1H), 1.22 (t, *J* = 7.1 Hz, CH₃, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 172.8, 162.15 (d, *J* = 246.2 Hz), 151.2, 137.9, 135.91 (d, *J* = 3.4 Hz), 129.40 (d, *J* = 8.1 Hz), 128.8, 128.7, 128.25, 128.23, 128.0, 127.5, 127.3, 127.1, 123.9, 123.7, 116.02 (d, *J* = 21.4 Hz), 107.3, 79.8, 65.7, 61.4, 52.3, 48.0, 33.5, 14.4. IR (CH₂Cl₂, cm⁻¹): 3452, 3057, 2983, 2925, 2854, 1890, 1737, 1616, 1606, 1554, 1509, 1497, 1376, 1353, 1265, 1226, 1195, 1161, 1099, 1028, 839, 813, 736. R_f = 0.24 (EtOAc/Hexane (2:8), 254 nm). HRMS (APCI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₆H₂₆FN₂O₄ 449.1877; Found 449.1853.

(dia)-Ethyl 1-benzyl-5-(1-(4-bromophenyl)-2-nitroethyl)indoline-2-carboxylate (12ce). Compound **12ce** was obtained using **GP3**. Thin layer chromatography (EtOAc/Hexane (2:8)) gave the product as light yellow oil (58 mg, 52% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.48 – 7.40 (m, =CH, 2H), 7.34 – 7.19 (m, =CH, 5H), 7.17 – 7.00 (m, =CH, 2H), 6.87 – 6.81 (m, =CH, 2H), 6.35 – 6.31 (m, =CH, 1H), 4.91 – 4.80 (m, CH₂, 2H), 4.76 – 4.67 (m, CH, 1H), 4.48 (d, *J* = 15.5 Hz, A part of AB system, CH₂, 1H), 4.27 (d, *J* = 15.5 Hz, B part of AB system, CH₂, 1H), 4.26 – 4.24 (m, CH, 1H), 4.16 – 4.08 (m, CH₂, 2H), 3.33 (dd, *J* = 16.1, 10.4 Hz, CH₂, 1H), 3.19 – 3.10 (m, CH₂, 1H), 1.21 (t, *J* = 7.1 Hz, CH₃, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 172.8, 161.9, 151.3, 139.2, 138.9, 138.1, 137.8, 132.3, 132.2, 131.3, 129.6, 129.5, 128.83, 128.78, 128.3, 128.25, 128.21, 127.9, 127.54, 127.50, 127.3, 127.1, 126.5, 125.3, 123.8, 123.7, 121.7, 121.5, 121.3, 112.0, 111.0, 107.3, 79.5, 65.7, 61.4, 61.0, 52.3, 48.6, 48.3, 48.2, 33.5, 14.5, 14.4. R_f = 0.28 (EtOAc/Hexane (2:8), 254 nm). HRMS (APCI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₆H₂₆BrN₂O₄ 509.1070; Found 509.1081.

General Procedure 4 (GP4): Preparation of C5-Alkylated Indoles (14aa-ak)

To a solution of *N*-benzyl indoline derivatives (1.0 equiv.) in CH₂Cl₂ (6 mL), DEAD (1.1 equiv.) was added. The mixture was stirred at the room temperature for 2 h, then concentrated and purified by silica gel chromatography to afford desired C5-alkylated indoles.

(±)-1-Benzyl-5-(2-nitro-1-phenylethyl)-1H-indole (14aa). Compound **14aa** was obtained using **GP4**. Column chromatography (EtOAc/Hexane (2:8)) gave the product as light green oil (195 mg, 55% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.50 – 7.49 (m, =CH, 1H), 7.34 – 7.19 (m, =CH, 9H), 7.14 – 7.07 (m, =CH, 3H), 7.03 – 6.99 (m, =CH, 1H), 6.49 (d, *J* = 3.0 Hz, =CH, 1H), 5.27 (s, CH₂, 2H), 5.10 – 4.96 (m, CH, CH₂, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 140.1, 137.2, 135.6, 130.4, 129.03, 129.0, 128.9, 128.8, 127.72, 127.7,

1
2
3 127.3, 126.8, 121.7, 119.8, 110.3, 101.8, 79.8, 50.2, 49.1. IR (CH₂Cl₂, cm⁻¹): 3445, 3029, 2917, 1953,
4 1603, 1551, 1485, 1453, 1377, 1263, 1183, 1078, 884, 804, 760. Anal. Calcd for C₂₃H₂₀N₂O₂: C, 77.51;
5 H, 5.66; N, 7.86; found: C, 77.47; H, 5.77; N, 7.63. Rf = 0.70 (EtOAc/Hexane (4:6), 254 nm). HRMS (APCI-
6 TOF) m/z: [M + H]⁺ Calcd for C₂₃H₂₁N₂O₂ 357.1603; Found 357.1581.
7
8
9

10
11 (*±*)-1-Benzyl-5-(2-nitro-1-(4-(trifluoromethyl)phenyl)ethyl)-1H-indole (**14ab**). Compound **14ab** was
12 obtained using **GP4**. Column chromatography (EtOAc/Hexane (2:8)) gave the product as light green oil
13 (187 mg, 89% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.58 (d, *J* = 8.1 Hz, =CH, 2H), 7.50 (s, =CH, 1H), 7.42
14 (d, *J* = 8.1 Hz, =CH, 2H), 7.33 – 7.27 (m, =CH, 2H), 7.28 – 7.23 (m, =CH, 2H), 7.16 (d, *J* = 3.1 Hz, =CH, 1H),
15 7.12 – 7.11 (m, =CH, 2H), 6.99 (dd, *J* = 8.5, 1.6 Hz, =CH, 1H), 6.53 (d, *J* = 3.1 Hz, =CH, 1H), 5.29 (s, CH₂,
16 2H), 5.11 – 4.99 (m, CH, CH₂, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 144.4, 137.3, 135.9, 129.7, 129.5, 129.3,
17 129.0, 128.3 (2C), 128.0, 127.08, 127.04, 126.1 – 126.0 (m, 1C), 121.7, 120.0, 110.7, 102.0, 79.5, 50.4,
18 49.0. IR (CH₂Cl₂, cm⁻¹): 3434, 2920, 1619, 1553, 1483, 1376, 1326, 1261, 1165, 1116, 1069, 1017, 858,
19 840, 799. Anal. Calcd for C₂₄H₁₉F₃N₂O₂: C, 67.92; H, 4.51; N, 6.60; found: C, 68.03; H, 4.46; N, 6.50. Rf =
20 0.70 (EtOAc/Hexane (4:6), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₄H₂₀F₃N₂O₂ 425.1477;
21 Found 425.1454.
22
23
24
25
26
27
28
29

30
31 (*±*)-4-(1-(1-Benzyl-1H-indol-5-yl)-2-nitroethyl)phenol (**14ac**). Compound **14ac** was obtained using **GP4**.
32 Column chromatography (EtOAc/Hexane (3:7)) gave the product as yellow oil (201 mg, 77% yield). ¹H
33 NMR (400 MHz, CDCl₃) δ 7.50 – 7.49 (m, =CH, 1H), 7.32 – 7.25 (m, =CH, 3H), 7.22 (d, *J* = 8.5 Hz, =CH,
34 1H), 7.16 – 7.08 (m, =CH, 5H), 7.01 (dd, *J* = 8.5, 1.7 Hz, =CH, 1H), 6.76 – 6.68 (m, =CH, 2H), 6.52 (d, *J* =
35 3.1 Hz, =CH, 1H), 5.38 (bs, OH, 1H), 5.26 (s, CH₂, 2H), 5.06 – 4.85 (m, CH, CH₂, 3H). ¹³C NMR (100 MHz,
36 CDCl₃) δ 155.0, 137.5, 135.8, 132.4, 130.9, 129.3, 129.1(2C), 129.0, 127.9, 127.0, 121.9, 119.8, 115.9,
37 110.5, 101.9, 80.2, 50.4, 48.6. IR (CH₂Cl₂, cm⁻¹): 3391, 3028, 2919, 1884, 1703, 1613, 1550, 1514, 1377,
38 1264, 1178, 1045, 885, 814, 732. Anal. Calcd for C₂₃H₂₀N₂O₃: C, 74.18; H, 5.41; N, 7.52; found: C, 74.29;
39 H, 5.23; N, 7.47. Rf = 0.23 (EtOAc/Hexane (4:6), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for
40 C₂₃H₂₁N₂O₃ 373.1552; Found 373.1528.
41
42
43
44
45
46
47

48
49 (*±*)-1-Benzyl-5-(1-(4-fluorophenyl)-2-nitroethyl)-1H-indole (**14ad**). Compound **14ad** was obtained using
50 **GP4**. Column chromatography (EtOAc/Hexane (2:8)) gave the product as light green oil (721 mg, 88%
51 yield). ¹H NMR (400 MHz, CDCl₃) δ 7.53 (s, =CH, 1H), 7.37 – 7.23 (m, =CH, 6H), 7.21 – 7.10 (m, =CH, 3H),
52 7.09 – 6.97 (m, =CH, 3H), 6.60 – 6.52 (m, =CH, 1H), 5.29 (s, CH₂, 2H), 5.09 – 4.91 (m, CH, CH₂, 3H). ¹³C
53 NMR (100 MHz, CDCl₃) δ 162.19 (d, *J* = 245.9 Hz), 137.5, 136.23 (d, *J* = 3.2 Hz), 135.8, 130.5, 129.57 (d,
54 *J* = 8.2 Hz), 129.51, 129.3, 129.0, 128.0, 127.1, 121.8, 119.9, 116.03 (d, *J* = 21.5 Hz), 110.7, 102.0, 80.0,
55 50.4, 48.6. IR (CH₂Cl₂, cm⁻¹): 3674, 3063, 3031, 2922, 2855, 1954, 1889, 1721, 1603, 1551, 1485, 1453,
56 1376, 1303, 1227, 1201, 1161, 1102, 1077, 1029, 1015, 960, 911, 886, 854, 837, 808. Anal. Calcd for
57
58
59
60

$C_{23}H_{19}FN_2O_2$: C, 73.78; H, 5.12; N, 7.48; found: C, 73.72; H, 5.05; N, 7.37. Rf = 0.52 (EtOAc/Hexane (4:6), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for $C_{23}H_{20}FN_2O_2$ 375.1509; Found 375.1484.

(±)-1-Benzyl-5-(1-(4-bromophenyl)-2-nitroethyl)-1H-indole (**14ae**). Compound **14ae** was obtained using **GP4**. Column chromatography (EtOAc/Hexane (2:8)) gave the product as brown oil (320 mg, 90% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.48 – 7.39 (m, =CH, 2H), 7.33 – 7.06 (m, =CH, 9H), 6.98 – 6.93 (m, =CH, 1H), 6.49 (d, J = 3.2 Hz, =CH, 1H), 5.26 (s, CH₂, 2H), 5.03 – 4.91 (m, CH, CH₂, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 139.2, 137.2, 135.6, 132.0, 129.8, 129.4, 129.3, 129.0, 128.8, 127.8, 126.8, 121.5, 121.3, 119.7, 110.5, 101.8, 79.5, 50.3, 48.5. IR (CH₂Cl₂, cm⁻¹): 3434, 2917, 1642, 1551, 1486, 1375, 1262, 1182, 1074, 1010, 729, 701. Anal. Calcd for $C_{23}H_{19}BrN_2O_2$: C, 63.46; H, 4.40; N, 6.44; found: C, 63.32; H, 4.29; N, 6.52 Rf = 0.76 (EtOAc/Hexane (4:6), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for $C_{23}H_{20}BrN_2O_2$ 435.0708; Found 435.0678.

(±)-4-(1-(1-Benzyl-1H-indol-5-yl)-2-nitroethyl)-N,N-dimethylaniline (**14af**). Compound **14af** was obtained using **GP4**. Column chromatography (EtOAc/Hexane (3:7)) gave the product as light green oil (163 mg, 78% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.49 (s, =CH, 1H), 7.32 – 7.24 (m, =CH, 4H), 7.20 (d, J = 8.6 Hz, =CH, 1H), 7.17 – 7.07 (m, =CH, 4H), 7.02 (d, J = 8.6 Hz, =CH, 1H), 6.67 (d, J = 8.6 Hz, =CH, 2H), 6.49 – 6.47 (m, =CH, 1H), 5.27 (s, CH₂, 2H), 4.98 (d, J = 7.4 Hz, CH₂, 2H), 4.94 – 4.85 (m, CH, 1H), 2.90 (s, CH₃, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 137.5, 131.4, 129.04, 129.0, 128.6, 127.9, 127.8, 127.0, 121.9, 119.7, 117.9, 115.9, 112.9, 110.3, 101.9, 80.4, 50.4, 48.5, 29.9. IR (CH₂Cl₂, cm⁻¹): 3473, 2919, 2845, 1733, 1337, 1220, 1079, 1042, 970, 884. Anal. Calcd for $C_{25}H_{25}N_3O_2$: C, 75.16; H, 6.31; N, 10.52; found: C, 75.03; H, 6.21; N, 10.59. Rf = 0.54 (EtOAc/Hexane (4:6), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for $C_{25}H_{26}N_3O_2$ 400.2025; Found 400.2001.

(±)-1-Benzyl-5-(1-(2,5-dimethoxyphenyl)-2-nitroethyl)-1H-indole (**14ag**). Compound **14ag** was obtained using **GP4**. Column chromatography (EtOAc/Hexane (3:7)) gave the product as light green oil (195 mg, 70% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.61 – 7.60 (m, =CH, 1H), 7.35 – 7.20 (m, =CH, 4H), 7.15 – 7.13 (m, =CH, 4H), 6.84 (d, J = 8.6 Hz, =CH, 1H), 6.79 – 6.76 (m, =CH, 2H), 6.54 (d, J = 3.1 Hz, 1H), 5.46 – 5.37 (m, CH, 1H), 5.27 (s, CH₂, 2H), 5.11 (dd, J = 12.9, 8.2 Hz, A part of AB system, CH₂, 1H), 5.02 (dd, J = 12.9, 8.2 Hz, B part of AB system, CH₂, 1H), 3.81 (s, CH₃, 3H), 3.73 (s, CH₃, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 153.9, 151.4, 137.6, 135.9, 130.0, 129.9, 129.2, 129.08, 129.03, 127.9, 127.1, 122.3, 120.3, 115.9, 112.2, 112.1, 110.3, 102.0, 78.8, 56.3, 55.9, 50.4, 43.6. IR (CH₂Cl₂, cm⁻¹): 3029, 3002, 2938, 2912, 2835, 2538, 1956, 1708, 1550, 1497, 1453, 1377, 1240, 1225, 1181, 1047, 1026, 880, 804. Anal. Calcd for $C_{25}H_{24}N_2O_4$: C, 72.10; H, 5.81; N, 6.73; found: C, 72.36; H, 5.90; N, 6.61. Rf = 0.60 (EtOAc/Hexane (4:6), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for $C_{25}H_{25}N_2O_4$ 417.1814; Found 417.1789.

1
2
3 (*±*)-1-Benzyl-5-(2-nitro-1-(3,4,5-trimethoxyphenyl)ethyl)-1H-indole (**14ah**). Compound **14ah** was
4 obtained using **GP4**. Column chromatography (EtOAc/Hexane (3:7)) gave the product as light green oil
5 (556 mg, 86% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.54 (s, =CH, 1H), 7.30 – 7.24 (m, =CH, 4H), 7.15 – 7.14
6 (m, =CH, 1H), 7.12 – 7.10 (m, =CH, 2H), 7.07 – 7.05 (m, =CH, 1H), 6.53 (s, =CH, 3H), 5.27 (s, CH₂, 2H),
7 5.04 – 4.97 (m, CH, CH₂, 3H), 3.84 (s, CH₃, 3H), 3.82 (s, CH₃, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 153.7,
8 137.50, 137.48, 135.93, 135.90, 130.5, 129.4, 129.2, 129.0, 127.9, 127.0, 121.7, 119.9, 110.5, 105.1,
9 102.0, 80.0, 61.0, 56.4, 50.4, 49.5. IR (CH₂Cl₂, cm⁻¹): 3060, 2935, 2839, 1954, 1727, 1590, 1551, 1508,
10 1485, 1422, 1332, 1238, 1184, 1127, 1004, 910, 805, 732. Anal. Calcd for C₂₆H₂₆N₂O₅: C, 69.94; H, 5.87;
11 N, 6.27; found: C, 70.16; H, 6.02; N, 6.09. R_f = 0.47 (EtOAc/Hexane (4:6), 254 nm). HRMS (APCI-TOF)
12 m/z: [M + H]⁺ Calcd for C₂₆H₂₇N₂O₅ 447.1920; Found 447.1890.

13
14
15
16
17
18
19
20
21 (*±*)-5-(1-(1H-indol-5-yl)-2-nitroethyl)-1-benzyl-1H-indole (**14aj**). Compound **14aj** was obtained using
22 **GP4**. Column chromatography (EtOAc/Hexane (4:6)) gave the product as green oil (74 mg, 80% yield).
23 ¹H NMR (400 MHz, CDCl₃) δ 8.08 (bs, NH, 1H), 7.56 (s, =CH, 2H), 7.34 – 7.24 (m, =CH, 4H), 7.21 (d, J =
24 8.6 Hz, =CH, 1H), 7.18 – 7.14 (m, =CH, 1H), 7.14 – 7.05 (m, =CH, 5H), 6.51 – 6.50 (m, =CH, 2H), 5.26 (s,
25 CH₂, 2H), 5.20 – 4.95 (m, CH, CH₂, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 137.6, 135.7, 135.1, 131.8, 131.6,
26 129.13, 129.10, 129.0, 128.3, 127.9, 127.0, 125.0, 122.4, 122.1, 119.9, 119.6, 111.7, 110.4, 102.9,
27 102.0, 80.6, 50.4, 49.4. IR (CH₂Cl₂, cm⁻¹): 3426, 2921, 1633, 1549, 1484, 1377, 1344, 1263, 1183, 1092,
28 883, 803, 764, 730. Anal. Calcd for C₂₅H₂₁N₃O₂: C, 75.93; H, 5.35; N, 10.63; found: C, 75.84; H, 5.22; N,
29 10.47. R_f = 0.32 (EtOAc/Hexane (4:6), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₅H₂₂N₃O₂
30 396.1712; Found 396.1683.

31
32
33
34
35
36
37
38 (*±*)-5-(1-(1H-indol-3-yl)-2-nitroethyl)-1-benzyl-1H-indole (**14ak**). Compound **14ak** was obtained using
39 **GP4**. Column chromatography (EtOAc/Hexane (4:6)) gave the product as light green oil (195 mg, 55%
40 yield). ¹H NMR (400 MHz, CDCl₃) δ 8.02 (bs, NH, 1H), 7.62 (s, =CH, 1H), 7.51 (d, J = 7.9 Hz, =CH, 1H),
41 7.34 – 7.24 (m, =CH, 5H), 7.23 – 7.18 (m, =CH, 2H), 7.16 – 6.99 (m, =CH, 5H), 6.50 – 6.49 (m, =CH, 1H),
42 5.30 (t, J = 8.0 Hz, CH, 1H), 5.26 (s, CH₂, 2H), 5.09 (dd, J = 12.4, 8.0 Hz, A part of AB system, CH₂, 1H),
43 4.97 (dd, J = 12.4, 8.0 Hz, A part of AB system, CH₂, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 137.3, 136.5,
44 135.8, 130.4, 129.0, 128.9, 128.8, 127.7, 126.9, 126.4, 122.5, 121.8, 121.5, 120.0, 119.8, 119.2, 115.4,
45 111.3, 110.1, 101.8, 80.2, 50.2, 41.7. IR (CH₂Cl₂, cm⁻¹): 3417, 2919, 1698, 1620, 1549, 1485, 1455, 1378,
46 1263, 1183, 1094, 910, 803, 734. Anal. Calcd for C₂₅H₂₁N₃O₂: C, 75.93; H, 5.35; N, 10.63; found: C, 75.90;
47 H, 5.46; N, 10.58. R_f = 0.22 (EtOAc/Hexane (4:6), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for
48 C₂₅H₂₂N₃O₂ 396.1712; Found 396.1683.

49
50
51
52
53
54
55
56
57
58 (*±*)-Ethyl 1-benzyl-5-(2-nitro-1-phenylethyl)-1H-indole-2-carboxylate (**14ca**). Compound **14ca** was
59 obtained using **GP4**. Thin layer chromatography (EtOAc/Hexane (2:8)) gave the product as light yellow
60

oil (41 mg, 82% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.58 (s, =CH, 1H), 7.36 – 7.30 (m, =CH, 4H), 7.30 – 7.18 (m, =CH, 6H), 7.17 – 7.13 (m, =CH, 1H), 7.05 (d, J = 6.8 Hz, =CH, 2H), 5.81 – 5.79 (m, CH_2 , 2H), 5.05 – 5.00 (m, CH, CH_2 , 3H), 4.33 (q, J = 7.1 Hz, CH_2 , 2H), 1.36 (t, J = 7.1 Hz, CH_3 , 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 162.0, 139.9, 138.9, 138.3, 132.0, 129.2, 128.8, 128.7, 127.9, 127.7, 127.4, 126.54, 126.50, 125.6, 121.4, 111.8, 111.1, 79.8, 60.9, 49.2, 48.2, 14.5. IR (CH_2Cl_2 , cm^{-1}): 3565, 2917, 2357, 1705, 1552, 1260, 1193, 1096, 730. Anal. Calcd for $\text{C}_{26}\text{H}_{24}\text{N}_2\text{O}_4$: C, 72.88; H, 5.65; N, 6.54; found: C, 72.77; H, 5.73; N, 6.43. Rf = 0.02 (EtOAc/Hexane (2:8), 254 nm). HRMS (APCI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{26}\text{H}_{25}\text{N}_2\text{O}_4$ 429.1814; Found 429.1786.

(±)-Ethyl 1-benzyl-5-(2-nitro-1-(4-(trifluoromethyl)phenyl)ethyl)-1H-indole-2-carboxylate (**14cb**). Compound **14cb** was obtained using **GP4**. Thin layer chromatography (EtOAc/Hexane (2:8)) gave the product as light yellow oil (35 mg, 75% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.60 – 7.52 (m, AA' part of AA'BB' system, =CH, 2H), 7.54 (s, =CH, 1H), 7.42 – 7.37 (m, BB' part of AA'BB' system, =CH, 2H), 7.35 – 7.28 (m, =CH, 2H), 7.27 – 7.16 (m, =CH, 3H), 7.10 (d, J = 8.8 Hz, =CH, 1H), 7.05 – 7.00 (m, =CH, 2H), 5.80 (s, CH_2 , 2H), 5.10 – 4.91 (m, CH, CH_2 , 3H), 4.44 – 4.26 (m, CH_2 , 2H), 1.35 (t, J = 6.2 Hz, CH_3 , 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 161.7, 143.7, 138.8, 137.9, 130.8, 128.8 (2C), 128.6, 128.1, 127.3, 126.4 (2C), 126.3, 125.98 (q, J = 3.7 Hz), 125.0, 121.2, 111.9, 110.8, 79.0, 60.8, 48.7, 48.0, 14.2. IR (CH_2Cl_2 , cm^{-1}): 3328, 2982, 2960, 2727, 2855, 1799, 1711, 1619, 1556, 1524, 1454, 1413, 1376, 1326, 1254, 1191, 1124, 1070, 1018, 752, 703. Anal. Calcd for $\text{C}_{27}\text{H}_{23}\text{F}_3\text{N}_2\text{O}_4$: C, 65.32; H, 4.67; N, 5.64; found: C, 65.00; H, 4.96; N, 5.56. Rf = 0.41 (EtOAc/Hexane (2:8), 254 nm). HRMS (APCI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{27}\text{H}_{24}\text{F}_3\text{N}_2\text{O}_4$ 497.1688; Found 497.1656.

(±)-Ethyl 1-benzyl-5-(1-(4-hydroxyphenyl)-2-nitroethyl)-1H-indole-2-carboxylate (**14cc**). Compound **14cc** was obtained using **GP4**. Thin layer chromatography (EtOAc/Hexane (3:7)) gave the product as light yellow oil (53 mg, 80% yield). ^1H NMR (400 MHz, Acetone- d_6) δ 8.34 (s, =CH, 1H), 7.74 (s, =CH, 1H), 7.46 (d, J = 8.7 Hz, =CH, 1H), 7.37 – 7.30 (m, =CH, 2H), 7.27 – 7.16 (m, =CH, 5H), 7.08 (d, J = 7.3 Hz, =CH, 2H), 6.80 (d, J = 8.5 Hz, =CH, 2H), 5.88 (s, CH_2 , 2H), 5.23 (dd, J = 8.3, 2.0 Hz, CH_2 , 2H), 4.94 (t, J = 8.3 Hz, CH, 1H), 4.31 (q, J = 7.1 Hz, CH_2 , 2H), 1.32 (t, J = 7.1 Hz, CH_3 , 3H). ^{13}C NMR (100 MHz, Acetone- d_6) δ 161.7, 156.7, 138.9, 138.8, 133.6, 131.6, 129.1, 128.7, 128.5, 127.3, 126.7, 126.5, 125.7, 121.2, 115.7, 111.8, 110.7, 79.5, 60.6, 48.6, 47.7, 13.9. IR (CH_2Cl_2 , cm^{-1}): 2917, 1706, 1360, 1190. Anal. Calcd for $\text{C}_{26}\text{H}_{24}\text{N}_2\text{O}_5$: C, 70.26; H, 5.44; N, 6.30; Found: C, 70.32; H, 5.31; N, 6.23. Rf = 0.12 (EtOAc/Hexane (3:7), 254 nm). HRMS (APCI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{26}\text{H}_{25}\text{N}_2\text{O}_5$ 445.1763; Found 445.1732.

(±)-Ethyl 1-benzyl-5-(1-(4-fluorophenyl)-2-nitroethyl)-1H-indole-2-carboxylate (**14cd**). Compound **14cd** was obtained using **GP4**. Thin layer chromatography (EtOAc/Hexane (2:8)) gave the product as light yellow oil (34 mg, 72% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.52 (s, =CH, 1H), 7.33 (s, =CH, 1H), 7.29 –

1
2
3 7.17 (m, =CH, 6H), 7.12 – 7.05 (m, =CH, 1H), 7.05 – 6.93 (m, =CH, 4H), 5.78 (s, CH₂, 2H), 4.97 (s, CH, CH₂,
4 3H), 4.31 (q, *J* = 7.1 Hz, CH₂, 2H), 1.33 (t, *J* = 7.1 Hz, CH₃, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.5 (d, *J* =
5 246.6 Hz), 160.8, 138.7, 138.0 (2C), 135.44 (d, *J* = 3.1 Hz), 131.6 (2C), 129.3 (d, *J* = 8.1 Hz), 128.6, 127.3,
6 126.3, 125.2, 121.0, 115.9 (d, *J* = 21.5 Hz), 111.7, 110.8, 79.5, 60.8, 48.2, 48.0, 14.3. IR (CH₂Cl₂, cm⁻¹):
7 3338, 3030, 2982, 2929, 2872, 2255, 1884, 1499, 1709, 1604, 1554, 1523, 1509, 1468, 1453, 1411,
8 1376, 1254, 1192, 1097, 1026, 910, 810, 729. Anal. Calcd for C₂₆H₂₃FN₂O₄: C, 69.94; H, 5.19; N, 6.27;
9 found: C, 69.75; H, 5.11; N, 6.34. R_f = 0.25 (EtOAc/Hexane (2:8), 254 nm). HRMS (APCI-TOF) *m/z*: [M +
10 H]⁺ Calcd for C₂₆H₂₄FN₂O₄ 447.1720; Found 447.1694.

11
12
13
14
15
16
17 (*±*)-Ethyl 1-benzyl-5-(1-(4-bromophenyl)-2-nitroethyl)-1H-indole-2-carboxylate (**14ce**). Compound **14ce**
18 was obtained using **GP4**. Thin layer chromatography (EtOAc/Hexane (2:8)) gave the product as light
19 yellow oil (35 mg, 78% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.52 (s, =CH, 1H), 7.46 – 7.40 (m, AA' part of
20 AA'BB' system, =CH, 2H), 7.33 (s, =CH, 1H), 7.30 – 7.16 (m, =CH, 4H), 7.15 – 7.05 (m, =CH, 3H), 7.05 –
21 7.00 (m, =CH, 2H), 5.79 (s, CH₂, 2H), 5.07 – 4.85 (m, CH, CH₂, 3H), 4.32 (q, *J* = 7.0 Hz, CH₂, 2H), 1.34 (t, *J*
22 = 7.0 Hz, CH₃, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 161.7, 138.74, 138.70, 137.9, 132.1 (2C), 131.2, 129.4,
23 128.7, 128.6, 127.3, 126.3, 125.1, 121.5, 121.1, 111.8, 110.8, 79.2, 60.8, 48.4, 48.0, 14.3. IR (CH₂Cl₂,
24 cm⁻¹): 3386, 2982, 2927, 2254, 1895, 1799, 1708, 1554, 1524, 1489, 1453, 1376, 1254, 1191, 1096,
25 1011, 909, 731. Anal. Calcd for C₂₆H₂₃BrN₂O₄: C, 61.55; H, 4.57; N, 5.52; found: C, 61.39; H, 4.50; N,
26 5.58. R_f = 0.46 (EtOAc/Hexane (2:8), 254 nm). HRMS (APCI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₆H₂₄BrN₂O₄
27 507.0919; Found 507.0894.

28
29
30
31
32
33
34
35
36
37 **Catalytic hydrogenation of 12aa:** (*±*)-1-Benzyl-5-(2-nitro-1-phenylethyl)indoline (**12aa**) (50 mg, 0.14
38 mmol) was dissolved in MeOH (5 mL) and 10% Pd/C (10 mg) was added. The mixture was stirred in H₂
39 atmosphere for 14 h. The Pd/C was removed by filtration and the solvent was evaporated, and the
40 product mixture was not separated by silica gel column chromatography.

41 42 43 44 **General Procedure 5 (GP5): N-Debenzylation with *t*-BuOK/DMSO and Oxygen**

45
46 DMSO (5 mL, 24 mmol) was added to a flame dried flask followed by (*±*)-1-benzyl-5-(2-nitro-1-
47 phenylethyl)indoline (428 mg, 1.39 mmol). Then *t*-BuOK (1.10 g, 9.76 mmol) was added to the mixture
48 and oxygen was bubbled into the solution, via a gas dispersion tube, for 10 min. Upon completion
49 (determined by TLC) the reaction was quenched with saturated ammonium chloride solution. The
50 product was extracted three times with EtOAc. The organic layers were combined, dried over Na₂SO₄
51 and concentrated. Products were purified by thin layer chromatography.

52
53
54
55
56
57 (*1H-Indol-5-yl*)(phenyl)methanone (**18**).⁴⁷ Compound **18** was obtained using **GP5**. Thin layer
58 chromatography (EtOAc/Hexane (2:8)) gave **18** as first fraction (120 mg, 39% yield; brown crystals, mp
59
60

1
2
3 146–147 °C (CH₂Cl₂/Hexane)). ¹H NMR (400 MHz, CDCl₃) δ 8.85 (bs, NH, 1H), 8.14 (s, =CH, 1H), 7.86 –
4 7.77 (m, =CH, 3H), 7.61 – 7.55 (m, =CH, 1H), 7.52 – 7.42 (m, =CH, 3H), 7.31 – 7.29 (m, =CH, 1H), 6.69 –
5 6.60 (m, =CH, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 197.7, 139.0, 138.4, 131.7, 130.0, 129.6, 128.2, 127.2,
6 125.9, 125.4, 124.2, 111.2, 104.2. IR (CH₂Cl₂, cm⁻¹): 3429, 2916, 2851, 2088, 1637, 1608, 1573, 1445,
7 1422, 1350, 1326, 1115, 1097, 881, 768. Anal. Calcd for C₁₅H₁₁NO: C, 81.43; H, 5.01; N, 6.33; found: C,
8 81.38; H, 5.08; N, 6.18. Rf = 0.35 (EtOAc/Hexane (3:7), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd
9 for C₁₅H₁₂NO 222.0919; Found 222.0896.

10
11
12
13
14
15
16 *(1-Benzylindoline-5-yl)(phenyl)methanone (19)*. Compound **19** was obtained using **GP5**. Thin layer
17 chromatography (EtOAc/Hexane (2:8)) gave **19** as second fraction (yellow oil, 55 mg, 42% yield). ¹H
18 NMR (400 MHz, CDCl₃) δ 7.74 – 7.68 (m, =CH, 2H), 7.68 – 7.66 (m, =CH, 1H), 7.63 – 7.59 (m, =CH, 1H),
19 7.53 – 7.48 (m, =CH, 1H), 7.47 – 7.41 (m, =CH, 2H), 7.38 – 7.24 (m, =CH, 5H), 6.43 (d, *J* = 8.3 Hz, 1H),
20 4.40 (s, CH₂, 2H), 3.54 (t, *J* = 8.5 Hz, CH₂, 2H), 3.07 (t, *J* = 8.5 Hz, CH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ
21 195.3, 156.3, 139.7, 137.3, 133.6, 131.2, 129.8, 129.6, 128.9, 128.2, 127.8, 127.7, 127.0, 126.6, 104.4,
22 52.7, 51.7, 27.8. IR (CH₂Cl₂, cm⁻¹): 3440, 2917, 2845, 2089, 1634, 1602, 1443, 1265, 1093, 739. Anal.
23 Calcd for C₂₂H₁₉NO: C, 84.31; H, 6.11; N, 4.47; found: C, 84.22; H, 6.09; N, 4.32. Rf = 0.60 (EtOAc/Hexane
24 (3:7), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₂H₂₀NO 314.1545; Found 314.1524.

25
26
27
28
29
30
31
32 *(1-Benzyl-1H-indol-5-yl)(phenyl)methanone (20)*. Compound **20** was obtained using **GP5**. Thin layer
33 chromatography (EtOAc/Hexane (2:8)) gave the product **20** as brown crystals (42 mg, 48% yield; mp
34 98–99 °C (CH₂Cl₂/Hexane)). ¹H NMR (400 MHz, CDCl₃) δ 8.13 (d, *J* = 1.5 Hz, =CH, 1H), 7.78 (ddd, *J* = 10.7,
35 7.8, 3.4 Hz, =CH, 3H), 7.59 – 7.52 (m, =CH, 1H), 7.50 – 7.43 (m, =CH, 2H), 7.37 – 7.23 (m, =CH, 4H), 7.19
36 (d, *J* = 3.0 Hz, =CH, 1H), 7.11 (d, *J* = 6.5 Hz, =CH, 2H), 6.63 (d, *J* = 3.0 Hz, =CH, 1H), 5.35 (s, CH₂, 2H). ¹³C
37 NMR (100 MHz, CDCl₃) δ 197.2, 139.0, 138.6, 136.9, 131.6, 129.91, 129.86, 129.5, 128.9, 128.1, 127.95,
38 127.91, 126.8, 125.5, 124.0, 109.6, 103.6, 50.3. IR (CH₂Cl₂, cm⁻¹): 3429, 2916, 2851, 2088, 1637, 1608,
39 1573, 1445, 1422, 1350, 1326, 1115, 1097, 881, 768. Anal. Calcd for C₂₂H₁₇NO: C, 84.86; H, 5.50; N,
40 4.50; found: C, 84.58; H, 5.68; N, 4.40. Rf = 0.36 (EtOAc/Hexane (3:7), 254 nm). HRMS (APCI-TOF) m/z:
41 [M + H]⁺ Calcd for C₂₂H₁₈NO 312.1388; Found 312.1381.

42 43 44 45 46 47 48 49 **General Procedure 6 (GP6): Debenzylation of C5-alkylated *N*-benzyl indolines (22aa-ai)**

50
51
52 To a stirred solution of *N*-benzyl indoline derivative (1 equiv.) in MeOH/CH₂Cl₂ (1:1; 6 mL), Boc₂O (1.5
53 equiv.) and 10% Pd/C (0.4 equiv.) was added. The mixture was stirred on H₂ atmosphere for 15h. After
54 the reaction is over, the mixture was filtered and evaporated. The residue was dissolved in CH₂Cl₂ (3
55 mL) and then was added TFA (1 mL). The reaction mixture was stirred for 2 h at ambient temperature,
56 solvent was removed under reduced pressure. The residue was dissolved in EtOAc (40 mL) and washed
57
58
59
60

with saturated NaHCO₃ and brine. The combined organic phase was dried with Na₂SO₄ and the solvent was evaporated to afford debenzoylation products.

(±)-5-(2-Nitro-1-phenylethyl)indoline (**22aa**). Compound **22aa** was obtained using **GP6**. Column chromatography (EtOAc/Hexane (1:9)) gave the product as light yellow oil (230 mg, 93% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.37 – 7.28 (m, =CH, 2H), 7.28 – 7.19 (m, =CH, 3H), 6.97 (s, =CH, 1H), 6.88 (d, *J* = 8.0 Hz, =CH, 1H), 6.56 (d, *J* = 8.0 Hz, =CH, 1H), 5.01 – 4.86 (m, CH₂, 2H), 4.80 (t, *J* = 8.2 Hz, CH, 1H), 3.70 (bs, NH, 1H), 3.53 (t, *J* = 8.4 Hz, CH₂, 2H), 2.98 (t, *J* = 8.4 Hz, CH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 151.4, 140.3, 130.5, 129.4, 129.1, 127.8, 127.5, 126.8, 124.3, 109.6, 79.9, 48.9, 47.67, 30.0. IR (CH₂Cl₂, cm⁻¹): 3390, 3059, 3028, 2957, 2923, 2851, 1616, 1549, 1495, 1476, 1433, 1377, 1321, 1254, 1184, 1104, 1055, 1028, 888, 813, 735. Anal. Calcd for C₁₆H₁₆N₂O₂: C, 71.62; H, 6.01; N, 10.44; found: C, 71.81; H, 6.15; N, 10.31. R_f = 0.28 (EtOAc/Hexane (3:7), 254 nm). HRMS (APCI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₆H₁₇N₂O₂ 269.1290; Found 269.1270.

(±)-5-(2-Nitro-1-(4-(trifluoromethyl)phenyl)ethyl)indoline (**22ab**). Compound **22ab** was obtained using **GP6**. Column chromatography (EtOAc/Hexane (1:9)) gave the product as light green oil (245 mg, 93% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.58 – 7.54 (m, AA' part of AA'BB' system, =CH, 2H), 7.38 – 7.34 (m, BB' part of AA'BB' system, =CH, 2H), 6.91 (s, =CH, 1H), 6.83 (d, *J* = 8.0 Hz, =CH, 1H), 6.54 (d, *J* = 8.0 Hz, =CH, 1H), 4.99 – 4.89 (m, CH₂, 2H), 4.88 – 4.80 (m, CH, 1H), 3.74 (bs, NH, 1H), 3.52 (t, *J* = 8.4 Hz, CH₂, 2H), 2.96 (t, *J* = 8.4 Hz, CH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 151.5, 144.2, 130.5, 128.1, 128.0 (2C), 126.6, 125.9 (q, *J* = 3.7 Hz), 125.4, 124.0, 109.4, 79.2, 48.4, 47.4, 29.7. IR (CH₂Cl₂, cm⁻¹): 3646, 3393, 2922, 2851, 1725, 1618, 1554, 1497, 1165, 1116, 1018, 889. Anal. Calcd for C₁₇H₁₅F₃N₂O₂: C, 60.71; H, 4.50; N, 8.33; found: C, 60.94; H, 4.54; N, 8.40. R_f = 0.14 (EtOAc/Hexane (3:7), 254 nm). HRMS (APCI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₇H₁₆F₃N₂O₂ 337.1164; Found 337.1144.

(±)-4-(1-(Indolin-5-yl)-2-nitroethyl)phenol (**22ac**). Compound **22ac** was obtained using **GP6**. Column chromatography (EtOAc/Hexane (2:8)) gave the product as brown crystals (198 mg, 87% yield; mp 133–134 °C (CH₂Cl₂/Hexane)). ¹H NMR (400 MHz, CDCl₃) δ 6.96 – 6.92 (m, =CH, 3H), 6.83 (d, *J* = 8.0 Hz, =CH, 1H), 6.58 (d, *J* = 8.0 Hz, =CH, 1H), 6.54 (d, *J* = 8.3 Hz, =CH, 2H), 5.54 (bs, NH, OH, 2H), 4.82 (d, *J* = 8.2 Hz, CH₂, 2H), 4.68 (t, *J* = 8.2 Hz, CH, 1H), 3.45 – 3.43 (m, CH₂, 2H), 2.90 (t, *J* = 8.0 Hz, CH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 155.3, 149.8, 131.5, 131.1, 130.1, 128.8, 126.7, 124.3, 115.8, 110.8, 79.9, 47.9, 47.4, 29.8. IR (CH₂Cl₂, cm⁻¹): 3348, 3021, 2958, 2918, 2850, 2687, 2611, 1886, 1613, 1550, 1514, 1445, 1438, 1378, 1322, 1250, 1176, 1105, 1056, 834. Anal. Calcd for C₁₆H₁₆N₂O₃: C, 67.59; H, 5.67; N, 9.85; found: C, 67.52; H, 5.59; N, 9.88. R_f = 0.11 (EtOAc/Hexane (3:7), 254 nm). HRMS (APCI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₆H₁₇N₂O₃ 285.1239; Found 285.1217.

1
2
3 (*±*)-5-(1-(4-Fluorophenyl)-2-nitroethyl)indoline (**22ad**). Compound **22ad** was obtained using **GP6**.
4 Column chromatography (EtOAc/Hexane (1:9)) gave the product as yellow oil (207 mg, 83% yield). ¹H
5 NMR (400 MHz, CDCl₃) δ 7.22 – 7.15 (m, =CH, 2H), 7.02 – 6.93 (m, =CH, 2H), 6.92 – 6.87 (m, =CH, 1H),
6 6.85 – 6.77 (m, =CH, 1H), 6.59 – 6.46 (m, =CH, 1H), 4.93 – 4.80 (m, CH₂, 2H), 4.76 (dd, *J* = 13.9, 7.5 Hz,
7 CH, 1H), 3.56 (bs, NH, 1H), 3.51 (m, CH₂, 2H), 2.95 (m, CH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 161.9 (d,
8 *J* = 246.3 Hz), 151.2, 135.8 (d, *J* = 2.9 Hz), 130.3, 129.2 (d, *J* = 8.0 Hz), 128.9, 126.5, 124.0, 115.8 (d, *J* =
9 21.4 Hz), 109.4, 79.7, 47.9, 47.4, 29.7. IR (CH₂Cl₂, cm⁻¹): 3392, 3048, 3018, 2958, 2921, 2853, 2741,
10 2853, 2741, 1890, 1724, 1615, 1604, 1547, 1508, 1477, 1435, 1377, 1321, 1253, 1226, 1161, 1101,
11 1056, 1025, 890, 835. Anal. Calcd for C₁₆H₁₅FN₂O₂: C, 67.12; H, 5.28; N, 9.78; found: C, 67.09; H, 5.12;
12 N, 9.66. Rf = 0.14 (EtOAc/Hexane (3:7), 254 nm). HRMS (APCI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₆H₁₆FN₂O₂
13 287.1196; Found 287.1175.
14
15
16
17
18
19
20
21

22 (*±*)-4-(1-(Indoline-5-yl)-2-nitroethyl)-*N,N*-dimethylaniline (**22af**). Compound **22af** was obtained using
23 **GP6**. Column chromatography (EtOAc/Hexane (2:8)) gave the product as brown crystals (350 mg, 80%
24 yield; mp 89–90 °C (CH₂Cl₂/Hexane)). ¹H NMR (400 MHz, CDCl₃) δ 7.09 – 7.03 (m, AA' part of AA'BB'
25 system, =CH, 2H), 6.92 (s, =CH, 1H), 6.83 (d, *J* = 7.9 Hz, =CH, 1H), 6.66 – 6.61 (m, AA' part of AA'BB'
26 system, =CH, 2H), 6.48 (d, *J* = 7.9 Hz, =CH, 1H), 4.83 (d, *J* = 8.1 Hz, CH₂, 2H), 4.66 (t, *J* = 8.1 Hz, CH, 1H),
27 3.62 (bs, NH, 1H), 3.44 (t, *J* = 8.4 Hz, CH₂, 2H), 2.90 (t, *J* = 8.4 Hz, CH₂, 2H), 2.87 (s, CH₃, 6H). ¹³C NMR
28 (100 MHz, CDCl₃) δ 150.9, 149.7, 130.2, 130.1, 128.3, 127.7, 126.5, 124.1, 112.8, 109.4, 80.1, 47.9, 47.5,
29 40.6, 29.8. IR (CH₂Cl₂, cm⁻¹): 3389, 2918, 2851, 1773, 1729, 1614, 1549, 1521, 1496, 1444, 1377, 1254,
30 1165, 1057, 946, 817. Anal. Calcd for C₁₈H₂₁N₃O₂: C, 69.43; H, 6.80; N, 13.49; found: C, 69.38; H, 6.70;
31 N, 13.34. Rf = 0.17 (EtOAc/Hexane (3:7), 254 nm). HRMS (APCI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₈H₂₂N₃O₂
32 312.1712; Found 312.1691.
33
34
35
36
37
38
39
40
41

42 (*±*)-5-(1-(2,5-Dimethoxyphenyl)-2-nitroethyl)indoline (**22ag**). Compound **22ag** was obtained using **GP6**.
43 Column chromatography (EtOAc/Hexane (2:8)) gave the product as light brown oil (221 mg, 87% yield).
44 ¹H NMR (400 MHz, CDCl₃) δ 6.98 (s, =CH, 1H), 6.89 (d, *J* = 8.0 Hz, =CH, 1H), 6.78 (d, *J* = 8.8 Hz, =CH, 1H),
45 6.73 – 6.69 (m, =CH, 1H), 6.68 – 6.65 (m, =CH, 1H), 6.52 (d, *J* = 8.0 Hz, =CH, 1H), 5.16 – 5.04 (m, CH, 1H),
46 4.95 (dd, *J* = 12.7, 7.1 Hz, A part of AB system, CH₂, 1H), 4.84 (dd, *J* = 12.7, 9.2 Hz, B part of AB system,
47 CH₂, 1H), 3.76 (s, CH₃, 3H), 3.69 (s, CH₃, 3H), 3.62 (bs, NH, 1H), 3.47 (t, *J* = 8.4 Hz, CH₂, 2H), 2.94 (t, *J* =
48 8.4 Hz, CH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 153.6, 151.1, 151.0, 130.0, 129.6, 128.5, 126.9, 124.4,
49 115.5, 111.93, 111.87, 109.3, 78.4, 56.1, 55.6, 47.5, 42.9, 29.8. IR (CH₂Cl₂, cm⁻¹): 3388, 2935, 2837,
50 2047, 1616, 1588, 1551, 1997, 1446, 1377, 1239, 1228, 1082, 1024, 807. Anal. Calcd for C₁₈H₂₀N₂O₄: C,
51 65.84; H, 6.14; N, 8.53; found: C, 65.72; H, 6.10; N, 8.40. Rf = 0.15 (EtOAc/Hexane (4:6), 254 nm). HRMS
52 (APCI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₈H₂₁N₂O₄ 329.1501; Found 329.1478.
53
54
55
56
57
58
59
60

1
2
3 (*±*)-5-(2-Nitro-1-(3,4,5-trimethoxyphenyl)ethyl)indoline (**22ah**). Compound **22ah** was obtained using
4 **GP6**. Column chromatography (EtOAc/Hexane (2:8)) gave the product as light green oil (260 mg, 85%
5 yield). ¹H NMR (400 MHz, CDCl₃) δ 6.95 (s, =CH, 1H), 6.87 (d, *J* = 8.0 Hz, =CH, 1H), 6.54 (d, *J* = 8.0 Hz,
6 =CH, 1H), 6.44 (s, =CH, 2H), 4.96 – 4.78 (m, CH₂, 2H), 4.72 (t, *J* = 8.2 Hz, CH, 1H), 3.80 (s, CH₃, 9H), 3.69
7 (bs, NH, 1H), 3.51 (t, *J* = 8.2 Hz, CH₂, 2H), 2.96 (t, *J* = 8.2 Hz, CH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 153.4,
8 151.2, 137.2, 135.6, 130.3, 128.9, 126.4, 124.0, 109.3, 104.8, 79.7, 60.8, 56.2, 48.9, 47.4, 29.7. IR
9 (CH₂Cl₂, cm⁻¹): 3442, 2924, 2840, 1620, 1551, 1497, 1462, 1328, 1247, 1126, 1005, 739. Anal. Calcd for
10 C₁₉H₂₂N₂O₅: C, 63.68; H, 6.19; N, 7.82; found: C, 63.75; H, 6.10; N, 7.71. R_f = 0.12 (EtOAc/Hexane (4:6),
11 254 nm). HRMS (APCI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₉H₂₃N₂O₅ 359.1607; Found 359.1583.

12
13
14
15
16
17
18
19 (*±*)-5-(1-(Furan-2-yl)-2-nitroethyl)indoline (**22ai**). Compound **22ai** was obtained using **GP6**. Column
20 chromatography (EtOAc/Hexane (2:8)) gave the product as dark yellow oil (175 mg, 87% yield). ¹H NMR
21 (400 MHz, CDCl₃) δ 7.35 – 7.31 (m, =CH, 1H), 7.00 – 6.96 (m, =CH, 1H), 6.90 – 6.85 (m, =CH, 1H), 6.59 –
22 6.42 (m, =CH, 1H), 6.34 – 6.24 (m, =CH, 1H), 6.10 – 6.05 (m, =CH, 1H), 4.97 – 4.89 (m, CH, 1H), 4.81 –
23 4.75 (m, CH₂, 1H), 4.74 – 4.65 (m, CH₂, 1H), 3.73 (bs, NH, 1H), 3.57 – 3.41 (m, CH₂, 2H), 3.00 – 2.92 (m,
24 CH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 153.0, 151.6, 142.3, 130.2, 127.0, 126.7, 124.1, 110.4, 109.4,
25 107.0, 78.6, 47.5, 43.2, 29.7. IR (CH₂Cl₂, cm⁻¹): 3441, 2089, 1633, 1552, 1497, 1377, 1260, 739. Anal.
26 Calcd for C₁₄H₁₄N₂O₃: C, 65.11; H, 5.46; N, 10.85; found: C, 65.02; H, 5.38; N, 10.81. R_f = 0.28
27 (EtOAc/Hexane (3:7), 254 nm). HRMS (APCI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₄H₁₅N₂O₃ 259.1083; Found
28 259.1062.

35 36 37 **General Procedure 7 (GP7): Preparation of Unprotected Indoles (23aa-ai)**

38
39 The C5-substitued indoline derivatives (**22aa-ai**) (1equiv.) was dissolved in CH₂Cl₂ (6 mL) and then DEAD
40 (1.1 mmol) was added to the solution. The reaction mixture was stirred for 2 h at room temperature.
41 After the reaction is over (monitored by TLC), the solution was concentrated on a rotary evaporator.
42 The residue was purified by silica gel column chromatography to obtain the C5-substitued 1*H*-indole
43 derivatives.

44
45
46
47
48 (*±*)-5-(2-Nitro-1-phenylethyl)-1*H*-indole (**23aa**). Compound **23aa** was obtained using **GP7**. Column
49 chromatography (EtOAc/Hexane (2:8)) gave the product as dark yellow oil (100 mg, 48% yield). ¹H NMR
50 (400 MHz, CDCl₃) δ 8.14 (s, NH, 1H), 7.52 (s, =CH, 1H), 7.35 - 7.26 (m, =CH, 5H), 7.25 – 7.20 (m, =CH,
51 2H), 7.05 (dd, *J* = 8.4 Hz, 1.4 Hz, =CH, 1H), 6.53 – 6.50 (m, =CH, 1H), 5.05 (s, CH, CH₂, 3H). ¹³C NMR (100
52 MHz, CDCl₃) δ 140.3, 135.2, 130.8, 129.1, 128.3, 127.9, 127.5, 125.3, 122.2, 119.7, 111.9, 102.8, 80.0,
53 49.3. IR (CH₂Cl₂, cm⁻¹): 3368, 1794, 1735, 1552, 1378, 1265, 1097, 894, 765. R_f=0.26 (EtOAc/Hexane
54 (2:8), 254 nm). HRMS (APCI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₆H₁₅N₂O₂ 267.1134; Found 267.1124.
55
56
57
58
59
60

1
2
3 (\pm)-5-(2-Nitro-1-(4-(trifluoromethyl)phenyl)ethyl)-1H-indole (**23ab**). Compound **23ab** was obtained
4 using **GP7**. Column chromatography (EtOAc/Hexane (2:8)) gave the product as dark yellow crystals
5 (456 mg, 46% yield; mp 92–93 °C (CH₂Cl₂/Hexane)). ¹H NMR (400 MHz, CDCl₃) δ 8.24 (s, NH, 1H), 7.59
6 (d, *J* = 8.2 Hz, =CH, 2H), 7.52 (m, =CH, 1H), 7.41 (d, *J* = 8.2 Hz, =CH, 2H), 7.32 (d, *J* = 8.4 Hz, =CH, 1H),
7 7.23 – 7.15 (m, =CH, 2H) 7.03 (dd, *J* = 8.4, 1.8 Hz, =CH, 1H), 6.55 (dd, *J* = 2.6, 1.7 Hz, =CH, 1H), 5.18 –
8 4.93 (m, CH, CH₂, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 144.5, 135.4, 130.0, 129.6, 128.5, 128.3, 126.2 –
9 126.0 (m, 1C), 125.6, 122.0, 119.8 – 119.7 (m, 1C), 112.2, 102.8, 79.5, 49.1. IR (CH₂Cl₂, cm⁻¹): 3426,
10 1554, 1326, 1165, 1115, 1018, 865, 732. Rf=0.13 (EtOAc/Hexane (2:8), 254 nm). HRMS (APCI-TOF) m/z:
11 [M + H]⁺ Calcd for C₁₇H₁₄F₃N₂O₂ 335.1007; Found 335.0995.
12
13
14
15
16
17
18

19 (\pm)-4-(1-(1H-indole-5-yl)-2-nitroethyl)phenol (**23ac**). Compound **23ac** was obtained using **GP7**. Column
20 chromatography (EtOAc/Hexane (3:7)) gave the product as dark yellow oil (384 mg, 54% yield). ¹H NMR
21 (400 MHz, CDCl₃) δ 8.16 (s, NH, 1H), 7.48 (s, =CH, 1H), 7.29 (d, *J* = 8.5 Hz, =CH, 1H), 7.20 – 7.15 (m, =CH,
22 1H), 7.12 (d, *J* = 8.6 Hz, =CH, 2H), 7.01 (dd, *J* = 8.5, 1.6 Hz, =CH, 1H), 6.72 (d, *J* = 8.6 Hz, =CH, 2H), 6.50
23 (d, *J* = 2.2 Hz, =CH, 1H), 5.04 – 4.88 (m, CH, OH, CH₂, 4H). ¹³C NMR (100 MHz, CDCl₃) δ 154.9, 135.1,
24 132.5, 131.1, 129.1, 128.3, 125.2, 122.1, 119.5, 115.9, 111.8, 102.8, 80.2, 48.6. IR (CH₂Cl₂, cm⁻¹): 3420,
25 1613, 1548, 1378, 1261, 1177, 814, 733. Rf=0.10 (EtOAc/Hexane (2:8), 254 nm). HRMS (APCI-TOF) m/z:
26 [M + H]⁺ Calcd for C₁₆H₁₅N₂O₃ 283.1083; Found 283.1083.
27
28
29
30
31
32

33 (\pm)-5-(1-(4-Fluorophenyl)-2-nitroethyl)-1H-indole (**23ad**). Compound **23ad** was obtained using **GP7**.
34 Column chromatography (EtOAc/Hexane (2:8)) gave the product as dark yellow crystals (285 mg, 46%
35 yield; mp 114–115 °C (CH₂Cl₂/Hexane)). ¹H NMR (400 MHz, CDCl₃) δ 8.19 (s, NH, 1H), 7.49 (s, =CH, 1H),
36 7.35 – 7.16 (m, =CH, 4H), 7.04 – 6.98 (m, =CH, 3H), 6.54 – 6.51 (m, =CH, 1H), 5.01 (s, CH, CH₂, 3H). ¹³C
37 NMR (100 MHz, CDCl₃) δ 162.2 (d, *J* = 246.2 Hz), 136.2 (d, *J* = 3.4 Hz), 135.3, 130.7, 129.5 (d, *J* = 8.0 Hz),
38 128.4, 125.5, 122.0, 119.6, 116.0 (d, *J* = 21.4 Hz), 112.0, 102.8, 80.0, 48.6. IR (CH₂Cl₂, cm⁻¹): 3426, 1557,
39 1377, 1224, 1160, 1015, 811, 731. Rf=0.12 (EtOAc/Hexane (2:8), 254 nm). HRMS (APCI-TOF) m/z: [M +
40 H]⁺ Calcd for C₁₆H₁₄FN₂O₂ 285.1039; Found 285.1028.
41
42
43
44
45
46
47

48 (\pm)-4-(1-(1H-indole-5-yl)-2-nitroethyl)-N,N-dimethylaniline (**23af**). Compound **23af** was obtained using
49 **GP7**. Column chromatography (EtOAc/Hexane (3:7)) gave the product as dark yellow oil (374 mg, 40%
50 yield). ¹H NMR (400 MHz, CDCl₃) δ 8.18 (s, NH, 1H), 7.58 (s, =CH, 1H), 7.23 (d, *J* = 8.6 Hz, 2H), 7.20 (d, *J*
51 = 8.5 Hz, 1H), 7.13 – 7.06 (m, =CH, 2H), 6.77 (d, *J* = 8.6 Hz, =CH, 2H), 6.55 (s, =CH, 1H), 5.13 – 4.93 (m,
52 CH, CH₂, 3H), 2.96 (s, CH₃, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 150.2, 135.2, 131.6, 128.7, 128.4, 128.3,
53 125.5, 122.2, 119.5, 113.2, 112.0, 102.6, 80.5, 48.8, 40.9. IR (CH₂Cl₂, cm⁻¹): 3420, 2914, 1613, 1549,
54 1347, 1065, 816, 733. Rf=0.15 (EtOAc/Hexane (2:8), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for
55 C₁₈H₂₀N₃O₂ 310.1556; Found 310.1549.
56
57
58
59
60

1
2
3 (\pm)-5-(1-(2,5-Dimethoxyphenyl)-2-nitroethyl)-1H-indole (**23ag**). Compound **23ag** was obtained using
4 **GP7**. Column chromatography (EtOAc/Hexane (3:7)) gave the product as light brown crystals (442 mg,
5 52% yield; mp 158–159 °C (CH₂Cl₂/Hexane)). ¹H NMR (400 MHz, CDCl₃) δ 8.16 (bs, NH, 1H), 7.54 (s, =CH,
6 1H), 7.31 (d, *J* = 8.4 Hz, =CH, 1H), 7.20 – 7.13 (m, =CH, 1H), 7.10 (dd, *J* = 8.4, 1.7 Hz, =CH, 1H), 6.83 –
7 6.77 (m, =CH, 1H), 6.75 – 6.70 (m, =CH, 2H), 6.51 – 6.48 (m, =CH, 1H), 5.42 – 5.31 (m, CH, 1H), 5.08 (dd,
8 *J* = 12.9, 8.0 Hz, CH₂, 1H), 4.99 (dd, *J* = 12.9, 8.0 Hz, CH₂, 1H), 3.79 (s, CH₃, 3H), 3.70 (s, CH₃, 3H). ¹³C
9 NMR (100 MHz, CDCl₃) δ 153.8, 151.3, 135.3, 130.2, 129.9, 129.3, 124.9, 122.6, 120.0, 115.8, 112.13,
10 112.10, 111.6, 102.9, 78.7, 56.3, 55.8, 43.6. IR (CH₂Cl₂, cm⁻¹): 3426, 2835, 1549, 1223, 1047, 1024, 894,
11 732. R_f = 0.13 (EtOAc/Hexane (3:7), 254 nm). HRMS (APCI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₈H₁₉N₂O₄
12 327.1345; Found 327.1338.

13
14
15
16
17
18
19
20
21 (\pm)-5-(2-Nitro-1-(3,4,5-trimethoxyphenyl)ethyl)-1H-indole (**23ah**). Compound **23ah** was obtained using
22 **GP7**. Column chromatography (EtOAc/Hexane (3:7)) gave the product as white crystals (280 mg, 50%
23 yield; mp 152–153 °C (CH₂Cl₂/Hexane)). ¹H NMR (400 MHz, CDCl₃) δ 8.27 (s, NH, 1H), 7.50 (s, =CH, 1H),
24 7.34 (d, *J* = 8.4 Hz, =CH, 1H), 7.21 (t, *J* = 2.8 Hz, =CH, 1H), 7.05 (dd, *J* = 8.4, 1.6 Hz, =CH, 1H), 6.54 – 6.51
25 (m, =CH, 3H), 5.06 – 4.99 (m, CH, CH₂, 3H), 3.81 (s, CH₃, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 153.6, 137.4,
26 135.9, 135.3, 130.7, 128.4, 125.3, 122.0, 119.6, 111.9, 105.1, 102.9, 80.0, 61.0, 56.4, 49.5. IR (CH₂Cl₂,
27 cm⁻¹): 3368, 2938, 2839, 1591, 1551, 1461, 1126, 733. R_f = 0.11 (EtOAc/Hexane (3:7), 254 nm). HRMS
28 (APCI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₉H₂₁N₂O₅ 357.1450; Found 357.1437.

29
30
31
32
33
34
35 (\pm)-5-(1-(Furan-2-yl)-2-nitroethyl)-1H-indole (**23ai**). Compound **23ai** was obtained using **GP7**. Column
36 chromatography (EtOAc/Hexane (3:7)) gave the product as dark yellow oil (532 mg, 58% yield). ¹H-
37 NMR (400 MHz, CDCl₃) δ 8.20 (s, NH, 1H), 7.55 (s, =CH, 1H), 7.41 – 7.32 (m, =CH, 2H), 7.24 – 7.17 (m,
38 =CH, 1H), 7.10 (dd, *J* = 8.4, 1.7 Hz, =CH, 1H), 6.56 – 6.48 (m, =CH, 1H), 6.31 (dd, *J* = 3.2, 1.9 Hz, =CH, 1H),
39 6.13 (d, *J* = 3.3 Hz, =CH, 1H), 5.15 – 4.97 (m, CH₂, 2H), 4.85 (dd, *J* = 11.3, 6.3 Hz, CH, 1H). ¹³C NMR (100
40 MHz, CDCl₃) δ 153.3, 135.6, 128.5, 128.4, 125.3, 122.0, 120.3, 111.8, 110.6, 107.3, 104.8, 103.0, 44.0,
41 29.9. IR (CH₂Cl₂, cm⁻¹): 3427, 1633, 1552, 1376, 1260, 1013, 805, 734. R_f=0.25 (EtOAc/Hexane (2:8),
42 254 nm). HRMS (APCI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₄H₁₃N₂O₃ 257.0926; Found 257.0912.

43 44 45 46 47 48 49 **General Procedure 8 (GP8): Reduction of Nitro Groups in *N*-Benzylindolines (25aa-ak)**

50
51 NaBH₄ (102.2 mg, 2.70 mmol, 5 equiv.) was added to a suspension of C5-substitued *N*-benzylindoline
52 derivatives (1 equiv.) and NiCl₂·6H₂O (1 equiv.) in methanol (4 mL) at 0 °C and the mixture was stirred
53 at 0 °C for 30 min. The reaction mixture was quenched by addition of saturated NH₄Cl solution at 0 °C
54 and extracted with CH₂Cl₂ (30 mL). The combined organic layers were washed with brine, dried over
55 anhydrous Na₂SO₄. After filtration of the drying agent, the filtrate was concentrated to dryness in
56
57
58
59
60

vacuo. The residue was dissolved in 0.5 mL methanol, then HCl (12 M, 1.2 equiv.) was added dropwise to the solution and purified by recrystallization (diethyl ether at 2 °C) to give analytically pure products.

(±)-2-(1-Benzylindoline-5-yl)-2-phenylethane-1-amine hydrochloride (25aa). Compound **25aa** was obtained using **GP8** and recovered as purple crystals (178 mg, 97% yield; mp 196.6–197.6 °C). ¹H NMR (400 MHz, CD₃OD) δ 7.55 (s, =CH, 2H), 7.54 – 7.36 (m, =CH, 10H), 7.37 – 7.23 (m, =CH, 1H), 4.74 (s, CH₂, 2H), 4.48 (t, *J* = 8.0 Hz, CH, 1H), 3.91 (t, *J* = 7.5 Hz, CH₂, 2H), 3.73 (dd, *J* = 8.0, 2.7 Hz, CH₂, 2H), 3.20 (t, *J* = 7.5 Hz, CH₂, 2H). ¹³C NMR (100 MHz, CD₃OD) δ 143.9, 139.9, 139.0, 137.1, 131.3, 130.1, 129.7, 129.2, 129.1, 128.4, 127.9, 127.7, 126.0, 120.4, 60.3, 53.9, 48.8, 43.2, 27.8. Anal. Calcd for C₂₃H₂₅ClN₂: C, 75.70; H, 6.91; N, 7.68; found: C, 75.63; H, 7.00; N, 7.53. R_f = 0.76 (MeOH/CH₂Cl₂ (1:19), 254 nm). HRMS (APCI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₃H₂₅N₂ 329.2012; Found 329.2002.

(±)-2-(1-Benzylindoline-5-yl)-2-(4-(trifluoromethyl)phenyl)ethane-1-amine hydrochloride (25ab). Compound **25ab** was obtained using **GP8** and recovered as purple crystals (192 mg, 86% yield; mp 158.2–159.2 °C). ¹H NMR (400 MHz, CD₃OD) δ 7.72 – 7.63 (m, =CH, 4H), 7.60 (s, =CH, 1H), 7.55 – 7.38 (m, =CH, 7H), 4.74 (s, CH₂, 2H), 4.69 (t, *J* = 8.0 Hz, CH, 1H), 3.89 (t, *J* = 7.4 Hz, CH₂, 2H), 3.79 (d, *J* = 8.0 Hz, CH₂, 2H), 3.20 (t, *J* = 7.4 Hz, CH₂, 2H). ¹³C NMR (100 MHz, CD₃OD) δ 144.4, 142.8, 139.6, 137.2 (2C), 131.1 (2C), 130.0, 129.9, 129.1, 128.7 (2C), 128.4, 126.0 (m, 1C), 120.2, 60.2, 54.0, 48.6, 42.8, 27.8. Anal. Calcd for C₂₄H₂₄ClF₃N₂: C, 66.59; H, 5.59; N, 6.47; found: C, 66.70; H, 5.68; N, 6.29. R_f = 0.20 (MeOH/CH₂Cl₂ (1:19), 254 nm). HRMS (APCI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₄H₂₄F₃N₂ 397.1892; Found 397.1868.

(±)-2-(1-Benzylindoline-5-yl)-2-(4-fluorophenyl)ethane-1-amine hydrochloride (25ad). Compound **25ad** was obtained using **GP8** and recovered as pink crystals (182 mg, 94% yield; mp 72.1–73.1 °C). ¹H NMR (400 MHz, CD₃OD) δ 7.63 – 7.33 (m, =CH, 10H), 7.14 – 7.08 (m, =CH, 2H), 4.71 (s, CH₂, 2H), 4.50 (t, *J* = 8.1 Hz, CH, 1H), 3.87 (t, *J* = 7.5 Hz, CH₂, 2H), 3.69 (d, *J* = 8.1 Hz, CH₂, 2H), 3.17 (t, *J* = 7.5 Hz, CH₂, 2H). ¹³C NMR (100 MHz, CD₃OD) δ 162.3 (d, *J* = 245.2 Hz), 143.2, 139.7, 136.9, 135.8 (d, *J* = 3.2 Hz), 131.0, 130.04, 129.98, 129.8 (d, *J* = 8.2 Hz), 129.1, 128.2, 125.7, 119.7, 115.8 (d, *J* = 21.7 Hz), 60.0, 54.0, 48.2, 43.1, 27.7. Anal. Calcd for C₂₃H₂₄ClFN₂: C, 72.15; H, 6.32; N, 7.32; found: C, 72.01; H, 6.42; N, 7.45. R_f = 0.63 (MeOH/CH₂Cl₂ (1:19), 254 nm). HRMS (APCI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₃H₂₄FN₂ 347.1924; Found 347.1903.

(±)-2-(1-Benzylindoline-5-yl)-2-(4-bromophenyl)ethane-1-amine hydrochloride (25ae). Compound **25ae** was obtained using **GP8** and recovered as pink crystals (171 mg, 87% yield; mp 115.6–116.6 °C). ¹H NMR (400 MHz, CD₃OD) δ 7.70 – 7.19 (m, =CH, 12H), 4.65 (s, CH₂, 2H), 4.47 (t, *J* = 7.8 Hz, CH, 1H), 3.79 (t, *J* = 7.0 Hz, CH₂, 2H), 3.69 (dd, *J* = 7.8, 4.8 Hz, CH₂, 2H), 3.14 (t, *J* = 7.0 Hz, CH₂, 2H). ¹³C NMR (100 MHz, CD₃OD) δ 139.3, 136.5, 136.4, 132.2, 132.1, 130.8, 130.7, 129.8, 129.2, 129.0, 127.8, 125.6, 121.4,

1
2
3 118.5, 59.6, 53.9, 48.3, 42.9, 27.8. Anal. Calcd for C₂₃H₂₄BrClN₂: C, 62.25; H, 5.45; N, 6.31; found: C,
4 62.03; H, 5.13; N, 6.50. R_f = 0.63 (MeOH/CH₂Cl₂ (1:19), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd
5 C₂₃H₂₄BrN₂ 407.1123; Found 407.1088.
6
7

8
9 (*±*)-4-(2-Amino-1-(1-benzylindoline-5-yl)ethyl)-N,N-dimethylaniline hydrochloride (**25af**). Compound
10 **25af** was obtained using **GP8** and recovered as yellow crystals (169 mg, 91% yield; mp 178.6–179.6 °C).
11 ¹H NMR (400 MHz, CD₃OD) δ 7.67 – 7.54 (m, =CH, 4H), 7.37 – 7.24 (m, =CH, 5H), 7.20 – 7.01 (m, =CH,
12 2H), 6.66 (d, *J* = 8.1 Hz, =CH, 1H), 4.38 (t, *J* = 8.1 Hz, CH, 1H), 4.28 (s, CH₂, 2H), 3.64 (d, *J* = 8.1 Hz, CH₂,
13 2H), 3.35 (t, *J* = 8.1 Hz, CH₂, 2H), 3.22 (s, CH₃, 6H), 2.93 (t, *J* = 8.1 Hz, CH₂, 2H). ¹³C NMR (100 MHz,
14 CD₃OD) δ 142.88, 142.85, 142.4 (2C), 136.8, 132.6, 129.8, 128.5 (2C), 127.6, 127.2, 124.2, 120.7, 109.7,
15 54.5, 53.5, 48.3, 45.6, 43.2, 28.1. Anal. Calcd for C₂₅H₃₀ClN₃: C, 73.60; H, 7.41; N, 10.30; found: C, 73.66;
16 H, 7.32; N, 10.46. R_f = 0.80 (MeOH/CH₂Cl₂ (1:19), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for
17 C₂₅H₃₀N₃ 372.2440; Found 372.2425.
18
19
20
21
22
23

24
25 (*±*)-2-(1-Benzylindoline-5-yl)-2-(2,5-dimethoxyphenyl)ethane-1-amine hydrochloride (**25ag**).
26 Compound **25ag** was obtained using **GP8** and recovered as purple crystals (175 mg, 94% yield; mp
27 217.8–218.8 °C). ¹H NMR (400 MHz, CD₃OD) δ 7.52 – 7.34 (m, =CH, 8H), 6.96 – 6.93 (m, =CH, 1H), 6.86
28 (m, CH, 2H), 4.76 (t, *J* = 8.1 Hz, CH, 1H), 4.70 (s, CH₂, 2H), 3.87 (t, *J* = 7.5 Hz, CH₂, 2H), 3.78 (s, CH₃, 3H),
29 3.75 (s, CH₃, 3H), 3.32 – 3.28 (m, CH₂, 2H). 3.15 (t, *J* = 7.5 Hz, CH₂, 2H). ¹³C NMR (100 MHz, CD₃OD) δ
30 154.3, 151.4, 143.1, 139.2, 136.5, 131.0, 130.0, 129.9, 129.1, 128.5, 128.4, 125.9, 119.4, 114.8, 112.7,
31 112.2, 60.1, 55.2, 55.0, 54.0, 42.8, 42.2, 27.7. Anal. Calcd for C₂₅H₂₉ClN₂O₂: C, 70.66; H, 6.88; N, 6.59;
32 found: C, 70.51; H, 6.75; N, 6.57. R_f = 0.79 (MeOH/CH₂Cl₂ (1:19), 254 nm). HRMS (APCI-TOF) m/z: [M +
33 H]⁺ Calcd for C₂₅H₂₉N₂O₂ 389.2229; Found 389.2205.
34
35
36
37
38
39

40
41 (*±*)-2-(1-Benzylindoline-5-yl)-2-(3,4,5-trimethoxyphenyl)ethane-1-amine hydrochloride (**25ah**).
42 Compound **25ah** was obtained using **GP8** and recovered as light brown crystals (168 mg, 90% yield;
43 mp 162–163 °C). ¹H NMR (400 MHz, CD₃OD) δ 7.53 (s, =CH, 1H), 7.51 – 7.35 (m, =CH, 7H), 6.71 (s, =CH,
44 2H), 4.68 (s, CH₂, 2H), 4.46 – 4.35 (m, CH, 1H), 3.86 – 3.82 (m, CH₃, CH₂, 8H), 3.73 – 3.65 (m, CH₃, CH₂,
45 5H), 3.17 (t, *J* = 7.4 Hz, CH₂, 2H). ¹³C NMR (100 MHz, CD₃OD) δ 153.9, 143.1, 139.9, 137.5, 136.6, 135.6,
46 130.9, 130.3, 129.90, 129.04, 127.9, 125.6, 119.2, 105.3, 59.8, 55.7, 54.0, 49.2 (2C), 42.9, 27.7. Anal.
47 Calcd for C₂₆H₃₁ClN₂O₃: C, 68.64; H, 6.87; N, 6.16; found: C, 68.44; H, 6.78; N, 6.37. R_f = 0.47
48 (MeOH/CH₂Cl₂ (1:19), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₆H₃₁N₂O₃ 419.2335; Found
49 419.2309.
50
51
52
53
54
55

56
57 (*±*)-2-(1-Benzylindoline-5-yl)-2-(furan-2-yl)ethane-1-amine hydrochloride (**25ai**). Compound **25ai** was
58 obtained using **GP8** and recovered as brown crystals (193 mg, 88% yield; mp 110–111 °C). ¹H NMR (400
59 MHz, CD₃OD) δ 7.60 – 7.38 (m, =CH, 9H), 6.44 – 6.36 (m, =CH, 2H), 4.76 (s, CH₂, 2H), 4.68 – 4.59 (m, CH,
60

1
2
3 1H), 3.94 - 3.84 (m, CH₂, 2H), 3.73 - 3.63 (m, CH₂, 1H), 3.56 - 3.45 (m, CH₂, 1H), 3.24 - 3.13 (m, CH₂,
4 2H). ¹³C NMR (100 MHz, CD₃OD) δ 152.2, 141.4, 139.5, 137.1, 131.2, 130.1, 129.8, 129.1, 128.5, 126.1,
5 120.3, 110.63, 110.60, 107.9, 60.3, 54.0, 42.9, 42.5, 27.7. Anal. Calcd for C₂₁H₂₃ClN₂O: C, 71.08; H, 6.53;
6 N, 7.89; found: C, 71.00; H, 6.58 N, 7.69. R_f = 0.77 (MeOH/CH₂Cl₂ (1:19), 254 nm). HRMS (APCI-TOF)
7 m/z: [M + H]⁺ Calcd for C₂₁H₂₃N₂O 319.1810; Found 319.1788.

8
9
10
11
12 (*±*)-2-(1-Benzylindoline-5-yl)-2-(1H-indole-3-yl)ethane-1-amine hydrochloride (**25ak**). Compound **25ak**
13 was obtained using **GP8** and recovered as purple crystals (157 mg, 84% yield; mp 140–141 °C). ¹H NMR
14 (400 MHz, CD₃OD) δ 7.52 - 7.47 (m, =CH, 2H), 7.46 - 7.34 (m, =CH, 9H), 7.11 (t, *J* = 7.5 Hz, =CH, 1H),
15 6.97 (t, *J* = 7.5 Hz, =CH, 1H), 4.70 (t, *J* = 8.0 Hz, CH, 1H), 4.65 (s, CH₂, 2H), 3.83 (t, *J* = 7.6 Hz, CH₂, 2H),
16 3.35 (s, NH, 1H), 3.33 - 3.27 (m, CH₂, 2H), 3.11 - 3.04 (m, CH₂, 2H). ¹³C NMR (100 MHz, CD₃OD) δ 144.0,
17 139.4, 137.4, 136.5 (2C), 130.9, 130.0, 129.0, 128.3, 126.3, 125.8, 122.4, 121.9, 119.2, 119.0, 118.2,
18 112.8, 111.5, 60.0, 53.9, 43.4, 41.1, 27.6. Anal. Calcd for C₂₅H₂₆ClN₃: C, 74.33; H, 6.49; N, 10.40; found:
19 C, 74.48; H, 6.76; N, 10.55. R_f = 0.22 (MeOH/CH₂Cl₂ (1:19), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺
20 Calcd for C₂₅H₂₆N₃ 368.2127; Found 368.2114.

21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

General Procedure 9 (GP9): Reduction of Nitro Groups in *N*-Benzylindoles (14aa-ak)

NaBH₄ (102.2 mg, 2.70 mmol, 5 equiv) was added to a suspension of C5-substituted *N*-benzylindole
derivatives (1 equiv.) and NiCl₂·6H₂O (1 equiv.) in methanol (4 mL) at 0 °C and the mixture was stirred
at 0 °C for 30 min. The reaction mixture was quenched by addition of saturated NH₄Cl solution at 0 °C
and extracted with CH₂Cl₂ (30 mL). The combined organic layers were washed with brine, dried over
anhydrous Na₂SO₄. After filtration of the drying agent, the filtrate was concentrated to dryness in
vacuo. The residue was purified by silica gel column chromatography to obtain the **26aa-26ak**.

(*±*)-2-(1-Benzyl-1H-indol-5-yl)-2-phenylethane-1-amine (**26aa**). Compound **26aa** was obtained using
GP9. Column chromatography (EtOAc/Hexane (3:7)) gave the product as dark yellow oil (58 mg, 93%
yield). ¹H NMR (400 MHz, CDCl₃) δ 7.55 (s, =CH, 1H), 7.33 - 7.25 (m, =CH, 7H), 7.24 - 7.15 (m, =CH, 2H),
7.14 - 7.09 (m, =CH, 3H), 7.06 (d, *J* = 8.5 Hz, =CH, 1H), 6.52 (d, *J* = 3.1 Hz, =CH, 1H), 5.28 (s, CH₂, 2H),
4.11 (t, *J* = 7.4 Hz, CH, 1H), 3.38 (d, *J* = 7.4 Hz, CH₂, 2H), 2.31 (bs, NH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ
143.8, 137.7, 135.5, 133.8, 129.1, 129.0, 128.9, 128.8, 128.3, 127.9, 127.1, 126.5, 122.6, 120.2, 110.2,
101.8, 55.0, 50.4, 47.3. IR (CH₂Cl₂, cm⁻¹): 3363, 3059, 3027, 2923, 2853, 1950, 1874, 1646, 1601, 1484,
1452, 1355, 1311, 1263, 1182, 1029, 801. Anal. Calcd for C₂₃H₂₂N₂: C, 84.63; H, 6.79; N, 8.58; found: C,
84.55; H, 6.73; N, 8.68. R_f = 0.28 (MeOH/CH₂Cl₂ (1:19), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd
C₂₃H₂₃N₂ 327.1861; Found 327.1840.

1
2
3 (\pm)-2-(1-Benzyl-1H-indol-5-yl)-2-(4-(trifluoromethyl)phenyl)ethan-1-amine (**26ab**). Compound **26ab**
4 was obtained using **GP9**. Column chromatography (EtOAc/Hexane (3:7)) gave the product as light
5 brown oil (66 mg, 78% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.55 – 7.49 (m, =CH, 3H), 7.36 (d, J = 8.1 Hz,
6 =CH, 2H), 7.33 – 7.22 (m, =CH, 3H), 7.20 (d, J = 8.5 Hz, =CH, 1H), 7.16 – 7.04 (m, =CH, 3H), 6.97 (d, J =
7 8.5 Hz, =CH, 1H), 6.50 (d, J = 3.1 Hz, =CH, 1H), 5.25 (s, CH_2 , 2H), 4.31 – 4.24 (m, CH, 1H), 4.25 – 4.10 (m,
8 CH_2 , 2H), 3.37 (bs, NH_2 , 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 147.3, 137.5, 135.7, 132.0, 129.3, 129.1, 129.0,
9 128.97 (q, J = 32.2 Hz), 128.6, 127.9, 127.0, 125.7 (q, J = 3.7 Hz), 123.1, 122.3, 120.4, 110.6, 101.9, 52.8,
10 50.4, 46.0. IR (CH_2Cl_2 , cm^{-1}): 3435, 2925, 2089, 1637, 1511, 1484, 1453, 1326, 1264, 1164, 1121, 1068,
11 1017, 834. Anal. Calcd for $\text{C}_{24}\text{H}_{21}\text{F}_3\text{N}_2$: C, 73.08; H, 5.37; N, 7.10; found: C, 73.20; H, 5.45; N, 7.18. Rf =
12 0.30 (MeOH/ CH_2Cl_2 (1:19), 254 nm). HRMS (APCI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{24}\text{H}_{22}\text{F}_3\text{N}_2$ 395.1735;
13 Found 395.1711.
14
15
16
17
18
19
20
21

22 (\pm)-4-(2-Amino-1-(1-benzyl-1H-indol-5-yl)ethyl)phenol (**26ac**). Compound **26ac** was obtained using
23 **GP9**. Column chromatography (MeOH/ CH_2Cl_2 (2:8)) gave the product as dirty white crystals (161 mg,
24 92% yield; mp 96.2–97.2 °C (CH_2Cl_2 /Hexane)). ^1H NMR (400 MHz, CD_3OD) δ 7.44 (s, =CH, 1H), 7.22 –
25 6.87 (m, =CH, 10H), 6.73 – 6.67 (m, =CH, 2H), 6.41 (d, J = 3.1 Hz, =CH, 1H), 5.19 (s, CH_2 , 2H), 3.98 (t, J =
26 7.5 Hz, CH, 1H), 3.25 – 3.15 (m, CH_2 , 2H). ^{13}C NMR (100 MHz, CD_3OD) δ 155.9, 138.3, 135.4, 134.1,
27 133.5, 129.3, 128.9, 128.8, 128.4, 127.2, 126.7, 121.7, 119.5, 115.2, 110.0, 101.1, 52.4, 49.6, 46.0. IR
28 (CH_2Cl_2 , cm^{-1}): 3347, 2925, 1707, 1611, 1514, 1484, 1355, 1264, 1176, 1029, 959, 833, 732. Anal. Calcd
29 for $\text{C}_{23}\text{H}_{22}\text{N}_2\text{O}$: C, 80.67; H, 6.48; N, 8.18; found: C, 80.88; H, 6.30; N, 8.02. Rf = 0.20 (MeOH/ CH_2Cl_2
30 (1:19), 254 nm). HRMS (APCI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{23}\text{H}_{23}\text{N}_2\text{O}$ 343.1810; Found 343.1787.
31
32
33
34
35
36
37
38

39 (\pm)-2-(1-Benzyl-1H-indol-5-yl)-2-(4-fluorophenyl)ethan-1-amine (**26ad**). Compound **26ad** was obtained
40 using **GP9**. Column chromatography (EtOAc/Hexane (3:7)) gave the product as dark yellow oil (178 mg,
41 92% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.52 (s, =CH, 1H), 7.35 – 7.19 (m, =CH, 6H), 7.15 – 7.09 (m, =CH,
42 3H), 7.04 – 6.93 (m, =CH, 3H), 6.51 (d, J = 3.0 Hz, 1H), 5.28 (s, CH_2 , 2H), 4.11 – 4.03 (s, CH, 1H), 3.47 –
43 3.23 (m, CH_2 , 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 161.6 (d, J = 244.3 Hz), 138.7, 137.4, 135.5, 132.6, 129.6
44 (d, J = 7.8 Hz), 129.1, 129.0, 128.9, 127.8, 126.9, 122.2, 120.1, 115.5 (d, J = 21.1 Hz), 110.3, 101.7, 50.2,
45 30.4, 29.8. IR (CH_2Cl_2 , cm^{-1}): 3641, 3371, 3300, 3032, 2924, 2855, 1887, 1727, 1602, 1507, 1484, 1355,
46 1222, 1159, 1093, 960, 851, 806. Anal. Calcd for $\text{C}_{23}\text{H}_{21}\text{FN}_2$: C, 80.21; H, 6.15; N, 8.13; found: C, 80.09;
47 H, 6.02; N, 8.19. Rf = 0.28 (MeOH/ CH_2Cl_2 (1:19), 254 nm). HRMS (APCI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for
48 $\text{C}_{23}\text{H}_{22}\text{FN}_2$ 345.1767; Found 345.1741.
49
50
51
52
53
54
55

56 (\pm)-2-(1-Benzyl-1H-indol-5-yl)-2-(4-bromophenyl)ethan-1-amine (**26ae**). Compound **26ae** was obtained
57 using **GP9**. Column chromatography (EtOAc/Hexane (3:7)) gave the product as light yellow oil (53 mg,
58 81% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.50 (s, =CH, 1H), 7.39 (d, J = 8.2, =CH, 2H), 7.31 – 7.24 (m, =CH,
59 1H), 7.15 – 7.08 (m, =CH, 6H), 7.04 – 6.93 (m, =CH, 3H), 6.51 (d, J = 3.0 Hz, 1H), 5.28 (s, CH_2 , 2H), 4.11 – 4.03 (s, CH, 1H), 3.47 –
60 3.23 (m, CH_2 , 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 161.6 (d, J = 244.3 Hz), 138.7, 137.4, 135.5, 132.6, 129.6
(d, J = 7.8 Hz), 129.1, 129.0, 128.9, 127.8, 126.9, 122.2, 120.1, 115.5 (d, J = 21.1 Hz), 110.3, 101.7, 50.2,
30.4, 29.8. IR (CH_2Cl_2 , cm^{-1}): 3641, 3371, 3300, 3032, 2924, 2855, 1887, 1727, 1602, 1507, 1484, 1355,
1222, 1159, 1093, 960, 851, 806. Anal. Calcd for $\text{C}_{23}\text{H}_{20}\text{BrN}_2$: C, 78.15; H, 5.85; N, 8.00; found: C, 78.15;
H, 5.85; N, 8.00. Rf = 0.28 (MeOH/ CH_2Cl_2 (1:19), 254 nm). HRMS (APCI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for
 $\text{C}_{23}\text{H}_{21}\text{BrN}_2$ 395.1035; Found 395.1015.

4H), 7.20 (d, $J = 8.4$ Hz, =CH, 1H), 7.12 (m, =CH, 4H), 6.98 (d, $J = 8.4$ Hz, =CH, 1H), 6.50 (d, $J = 3.0$ Hz, =CH, 1H), 5.26 (s, CH₂, 2H), 4.09 (t, $J = 7.3$ Hz, CH, 1H), 3.40 – 3.20 (m, CH₂, 2H), 3.30 – 3.10 (m, NH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 142.6, 137.6, 135.6, 132.9, 131.8, 130.0, 129.2, 129.1, 129.0, 127.9, 127.1, 122.4, 120.4, 120.2, 110.4, 101.8, 53.6, 50.4, 46.7. IR (CH₂Cl₂, cm⁻¹): 3025, 2918, 2852, 2358, 1686, 1552, 1486, 1453, 1355, 1260, 1182, 1073, 1009, 726. Anal. Calcd for C₂₃H₂₁BrN₂: C, 68.15; H, 5.22; N, 6.91; found: C, 67.98; H, 5.07; N, 6.82 Rf = 0.17 (MeOH/CH₂Cl₂ (1:19), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₃H₂₂BrN₂ 405.0966; Found 405.0954.

(±)-4-(2-Amino-1-(1-benzyl-1H-indol-5-yl)ethyl)-N,N-dimethylaniline (**26af**). Compound **26af** was obtained using **GP9**. Column chromatography (EtOAc/Hexane (4:6)) gave the product as light brown oil (178 mg, 92% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.50 (s, CH, 1H), 7.33 – 7.21 (m, 3H), 7.21 – 6.95 (m, 7H), 6.68 (d, $J = 8.5$ Hz, 2H), 6.47 (d, $J = 2.9$ Hz, 1H), 5.25 (s, CH₂, 2H), 3.99 (t, $J = 7.4$ Hz, CH, 1H), 3.31 (d, $J = 7.4$ Hz, CH₂, 2H), 2.88 (s, CH₃, 6H), 1.83 (bs, NH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 149.5, 137.8, 135.4, 134.6, 131.7, 129.1, 129.0, 128.9, 128.7, 127.8, 127.1, 122.6, 120.0, 113.2, 110.1, 101.8, 53.9, 50.4, 47.5, 41.0. IR (CH₂Cl₂, cm⁻¹): 3625, 3365, 3030, 2923, 2802, 1873, 1704, 1613, 1519, 1483, 1352, 1264, 1183, 1132, 1029, 947, 816, 733. Anal. Calcd for C₂₅H₂₇N₃: C, 81.26; H, 7.37; N, 11.37; found: C, 81.16; H, 7.30; N, 11.24. Rf = 0.12 (MeOH/CH₂Cl₂ (1:19), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₅H₂₈N₃ 370.2283; Found 370.2262.

(±)-2-(1-Benzyl-1H-indol-5-yl)-2-(2,5-dimethoxyphenyl)ethan-1-amine (**26ag**). Compound **26ag** was obtained using **GP9**. Column chromatography (EtOAc/Hexane (4:6)) gave the product as dark brown oil (178 mg, 92% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.60 (s, =CH, 1H), 7.37 – 7.19 (m, =CH, 4H), 7.17 – 7.07 (m, =CH, 4H), 6.87 (m, =CH, 1H), 6.80 (d, $J = 8.8$ Hz, =CH, 1H), 6.73 – 6.67 (m, =CH, 1H), 6.52 (d, $J = 2.7$ Hz, =CH, 1H), 5.25 (s, CH₂, 2H), 4.58 (s, CH, 1H), 3.76 (s, CH₃, 3H), 3.74 (s, CH₃, 3H), 3.33 (bs, CH₂, 2H), 2.03 (bs, NH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 153.9, 151.9, 137.8, 135.5, 133.7, 133.4, 129.1, 129.0, 128.7, 127.8, 127.1, 123.0, 120.5, 115.2, 112.0, 110.8, 110.0, 101.8, 56.4 (2C), 55.9, 50.4, 46.7. IR (CH₂Cl₂, cm⁻¹): 3366, 2932, 1705, 1587, 1496, 1280, 1049, 877, 800, 732. Anal. Calcd for C₂₅H₂₆N₂O₂: C, 77.69; H, 6.78; N, 7.25; found: C, 77.58; H, 6.71; N, 7.13. Rf = 0.24 (MeOH/CH₂Cl₂ (1:19), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₅H₂₇N₂O₂ 387.2073; Found 387.2049.

(±)-2-(1-Benzyl-1H-indol-5-yl)-2-(3,4,5-trimethoxyphenyl)ethan-1-amine (**26ah**). Compound **26ah** was obtained using **GP9**. Column chromatography (EtOAc/Hexane (4:6)) gave the product as dirty white crystals (88 mg, 86% yield; mp 212–213 °C (CH₂Cl₂/Hexane)). ¹H NMR (400 MHz, CDCl₃) δ 7.53 (s, =CH, 1H), 7.30 – 7.19 (m, =CH, 4H), 7.00 – 7.07 (m, =CH, 4H), 6.50 – 6.54 (m, =CH, 2H), 6.44 (d, $J = 3.0$ Hz, =CH, 1H), 5.20 (s, CH₂, 2H), 4.50 – 4.40 (m, CH, 1H), 3.74 (s, CH₃, 6H), 3.70 (s, CH₃, 3H), 3.65 – 3.50 (m, CH₂, NH₂, 4H). ¹³C NMR (100 MHz, CDCl₃) δ 153.6, 137.5, 137.0, 136.5, 135.8, 130.9, 129.22, 129.20,

1
2
3 129.0, 127.9, 127.0, 121.9, 120.0, 110.6, 105.3, 101.9, 60.9, 56.4, 50.4, 49.3, 44.6. IR (CH₂Cl₂, cm⁻¹):
4 3435, 2090, 1636, 1509, 1454, 1424, 1353, 1236, 1125, 726. Anal. Calcd for C₂₆H₂₈N₂O₃: C, 74.97; H,
5 6.78; N, 6.73; found: C, 74.90; H, 6.71; N, 6.85. R_f = 0.13 (MeOH/CH₂Cl₂ (1:19), 254 nm). HRMS (APCI-
6 TOF) m/z: [M + H]⁺ Calcd for C₂₆H₂₉N₂O₃ 417.2178; Found 417.2151.
7
8
9

10
11 (*±*)-2-(1-Benzyl-1H-indol-5-yl)-2-(1H-indol-5-yl)ethan-1-amine (**26aj**). Compound **26aj** was obtained
12 using **GP9**. Column chromatography (EtOAc/Hexane (4:6)) gave the product as yellow oil (178 mg, 92%
13 yield). ¹H NMR (400 MHz, CDCl₃) δ 8.71 (bs, NH, 1H), 7.55 - 7.54 (m, =CH, 2H), 7.36 - 6.99 (m, =CH,
14 11H), 6.48 (dd, *J* = 7.5, 2.8 Hz, 2H), 5.25 (s, CH₂, 2H), 4.18 (t, *J* = 7.4 Hz, CH, 1H), 3.44 - 3.36 (m, CH₂,
15 2H), 2.05 (bs, NH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 137.8, 135.4, 135.0, 134.9, 134.8, 129.1, 129.0,
16 128.8, 128.3, 127.8, 127.0, 124.9, 122.80, 122.78, 120.0, 119.7, 111.6, 110.1, 102.3, 101.8, 53.8, 50.3,
17 30.0. Anal. Calcd for C₂₅H₂₃N₃: C, 82.16; H, 6.34; N, 11.50; found: C, 82.02; H, 6.27; N, 11.40. IR (CH₂Cl₂,
18 cm⁻¹): 3413, 2923, 2851, 1641, 1483, 1454, 1343, 1123, 1090, 803, 727.1. R_f = 0.12 (MeOH/CH₂Cl₂
19 (1:19), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for C₂₅H₂₄N₃ 366.1970; Found 366.1947.
20
21
22
23
24
25

26
27 (*±*)-2-(1-Benzyl-1H-indol-5-yl)-2-(1H-indol-3-yl)ethan-1-amine (**26ak**). Compound **26ak** was obtained
28 using **GP9**. Column chromatography (EtOAc/Hexane (4:6)) gave the product as dirty white crystals (88
29 mg, 86% yield; mp 212–213 °C (CH₂Cl₂/Hexane)). ¹H NMR (400 MHz, CDCl₃) δ 8.17 (bs, NH, 1H), 7.60 (s,
30 =CH, 1H), 7.51 (d, *J* = 7.9 Hz, =CH, 1H), 7.36 - 7.21 (m, =CH, 4H), 7.21 - 7.07 (m, =CH, 5H), 7.07 - 6.94
31 (m, =CH, 3H), 6.48 (d, *J* = 2.9 Hz, =CH, 1H), 5.24 (s, CH₂, 2H), 4.35 - 4.26 (m, CH, 1H), 3.52 - 3.40 (m,
32 CH₂, 1H), 3.37 - 3.24 (m, CH₂, 1H), 1.73 (bs, NH₂, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 137.7, 136.7, 135.6,
33 134.19, 134.17, 129.0, 128.9, 128.6, 127.8, 127.4, 127.1, 122.5, 122.2, 121.4, 120.4, 119.8, 119.5,
34 111.3, 110.0, 101.7, 50.4, 47.9, 47.1. IR (CH₂Cl₂, cm⁻¹): 3412, 3098, 3053, 2923, 1586, 1484, 1455, 1337,
35 1264, 1181, 1091, 884, 799. Anal. Calcd for C₂₅H₂₃N₃: C, 82.16; H, 6.34; N, 11.50; found: C, 82.04; H,
36 6.10; N, 11.39. R_f = 0.10 (MeOH/CH₂Cl₂ (1:19), 254 nm). HRMS (APCI-TOF) m/z: [M + H]⁺ Calcd for
37 C₂₅H₂₄N₃ 366.1970; Found 366.1946.
38
39
40
41
42
43
44

45
46 (*±*)-2-(1H-Indol-5-yl)-2-phenylethan-1-amine (**27aa**). Compound **27aa** was obtained using **GP9**. Column
47 chromatography (MeOH/CH₂Cl₂ (2:8)) gave the product as white crystals (160 mg, 92% yield; mp 97–
48 98 °C (CH₂Cl₂/Hexane)). ¹H NMR (400 MHz, CD₃OD) δ 7.48 (s, =CH, 1H), 7.34 (d, *J* = 8.3 Hz, =CH, 1H),
49 7.29 - 7.11 (m, =CH, NH, 7H), 7.15 (bs, =CH, 1H), 7.01 (d, *J* = 6.6 Hz, =CH, 1H), 6.42 (s, =CH, 1H), 4.08
50 (d, *J* = 4.7 Hz, CH, 1H), 3.34 - 3.22 (m, CH₂, 2H). ¹³C NMR (100 MHz, CD₃OD) δ 143.7, 135.5, 132.7, 128.6,
51 128.4, 127.8, 126.2, 125.0, 121.6, 119.1, 111.3, 101.1, 53.6, 46.0. IR (CH₂Cl₂, cm⁻¹): 3368, 1794,
52 1735, 1552, 1378, 1265, 1097, 894, 765. R_f = 0.12 (MeOH/CH₂Cl₂ (1:19), 254 nm). HRMS (APCI-TOF) m/z:
53 [M + H]⁺ Calcd for C₁₆H₁₇N₂ 237.1392; Found 237.1381.
54
55
56
57
58
59
60

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: XXX

NMR spectra for all compounds (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: nsarac@atauni.edu.tr

ORCID

Berrak Ertugrul: 0000-0002-9042-4602

Haydar Kilic: 0000-0002-7009-9953

Farrokh Lafzi: 0000-0002-3371-0899

Nurullah Saracoglu: 0000-0002-1504-7480

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We would like to thank The Scientific and Technological Research Council of Turkey (TÜBİTAK) (Project No: 114Z200) for its financial support.

■ REFERENCES

(1) (a) Taber, D. F.; Tirunahari, P. K. Indole Synthesis: A Review and Proposed Classification. *Tetrahedron* **2011**, *67*, 7195–7210. (b) Higuchi, K.; Kawasaki, T. Simple Indole Alkaloids and Those with a Nonrearranged Monoterpenoid Unit. *Nat. Prod. Rep.* **2007**, *24*, 843–868. (c) Kochanowska-Karamyan, A. J.; Hamann, M. T. Marine Indole Alkaloids: Potential New Drug Leads for the Control of Depression and Anxiety. *Chem. Rev.* **2010**, *110*, 4489–4497. (d) Inman, M.; Moody, C. J. Indole Synthesis—Something Old, Something New. *Chem. Sci.* **2013**, *4*, 29–41. (e) Xu, W.; Gavia, D. J.; Tang, Y. Biosynthesis of Fungal Indole Alkaloids. *Nat. Prod. Rep.* **2014**, *31*, 1474–1487. (f) Sravanthi, T. V.; Manju, S. L. Indoles—A Promising Scaffold for Drug Development. *Eur. J. Pharm. Sci.* **2016**, *91*, 1–10.

(2) (a) Zhang, M. Z.; Mulholland, N.; Beattie, D.; Irwin, D.; Gu, Y. C.; Chen, Q.; Yang, G. F.; Clough, J. Synthesis and Antifungal Activity of 3-(1,3,4-Oxadiazol-5-yl)-indoles and 3-(1,3,4-Oxadiazol-5-yl) Methyl-Indoles. *Eur. J. Med. Chem.* **2013**, *63*, 22–32. (b) Young, S. N. How to Increase Serotonin in the Human Brain without Drugs. *J. Psychiatry Neurosci.* **2007**, *32*, 394–399. (c) Nichols, D. E.; Nichols, C. D. Serotonin Receptors. *Chem. Rev.* **2008**, *108*, 1614–1641. (d) Zhang, M. Z.; Chen, Q.; Yang, G. F. A Review on Recent Developments of Indole-Containing Antiviral Agents. *Eur. J. Med. Chem.* **2015**, *89*, 421–441. (e) Feniuk, W.; Humphrey, P. P. A. The Development of a Highly Selective 5-HT₁ Receptor Agonist, Sumatriptan, for the Treatment of Migraine. *Drug Dev. Res.* **1992**, *26*, 235–240. (f) Kaushik, N. K.; Kaushik, N.; Attri, P.; Kumar, N.; Kim, C. H.; Verma, A. K.; Choi, E. H. Biomedical Importance of Indoles. *Molecules* **2013**, *18*, 6620–6662.

(3) Taylor, R. D.; MacCoss, M.; Lawson, A. D. G. Rings in Drugs: Miniperspective. *J. Med. Chem.* **2014**, *57*, 5845–5859.

(4) (a) Sheftell, F. D.; Bigal, M. E.; Tepper, S. J.; Rapaport, A. M. Sumatriptan: A Decade of Use and Experience in the Treatment of Migraine. *Expert Rev. Neurother.* **2004**, *4*, 199–209. (b) Pal, A.; Gautam, A.; Munjal, S. Pharmacokinetic Characterization and Dose Selection of a Novel Sumatriptan Nasal Spray Formulation, DFN-02. *J. Clin. Pharmacol.* **2017**, *57*, 1472–1478.

(5) (a) Takiya, L.; Piccininni, L. C.; Kamath, V. Safety and Efficacy of Eletriptan in the Treatment of Acute Migraine. *Pharmacother.* **2006**, *26*, 115–128. (b) McHarg, A. D.; Napier, C. M.; Stewart, M.; Melrose, H. L.; Wallis, R. M. The Functional Activity of Eletriptan and other 5-HT_{1B/1D} Agonists at the Human Recombinant 5-HT_{1B} and 5-HT_{1D} Receptors. *Headache* **1999**, *39*, 369–370. (c) Hoskin, K. L.; Lambert, G. A.; Donaldson, C.; Zagami, A. S. The 5-Hydroxytryptamine_{1B/1D/1F} Receptor Agonists Eletriptan and Naratriptan Inhibit Trigeminovascular Input to the Nucleus Tractus Solitarius in the Cat. *Brain Res.* **2004**, *998*, 91–99. (d) Capi, M.; Curto, M.; Lionetto, L.; de Andrés, F.; Gentile, G.; Negro, A.; Martelletti, P. Eletriptan in the Management of Acute Migraine: An Update on the Evidence for Efficacy, Safety, and Consistent Response. *Ther. Adv. Neurol. Disord.* **2016**, *9*, 414–423.

(6) (a) Bourinbaiar, A. S.; Lee–Huang, S. The non-Steroidal anti-Inflammatory Drug, Indomethacin, as an Inhibitor of HIV Replication. *FEBS Lett.* **1995**, *360*, 85–88. (b) Schuna, A. A. Update on Treatment of Rheumatoid Arthritis. *J. Am. Pharm. Assoc.* **1998**, *38*, 728–737. (c) Goodnight, S. H. Aspirin Therapy for Cardiovascular Disease. *Curr. Opin. Hematol.* **1996**, *3*, 355–360. (d) Rodriguez, L. A.; Varas, C.; Patrono, C. Differential Effects of Aspirin and non-Aspirin Nonsteroidal Antiinflammatory Drugs in the Primary Prevention of Myocardial Infarction in Postmenopausal Women. *Epidemiology* **2000**, *11*, 382–387. (e) Sloane, P. D. Advances in the Treatment of Alzheimer's Disease. *Am. Fam. Physician* **1998**, *58*, 1577–1586. (f) Flynn, B. L.; Theesen, K. A. Pharmacologic Management of Alzheimer Disease Part III: Nonsteroidal Antiinflammatory Drugs—Emerging Protective Evidence?. *Ann. Pharmacother.* **1999**, *33*, 840–849. (g) Jones, M. K.; Wang, H.; Peskar, B. M.; Levin, E.; Itani, R. M.; Sarfels, I. J.; Tarnawski, A. S. Inhibition of Angiogenesis by Nonsteroidal anti-Inflammatory Drugs: Insight into Mechanisms and Implications for Cancer Growth and Ulcer Healing. *Nat. Med.* **1999**, *5*, 1418–1423. (h) Matos, C.; Lima, J. L. C.; Reis, S.; Lopes, A.; Bastos, M. Interaction of Antiinflammatory Drugs with EPC Liposomes: Calorimetric Study in a Broad Concentration Range. *Biophys. J.* **2004**, *2*, 946–954.

(7) (a) Wu, Q. X.; Crews, M. S.; Draskovic, M.; Sohn, J.; Johnson, T. A.; Tenney, K.; Valeriote, F. A.; Yao, X. J.; Bjeldanes, L. F.; Crews, P. Azonazine, a Novel Dipeptide from a Hawaiian Marine Sediment-Derived Fungus, *Aspergillus Insulicola*. *Org. Lett.* **2010**, *12*, 4458–4461. (b) Kam, T. S.; Tan, S. J.; Ng, S. W.; Komiyama, K. Bipleiophylline, an Unprecedented Cytotoxic Bisindole Alkaloid Constituted from the Bridging of Two Indole Moieties by an aromatic Spacer Unit. *Org. Lett.* **2008**, *10*, 3749–3752. (c) Li, X. N.; Zhang, Y.; Cai, X. H.; Feng, T.; Liu, Y. P.; Li, Y.; Ren, J.; Zhu, H. J.; Luo, X. D. Psychotripline: a New Trimeric Pyrroloindoline Derivative from *Psychotria pilifera*. *Org. Lett.* **2011**, *13*, 5896–5899. (d) Raju, R.; Piggott, A. M.; Conte, M.; Aalbersberg, W. G. L.; Feussner, K.; Capon, R. J. Nasesezines A and B: A New Dimeric Diketopiperazine Framework from a Marine-Derived Actinomycete, *Streptomyces* sp. *Org. Lett.* **2009**, *11*, 3862–3865. (e) Dong, J. Y.; Zhou, W.; Li, L.; Liu, Y. J.; Zhang, K. Q. A New Epidithiodioxopiperazine Metabolite Isolated from *Gliocladium roseum* YMF1.00133. *Chin. Chem. Lett.* **2006**, *17*, 922–924. (f) Zhang, W.; Liu, Z.; Li, S.; Yang, T.; Zhang, Q.; Ma, L.; Tian, X.; Zhang, H.; Huang, C.; Zhang, S.; Ju, J.; Shen, Y.; Zhang, C. Spiroindimicins A–D: New Bisindole Alkaloids from a Deep-Sea-Derived Actinomycete. *Org. Lett.* **2012**, *14*, 3364–3367. (g) Denizot, N.; Tomakinian, T.; Beaud, R.; Kouklovsky, C.; Vincent, G. Synthesis of 3-Arylated Indolines from Dearomatization of Indoles. *Tetrahedron Lett.* **2015**, *56*, 4413–4429. (h) Zhang, D.; Song, H.; Qin, Y. Total Synthesis of Indoline Alkaloids: A Cyclopropanation Strategy. *Acc. Chem. Res.* **2011**, *44*, 447–457.

(8) (a) Ruiz–Sanchis, P.; Savina, S. A.; Alberici, F.; Alvarez, M. Structure, Bioactivity and Synthesis of Natural Products with Hexahydropyrrolo[2,3-*b*]indole. *Chem. Eur. J.* **2011**, *17*, 1388–1408. (b) Witkop, B. From the "Ordeal Bean" (*Physostigma venenosum*) to the Ordeal of Alzheimer's Disease: Some of the Legacy of Percy Lavon Julian (1899–1975). *Heterocycles* **1998**, *49*, 9–27. (c) Crich, D.; Banerjee, A. Chemistry of the Hexahydropyrrolo[2,3-*b*]indoles: Configuration, Conformation, Reactivity, and Applications in Synthesis. *Acc. Chem. Res.* **2007**, *40*, 151–161. (d) Repka, L. M.; Reisman, S. E. Recent Developments in the Catalytic, Asymmetric Construction of Pyrroloindolines Bearing All-Carbon Quaternary Stereocenters. *J. Org. Chem.* **2013**, *78*, 12314–12320. (e) Shaw, K.–P.; Aracava, Y.; Akaike, A.; Daly, J. W.; Rickett, D. L.; Albuquerque, E. X. The reversible Cholinesterase Inhibitor Physostigmine Has Channel-Blocking and Agonist Effects on the Acetylcholine Receptor-Ion Channel Complex. *Mol. Pharmacol.* **1985**, *28*, 527–538.

1
2
3 (9) (a) Keating, G. M. Silodosin: A Review of Its Use in the Treatment of the Signs and Symptoms of Benign
4 Prostatic Hyperplasia. *Drugs* **2015**, 75, 207–217. (b) Barve, I. J., Chen, L. H., Wei, P. C., Hung, J. T., Sun, C. M.
5 Enantioselective Synthesis of (–)-(R) Silodosin by Ultrasound-Assisted Diastereomeric Crystallization.
6 *Tetrahedron* **2013**, 69, 2834–2843. (c) Yan, P. C., Zhang, X. Y., Hu, X. W., Zhang, B., Zhang, X. D., Zhao, M., Zhou,
7 Q. L. First Asymmetric Synthesis of Silodosin through Catalytic Hydrogenation by Using Ir-SIPHOX catalysts.
8 *Tetrahedron Lett.* **2013**, 54, 1449–1451. (d) Chapple, C. R.; Montorsi, F.; Tammela, T. L.; Wirth, M.; Koldewijn, E.;
9 Fernandez, E. F. Silodosin Therapy for Lower Urinary Tract Symptoms in Men with Suspected Benign Prostatic
10 Hyperplasia: Results of an International, Randomized, Double-Blind, Placebo- and Active-Controlled Clinical Trial
11 Performed in Europe. *Eur. Urol.* **2011**, 59, 342–352.

12
13 (10) (a) Almagro, L.; Fernandez-Perez, F.; Pedreno, M. A. Indole alkaloids from *Catharanthus roseus*:
14 Bioproduction and Their Effect on Human Health. *Molecules* **2015**, 20, 2973–3000. (b) Gul, W.; Hamann, M. T.
15 Indole Alkaloid Marine Natural Products: An Established Source of Cancer Drug Leads with Considerable Promise
16 for the Control of Parasitic, Neurological and Other Diseases. *Life Sci.* **2005**, 78, 442–453. (c) Yokoshima, S.; Ueda,
17 T., Kobayashi, S.; Sato, A., Kuboyama, T., Tokuyama, H., Fukuyama, T. Stereocontrolled Total Synthesis of (+)-
18 Vinblastine. *J. Am. Chem. Soc.* **2002**, 124, 2137–2139. (d) Ishikawa, H.; Colby, D. A.; Boger, D. L. Direct Coupling
19 of Catharanthine and Vindoline to Provide Vinblastine: Total Synthesis of (+)- and *ent*-(–)-Vinblastine. *J. Am.*
20 *Chem. Soc.* **2008**, 130, 420–421. (e) Ishikawa, H.; Colby, D. A.; Seto, S.; Va, P.; Tam, A.; Kakei, H.; Boger, D. L. Total
21 Synthesis of Vinblastine, Vincristine, Related Natural Products, and Key Structural Analogues. *J. Am. Chem. Soc.*
22 **2009**, 131, 4904–4916.

23
24 (11) (a) Andreani, A.; Rambaldi, M. Indole Derivatives as Agrochemicals. *J. Heterocycl. Chem.* **1988**, 25,
25 1519–1523. (b) Barden, T. C. Indoles: Industrial, Agricultural and Over-the-Counter Uses. *Top. Heterocycl. Chem.*
26 **2011**, 26, 31–46. (c) Nie, G.; Zhou, L., Guo, Q.; Zhang, S. A New Electrochromic Material from an Indole Derivative
27 and Its Application in High-Quality Electrochromic Devices. *Electrochem. Commun.* **2010**, 12, 160–163. (d)
28 Valentine, R. A.; Whyte, A.; Awaga, K.; Robertson, N. New Indole Trimers as Precursors for Molecular Electronic
29 Materials. *Tetrahedron Lett.* **2012**, 53, 657–660. (e) Park, M. S.; Choi, D. H.; Lee, B. S.; Lee, J. Y. Fused Indole
30 Derivatives as High Triplet Energy Hole Transport Materials for Deep Blue Phosphorescent Organic Light-Emitting
31 Diodes. *J. Mater. Chem.* **2012**, 22, 3099–3104.

32
33 (12) (a) Mino, T.; Ishikawa, M.; Nishikawa, K.; Wakui, K.; Sakamoto, M. Palladium-Catalyzed Asymmetric Allylic
34 Alkylation of Indoles by C–N Bond Axially Chiral Phosphine Ligands. *Tetrahedron: Asymmetry* **2013**, 24, 499–504.
35 (b) So, C. M.; Yeung, C. C.; Lau, C. P.; Kwong, F. Y. A New Family of Tunable Indolylphosphine Ligands by One-Pot
36 Assembly and Their Applications in Suzuki–Miyaura Coupling of Aryl Chlorides. *J. Org. Chem.* **2008**, 73, 7803–
37 7806.

38
39 (13) Sandtorv, A. H. Transition Metal-Catalyzed C–H Activation of Indoles. *Adv. Synth. Catal.* **2015**, 357,
40 2403–2435.

41
42 (14) (a) Guo, T.; Huang, F.; Yu, L.; Yu, Z. Indole Synthesis through Transition Metal-Catalyzed C–H Activation.
43 *Tetrahedron Lett.* **2015**, 56, 296–302. (b) Gribble, G. W. Recent Developments in Indole Ring Synthesis–
44 Methodology and Applications. *J. Chem. Soc. Perkin Trans. 1* **2000**, 1045–1075. (c) Zeni, G.; Larock, R. C. Synthesis
45 of Heterocycles via Palladium π -Olefin and π -Alkyne Chemistry. *Chem. Rev.* **2004**, 104, 2285–5309. (d) Humphrey,
46 G. R.; Kuethe, J. T. Practical Methodologies for the Synthesis of Indoles. *Chem. Rev.* **2006**, 106, 2875–2911. (e)
47 Cacchi, S., Fabrizi, G.; Goggiamani, A. Copper Catalysis in the Construction of Indole and Benzo[b]furan Rings.
48 *Org. Biomol. Chem.* **2011**, 9, 641–652. (f) Yoshikai, N.; Wei, Y. Synthesis of Pyrroles, Indoles, and Carbazoles
49 through Transition-Metal-Catalyzed C–H Functionalization. *Asian J. Org. Chem.* **2013**, 2, 466–478.

50
51 (15) Cacchi, S.; Fabrizi, G. Synthesis and Functionalization of Indoles Through Palladium-Catalyzed Reactions.
52 *Chem. Rev.* **2005**, 105, 2873–2920.

53
54 (16) (a) Fischer, E.; Jourdan, F. Ueber die Hydrazine der Brenztraubensäure. *Ber. Dtsch. Chem. Ges.* **1883**, 16,
55 2241–2245. (b) Park, I. K.; Suh, S. E.; Lim, B. Y.; Cho, C. G. Aryl Hydrazide Beyond as Surrogate of Aryl Hydrazine
56 in the Fischer Indolization: The Synthesis of *N*-Cbz-indoles, *N*-Cbz-carbazoles, and *N,N'*-Bis-Cbz-pyrrolo[2,3-
57 *f*]indoles. *Org. Lett.* **2009**, 11, 5454–5456. (c) Talaz, O.; Saracoglu, N. A Study on the Synthesis of Structural Analogs
58 of Bis-Indole Alkaloid Caulerpin: A Step-By-Step Synthesis of a Cyclic Indole-Tetramer. *Tetrahedron* **2010**, 66,
59 1902–1910.

- (17) (a) Bartoli, G.; Palmieri, G.; Bosco, M.; Dalpozzo, R. The reaction of Vinyl Grignard Reagents with 2-Substituted Nitroarenes: A New Approach to the Synthesis of 7-Substituted Indoles. *Tetrahedron Lett.* **1989**, 30, 2129–2132. (b) Bartoli, G.; Dalpozzo, R.; Nardi, M. Applications of Bartoli Indole Synthesis. *Chem. Soc. Rev.* **2014**, 43, 4728–4750.
- (18) (a) Larock, R. C.; Yum, E. K. Synthesis of Indoles via Palladium-Catalyzed Heteroannulation of Internal Alkynes. *J. Am. Chem. Soc.* **1991**, 113, 6689–6690. (b) Larock, R. C.; Yum, E. K.; Refvik, M. D. Synthesis of 2,3-Disubstituted Indoles via Palladium-Catalyzed Annulation of Internal Alkynes. *J. Org. Chem.* **1998**, 63, 7652–7662.
- (19) (a) Joucla, L.; Djakovitch, L. Transition Metal-Catalysed, Direct and Site-Selective N1-, C2- or C3-Arylation of the Indole Nucleus: 20 Years of Improvements. *Adv. Synth. Catal.* **2009**, 351, 673–714. (b) Bandini, M.; Eichholzer, A. Catalytic Functionalization of Indoles in a New Dimension. *Angew. Chem. Int. Ed.* **2009**, 48, 9608–9644. (c) Giri, R.; Thapa, S.; Kaffle, A. Palladium-Catalysed, Directed C–H Coupling with Organometallics. *Adv. Synth. Catal.* **2014**, 356, 1395–1411. (d) Kakiuchi, F.; Chatani, N. Catalytic Methods for C–H Bond Functionalization: Application in Organic Synthesis. *Adv. Synth. Catal.* **2003**, 345, 1077–1101. (e) Hussain, I.; Singh, T. Synthesis of Biaryls through Aromatic C–H Bond Activation: A Review of Recent Developments. *Adv. Synth. Catal.* **2014**, 356, 1661–1696.
- (20) (a) Maity, S.; Manna, S.; Rana, S.; Naveen, T.; Mallick, A.; Maiti, D. Efficient and Stereoselective Nitration of Mono- and Disubstituted Olefins with AgNO₂ and TEMPO. *J. Am. Chem. Soc.* **2013**, 135, 3355–3358. (b) Barrett, A. G. M.; Graboski, G. G. Conjugated Nitroalkenes: Versatile Intermediates in Organic Synthesis. *Chem. Rev.* **1986**, 86, 751–762. (c) Tripathi, C. B.; Kayal, S.; Mukherjee, S. Catalytic Asymmetric Synthesis of α,β -Disubstituted α,γ -Diaminophosphonic Acid Precursors by Michael Addition of α -Substituted Nitrophosphonates to Nitroolefins. *Org. Lett.* **2012**, 14, 3296–3299. (d) Huang, H. B.; Jacobsen, E. N. Highly Enantioselective Direct Conjugate Addition of Ketones to Nitroalkenes Promoted by a Chiral Primary Amine–Thiourea Catalyst. *J. Am. Chem. Soc.* **2006**, 128, 7170–7171. (e) Fioravanti, S.; Pellacani, L.; Tardella, P. A.; Vergari, M. C. Facile and Highly Stereoselective One-Pot Synthesis of Either (*E*- or (*Z*-Nitro Alkenes. *Org. Lett.* **2008**, 10, 1449–1451. (f) Evans, D. A.; Mito, S.; Seidel, D. Scope and Mechanism of Enantioselective Michael Additions of 1,3-Dicarbonyl Compounds to Nitroalkenes Catalyzed by Nickel(II)–Diamine Complexes. *J. Am. Chem. Soc.* **2007**, 129, 11583–11592. (g) Nair, D. K.; Mobin, S. M.; Nambhothiri, I. N. Synthesis of Imidazopyridines from the Morita–Baylis–Hillman Acetates of Nitroalkenes and Convenient Access to Alpidem and Zolpidem. *Org. Lett.* **2012**, 14, 4580–4583. (h) Corma, A.; Serna, P.; Garcia, H. Gold Catalysts Open a New General Chemoselective Route to Synthesize Oximes by Hydrogenation of α,β -Unsaturated Nitrocompounds with H₂. *J. Am. Chem. Soc.* **2007**, 129, 6358–6359. (i) Martin, N. J. A.; Ozores, L.; List, B. Organocatalytic Asymmetric Transfer Hydrogenation of Nitroolefins. *J. Am. Chem. Soc.* **2007**, 129, 8976–8977.
- (21) (a) Jayasundera, K. P.; Kusmus, D. N.; Deuilhe, L.; Etheridge, L.; Farrow, Z.; Lun, D. J.; Rowlands, G. J. The Synthesis of Substituted Amino[2.2]paracyclophanes. *Org. Biomol. Chem.* **2016**, 14, 10848–10860. (b) Mendez, I.; Rodriguez, R.; Polo, V.; Passarelli, V.; Lahoz, F. J.; Garcia-Orduna, P.; Carmona, D. Temperature Dual Enantioselective Control in a Rhodium-Catalyzed Michael–Type Friedel–Crafts Reaction: A Mechanistic Explanation. *Chem. Eur. J.* **2016**, 22, 11064–11083. (c) Zhang, X.; Zhang, Z.; Boissonault, J.; Cohen, S. M. Design and Synthesis of Squaramide–Based MOFs as Efficient MOF–Supported Hydrogen-Bonding Organocatalysts. *Chem. Commun.* **2016**, 52, 8585–8588. (d) Kusurkar, R. S.; Alkobati, N. A.; Gokule, A. S.; Puranik, V. G. Use of the Pictet–Spengler Reaction for the Synthesis of 1, 4-Disubstituted-1,2,3,4-Tetrahydro- β -carboline and 1, 4-Disubstituted- β -carboline: Formation of γ -Carbolines. *Tetrahedron* **2008**, 64, 1654–1662. (e) Rao, P. C.; Mandal, S. Friedel–Crafts Alkylation of Indoles with Nitroalkenes through Hydrogen-Bond-Donating Metal–Organic Framework. *ChemCatChem* **2017**, 9, 1172–1176. (f) Carmona, D.; Lamata, M. P.; Sanchez, A.; Viguri, F.; Oro, L. A. Enantioselective Friedel–Crafts Alkylations Catalysed by Well-Defined Iridium And Rhodium Half-Sandwich Complexes. *Tetrahedron: Asymmetry* **2011**, 22, 893–906. (g) Sheng, Y. F.; Li, G. Q.; Kang, Q.; Zhang, A. J.; You, S. L. Asymmetric Friedel–Crafts Reaction of 4,7-Dihydroindoles with Nitroolefins by Chiral Brønsted Acids under Low Catalyst Loading. *Chem. Eur. J.* **2009**, 15, 3351–3354.
- (22) (a) Shi, Y. C.; Wang, S. G.; Yin, Q.; You, S. L. *N*-Alkylation of Indole via Ring-Closing Metathesis/Isomerization/Mannich Cascade under Ruthenium/Chiral Phosphoric Acid Sequential Catalysis. *Org. Chem. Front.* **2014**, 1, 39–43. (b) Siddiki, S. H.; Kon, K.; Shimizu, K. I. Selective *N*-Alkylation of Indoles with Primary Alcohols Using a Pt/HBEA Catalyst. *Green Chem.* **2015**, 17, 173–177. (c) Ling, L.; Cao, J.; Hu, J.; Zhang, H. Copper-Catalyzed *N*-Alkylation of Indoles by *N*-Tosylhydrazones. *RSC Adv.* **2017**, 7, 27974–27980. (d) Jorapur, Y. R.; Jeong, J. M.; Chi, D. Y. Potassium Carbonate as a Base for the *N*-Alkylation of Indole and Pyrrole in Ionic Liquids. *Tetrahedron Lett.* **2006**, 47, 2435–2438.

- 1
2
3 (23) (a) Bayindir, S.; Erdogan, E.; Kilic, H.; Saracoglu, N. An Efficient Synthesis of New Aza-Substituted Indoles via Michael–Type Addition. *Synlett* **2010**, 1455–1458. (b) Kilic, H.; Bayindir, S.; Erdogan, E.; Saracoglu, N. Synthesis
4 of Highly *N*-Substituted Indole Library via Conjugate Additions of Indoline and Their Synthetic Tool Potentials.
5 *Tetrahedron* **2012**, 68, 5619–5630.
6
7
8 (24) (a) Kianmehr, E.; Ghanbari, M.; Faghih, N.; Rominger, F. A Palladium-Catalyzed One-Pot Procedure for the
9 Regioselective Dimerization and Cyanation of Indoles. *Tetrahedron Lett.* **2012**, 53, 1900–1904. (b) Zhang, Y.; Liu,
10 X.; Zhao, X.; Zhang, J.; Zhou, L.; Lin, L.; Feng, X. Enantioselective Friedel–Crafts Alkylation for Synthesis of 2-
11 Substituted Indole Derivatives. *Chem. Commun.* **2013**, 49, 11311–11313. (c) Jiao, L.; Bach, T. Regioselective Direct
12 C–H Alkylation of NH Indoles and Pyrroles by a Palladium/Norbornene–Cocatalyzed Process. *Synthesis* **2014**, 46,
13 35–41. (d) Jiao, L.; Bach, T. Palladium-Catalyzed Direct 2-Alkylation of Indoles by Norbornene–Mediated
14 Regioselective Cascade C–H Activation. *J. Am. Chem. Soc.* **2011**, 133, 12990–12993.
15
16 (25) (a) Cano, R.; Yus, M.; Ramon, D. J. Environmentally Friendly and Regioselective C₃-Alkylation of Indoles with
17 Alcohols Through a Hydrogen Autotransfer Strategy. *Tetrahedron Lett.* **2013**, 54, 3394–3397. (b) Li, S. S.; Lin, H.;
18 Zhang, X. M.; Dong, L. Ruthenium-Catalyzed Direct C₃ Alkylation of Indoles with α,β -Unsaturated Ketones. *Org.*
19 *Biomol. Chem.* **2015**, 13, 1254–1263. (c) Zheng, X.; Zhang, L.; Li, J.; Luo, S.; Cheng, J. P. Magnetic Nanoparticle
20 Supported Polyoxometalates (POMs) via Non-Covalent Interaction: Reusable Acid Catalysts and Catalyst
21 Supports for Chiral Amines. *Chem. Commun.* **2011**, 47, 12325–12327.
22
23 (26) Leitch, J. A.; Bhonoah, Y.; Frost, C. G. Beyond C₂ and C₃: Transition-Metal-Catalyzed C–H Functionalization
24 of Indole. *ACS Catal.* **2017**, 7, 5618–5627.
25
26 (27) Belsky, I.; Gertner, D.; Zilkha, A. Synthesis of Some 5-Trimethylsilylindoles. *J. Org. Chem.* **1968**, 33,
27 1348–1350.
28
29 (28) (a) Rodriguez, J. M.; Pujol, M. D. Straightforward Synthesis of Nitroolefins by Microwave- or Ultrasound-
30 Assisted Henry Reaction. *Tetrahedron Lett.* **2011**, 52, 2629–2632. (b) Jalal, S.; Sarkar, S.; Bera, K.; Maiti, S.; Jana,
31 U. Synthesis of Nitroalkenes Involving a Cooperative Catalytic Action of Iron(III) and Piperidine: A One-Pot
32 Synthetic Strategy to 3-Alkylindoles, 2*H*-Chromenes and *N*-Arylpyrrole. *Eur. J. Org. Chem.* **2013**, 4823–4828.
33
34 (29) Wang, G.; de Silva, G. P.; Wiebe, N. E.; Fehr, G. M.; Davis, R. L. Development of a Metal–Free Amine Oxidation
35 Method Utilizing DEAD Chemistry. *RSC Adv.* **2017**, 7, 48848–48852.
36
37 (30) Ji, H.; Jing, Q.; Huang, J.; Silverman, R. B. Acid-Facilitated Debenzylation of *N*-Boc, *N*-Benzyl Double Protected
38 2-Aminopyridinomethyl Pyrrolidine Derivatives. *Tetrahedron* **2012**, 68, 1359–1366.
39
40 (31) Bull, S. D.; Davies, S. G.; Fenton, G.; Mulvaney, A. W.; Prasad, R. S.; Smith, A. D. Chemoselective Oxidative
41 Debenzylation of Tertiary *N*-Benzyl Amines. *Chem. Commun.* **2000**, 337–338.
42
43 (32) Haddach, A. A.; Kelleman, A.; Deaton-Rewolinski, M. V. An efficient method for the *N*-Debenzylation of
44 Aromatic Heterocycles. *Tetrahedron Lett.* **2002**, 43, 399–402.
45
46 (33) Gigg, R.; Conant, R. Conversion of the *N*-Benzylacetamido Group into the Acetamido Group by Autoxidation
47 in Potassium *t*-Butoxide–Dimethyl Sulphoxide. *J. Chem. Soc., Chem. Commun.* **1983**, 465–466.
48
49 (34) Shendage, D. M.; Fröhlich, R.; Haufe, G. Highly Efficient Stereoconservative Amidation and Deamidation of
50 α -Amino Acids. *Org. Lett.* **2004**, 6, 3675–3678.
51
52 (35) Pavan Kumar, G.; Rambabu, D., Basaveswara Rao, M. V.; Pal, M. Iodine–Mediated Neutral and Selective *N*-
53 Boc Deprotection. *J. Chem.* **2013**, 2013, 1–5.
54
55 (36) Routier, S.; Sauge, L.; Ayerbe, N.; Coudert, G.; Mérour, J. Y. A Mild and Selective Method for *N*-Boc
56 Deprotection. *Tetrahedron Lett.* **2002**, 43, 589–591.
57
58 (37) Evans, E. F.; Lewis, N. J.; Kapfer, I.; Macdonald, G.; Taylor, R. J. *N*-*tert*-Butoxycarbonyl (BOC) Deprotection
59 using Boron Trifluoride Etherate. *Synth. Commun.* **1997**, 27, 1819–1825.
60

- 1
2
3 (38) Kamata, K.; Kasai, J.; Yamaguchi, K.; Mizuno, N., Efficient Heterogeneous Oxidation of Alkylarenes with
4 Molecular Oxygen. *Org. Lett.* **2004**, *6*, 3577–3580.
5
6 (39) Gao, P.; Sipos, G.; Foster, D.; Dorta, R., Developing NHC-Iridium Catalysts for the Highly Efficient
7 Enantioselective Intramolecular Hydroamination Reaction. *ACS Catal.* **2017**, *7*, 6060–6064.
8
9 (40) Presset, M.; Pignon, A.; Paul, J.; Le Gall, E.; Leonel, E.; Martens, T., Synthesis of Indolines by a Zn-Mediated
10 Mannich Reaction/Pd-Catalyzed Amination Sequence. *J. Org. Chem.* **2017**, *82*, 3302–3310.
11
12 (41) Hlasta, D. J.; Luttinger, D.; Perrone, M. H.; Silbernagel, M. J.; Ward, S. J.; Haubrich, D. R., Alpha 2-Adrenergic
13 Agonists/Antagonists: The Synthesis and Structure-Activity Relationships of a Series of Indolin-2-yl and
14 Tetrahydroquinolin-2-yl Imidazolines. *J. Med. Chem.* **1987**, *30*, 1555–1562.
15
16 (42) Jiao, L.-Y.; Oestreich, M., Oxidative Palladium(II)-Catalyzed C-7 Alkenylation of Indolines. *Org. Lett.* **2013**, *15*,
17 5374-5377.
18
19 (43) Ferraro, A.; Bernardi, L.; Fochi, M., Organocatalytic Enantioselective Transfer Hydrogenation of β -Amino
20 Nitroolefins. *Adv. Synth. Catal.* **2016**, *358*, 1561-1565.
21
22 (44) Pensa, A. V.; Cinelli, M. A.; Li, H.; Chreifi, G.; Mukherjee, P.; Roman, L. J.; Martasek, P.; Poulos, T. L.; Silverman,
23 R. B., Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric
24 Oxide Synthase Inhibitors. *J. Med. Chem.* **2017**, *60* (16), 7146–7165.
25
26 (45) Mehndiratta, S.; Wang, R.-S.; Huang, H. L.; Su, C. J.; Hsu, C. M.; Wu, Y. W.; Pan, S. L.; Liou, J. P., 4-Indolyl-*N*-
27 hydroxyphenylacrylamides as Potent HDAC Class I and IIB Inhibitors in vitro and in vivo. *Eur. J. Med. Chem.* **2017**,
28 *134*, 13–23.
29
30 (46) Wang, L.; Li, P.; Menche, D., Concise Synthesis of Tetrahydropyrans by a Tandem Oxa-Michael/Tsuji–Trost
31 Reaction. *Angew. Chem. Int. Ed.* **2010**, *49*, 9270-9273.
32
33 (47) Meng, G. R.; Szostak, M., Palladium-catalyzed Suzuki–Miyaura Coupling of Amides by Carbon–Nitrogen
34 Cleavage: General Strategy for Amide N–C Bond Activation. *Org. Biomol. Chem.* **2016**, *14*, 5690–5707.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60